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Abstract
Male breast cancer (MBC) is an uncommon disease accounting for only 1% of all breast can-
cers. Despite its rarity, the mortality associated with MBC and the increase in its incidence in
recent years, has led to a progressive interest on this subject. Retrospective studies have al-
ready demonstrated important differences between MBC and female breast cancer (FBC) but
the knowledge about its biological behaviour remains insufficient to define a personalised treat-
ment strategy to MBC patients.
The aim of the present work was to study MBC prognosis based on: the definition of better
intrinsic subgroups based on immunoexpression, the analysis of recurrence and of factors that
could predict response to adjuvant endocrine therapy.
From clinical records of 111 MBC patients treated in a tertiary cancer center (with a me-
dian follow-up of 5.5 years), information was selectively analysed to answer specific research
questions. Central pathology revision was performed with additional immunohistochemical (IHC)
analysis of the cases in which tumour blocks were available. Blood samples were collected from
patients who were in active treatment or surveillance in the center for genetic analysis.
The independent prognostic factors associated with poor outcome were: tumour size larger
than 2cm (HR: 1.8, 95% CI: 1.0-3.4 years, p = 0.049), the absence of expression of estrogen
receptor (HR: 4.9, 95% CI: 1.7-14.3 years, p = 0.004) and stage IV disease (HR: 5.3, 95% CI:
2.2-3.1 years, p < 0.001). The presence of lymph node metastasis seems to be related with
poor outcome in univariate analysis (HR: 1.8, 95% CI: 0.9-3.2 years, p=0.05). The two classifica-
tions used to define FBC subgroups (based on three and four IHC markers), could not be linearly
translated to MBC patients as some groups are rarely represented among these patients (triple
negative: 2.7%-3.2% and HER2 enriched non luminal ≤ 1%), and they lost their prognostic dis-
criminatory capacity when analysed only the most frequent groups (luminals). Cluster analysis
based on a six-IHC panel, identified two important prognostic subgroups with extreme outcomes:
one with better prognosis, composed by patients with tumours that express estrogen and pro-
gesterone receptor without expression of androgen receptor and HER2 and low ki67/p53, and
another with the worst survival, associated with patients that had tumours who did not express
progesterone receptor.
Recurrence was specifically analysed to evaluate its impact in survival outcome, using two
gender cohorts that were matched for age at diagnosis, histological grade, stage, type of tumour
and adjuvant treatments performed. MBC patients relapse more often to lung (p = 0.003) and
presented poorer survival than FBC and this result remains across all of the five groups defined
by relapse pattern. The difference in outcome seems to be related with the absence of sys-
temic palliative treatment in recurrence time that is more commonly registered in MBC patients
(21.1% vs 4.4%, p = 0.018). Patients treated with adjuvant tamoxifen categorized as poor ta-
moxifen metabolizers based on CYP2D6*4 polymorphism had also a higher risk of recurrence
(p = 0.0034) and this effect was still observed when controlled important prognostic factors like:
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size > 2cm (p = 0.001), nodal status (N0 vs N+, p = 0.004), and advanced disease (stage III
versus others, p < 0.001). These patients were associated with worse survival when tumours
were larger than 2cm.
In conclusion, MBC patients have poorer outcome than FBC patients, even when stratified
by important prognostic factors. Clinicians must look with major concerns for MBC patients that
present with tumours with more than 2cm, or have lymph nodes involved or do not express ER or
PR or present with distant metastasis at diagnosis (stage IV). Poor tamoxifen metabolizers based
on CYP2D6*4 polymorphism have higher risk for relapse and probably need a more aggressive
adjuvant approach. Considering recurrence time, palliative systemic treatment had a favourable
impact in MBC patients’ survival.
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Resumo
O carcinoma da mama no homem (CMH) é uma doença rara, correspondendo a apenas 1% de
todos os cancros da mama. Apesar da baixa incidência, o aumento progressivo do número de
casos nos últimos anos associado à elevada taxa de mortalidade, tem despertado o interesse
para esta patologia. Estudos retrospetivos demonstraram já diferenças importantes entre o CMH
e o carcinoma da mama na mulher (CMM), mas o conhecimento sobre o seu comportamento
biológico ainda é insuficiente para definir uma estratégia de tratamento personalizada para estes
doentes.
O objetivo do presente trabalho foi estudar o prognóstico dos doentes do sexo masculino
com carcinoma da mama baseado: na definição de melhores subgrupos de prognóstico a partir
de marcadores da imunohistoquímica (IHQ), na análise da recorrência e de fatores preditivos de
resposta à terapêutica endócrina adjuvante.
A partir dos registos clínicos de 111 doentes tratados em um centro oncológico (tempo de
follow-up mediano de 5.5 anos), foi colhida e analisada a informação de forma a responder
a perguntas de investigação específicas. Foi realizada revisão patológica central procedendo-
se a análise IHQ adicional nos casos em que os blocos de tumor estavam disponíveis, sendo
ainda colhidas amostras de sangue para análise genética nos doentes que se encontravam em
tratamento ativo ou em vigilância no centro.
Os fatores independentes de prognóstico associados a pior sobrevivência foram: tamanho
do tumor superior a 2cm (HR: 1.8, IC 95%: 1.0-3.4 anos, p = 0.049), a ausência de expressão
do receptor de estrogénio (HR: 4.9, IC 95%: 1.7-14.3 anos, p = 0.004) e o estádio IV (HR: 5.3,
IC 95%: 2.2-3.1 anos, p < 0.001). A metastização ganglionar locorregional parece estar rela-
cionada com pior prognóstico na análise univariada (HR: 1.8, IC 95%: 0.9-3.2 anos, p = 0.05).
As duas classificações utilizadas para definir subgrupos de prognóstico no CMM (com base em
três ou quatro marcadores da IHQ), não podem ser linearmente transpostas para os homens
com carcinoma da mama, já que alguns subgrupos são raramente descritos nestes doentes
(triplos negativos: 2.7%-3.2% e HER2 enriched não luminais ≤1%), perdendo a sua capaci-
dade discriminativa de prognóstico quando analisados apenas os subgrupos mais frequentes
(luminais). A análise por clusters, utilizando um painel de seis marcadores da IHQ, identificou
dois subgrupos de prognóstico com resultados extremos: um associado a melhor prognóstico,
composto pelos doentes com tumores que expressavam receptores de estrogénio e de proges-
terona sem expressão do receptor de andrógenio nem HER2 e com ki67 / p53 baixo e outro que
apresentava a pior sobrevivência, composto pelos doentes cujos tumores não expressavam o
receptor de progesterona.
A análise da recorrência baseou-se na comparação de duas coortes definidas por sexo,
que foram emparelhadas por idade ao diagnóstico, grau histológico, estádio, tipo de tumor e
tratamentos adjuvantes realizados. Os homens com carcinoma da mama recorreram mais fre-
quentemente para o pulmão (p = 0.003) e apresentaram pior sobrevivência do que as mulheres,
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mantendo-se esta tendência, de forma transversal nos cinco grupos definidos com base no
padrão de recorrência. Esta diferença parece relacionar-se com a ausência de tratamento palia-
tivo sistémico no diagnóstico da recorrência que se verifica mais frequentemente nos doentes
homens (21.1% vs 4.4%, p = 0.018). Aqueles categorizados como poor metabolizers do ta-
moxifeno, de acordo com o polimorfismo da CYP2D6*4, apresentaram, também, um maior risco
para recorrência (p = 0.0034) mantendo-se este resultado quando controlados importantes fa-
tores de prognóstico como: tamanho do tumor superior a 2 cm (p = 0.001), N status (N0 vs N+,
p = 0.004) e estádio avançado (estádio III vs os outros, p < 0.001). Estes doentes apesentaram
também pior sobrevivência quando os tumores eram maiores que 2 cm.
Em conclusão os homens com carcinoma da mama apresentam pior sobrevivência quando
comparados com as suas congéneres femininas mesmo quando controlados os principais fa-
tores de prognóstico. Na prática clinica, deverão ser considerados de maior risco para morte
por carcinoma da mama os doentes que apresentam tumores com mais de 2cm, ou que te-
nham envolvimento ganglionar locorregional ou que não expressam receptor de estrogénio ou
de progesterona ou que se diagnostiquem em estádio IV. Os categorizados como poor meta-
bolizers relativamente ao tamoxifeno com base no polimorfismo da CYP2D6*4 têm maior risco
de recorrência e provavelmente beneficiarão de uma abordagem adjuvante mais agressiva. A
realização de tratamento paliativo sistémico na primeira recorrência tem um impacto positivo na
sobrevivência destes doentes.
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Chapter 1
Introduction
Male breast cancer (MBC) is a rare disease, accounting for only 1% of all breast cancers (BC)
in Portugal [1] and in the USA [2] and 0.5% in the Nordic countries [3]. Its incidence has risen
over the past 25 years [4–7], from 1.0 per 100,000 in the late 1970s to about 1.2 per 100,000
in 2000-2004 [5], with an increasing interest on this subject, even though representing less than
0.5% of all cancer deaths in men annually [8].
Due to its rarity, no randomized trials have been conducted, with only one prospective study
published [9] and most knowledge still come from retrospective studies that cover several decades
[10], different geographic regions [11], and different patients’ approaches. Because of that, treat-
ment recommendations remain extrapolated from female breast cancer (FBC) trials, although
there are already many differences between the two diseases [12, 13].
Male are often older at diagnosis (67 vs 62 years) [12–19], presented with a painless subare-
olar lump, mainly in left breast and rarely in the upper outer quadrant [13, 20] that may involve
nipple retraction or bleeding [10, 21]. The majority of them have ductal carcinomas [22, 23] that
express hormonal receptors (estrogen receptor, ER: 91-95% vs 76-78% and progesterone re-
ceptor, PR: 80-81% vs 67% in male and female respectively), with lobular tumours being less
common in male [13, 24]. Black males seem to be more affected to this disease, compared
to white (ratios from USA, 1 male: 100 female in whites and 1:70 in blacks), and black race is
also associated with poor prognosis after adjust for clinical, demographic and treatment factors
[12, 25].
About 15-20% of male with BC have a family history of the disease, compared to only 7% in
general male population [13]. Genes involved in breast and ovarian cancer, BRCA1 and BRCA2,
inherited in an autosomal dominant pattern, are though to account for 80% of multiple-case breast
cancer families. Germline BRCA2 mutations have been reported in 4-14% of MBC patients, while
BRCA1 mutations are less frequent, occurring in up to 4% of these patients [26–32]. The highest
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prevalence of BRCA2 mutations in MBC patients is registered in Iceland where a founder mu-
tation is present in 40% of them [33]. The lifetime risk of developing breast cancer associated
with these mutations is inferior from that observed in female patients: 1-6% from BRCA1 and
7% from BRCA2 in female [34–36] and in the male population 0.1% [3, 35]. Male patients with
BRCA2 mutations seem to have BC in younger age and may have poorer survival [37]. Other
investigated genes that do not have a causal association with MBC disease are the androgen re-
ceptor gene, PTEN (Cowden’s syndrome), mismatch repair genes (hMLH1), BRIP1 and RAD51C
[38–43], with mixed data for PALB2, CHEK2 and CYP17 [29, 44–51]. Other risk factors related
to MBC are conditions associated with imbalance between estrogen and androgen, such as the
Klinefelter’s syndrome (resulting in a 50-fold increased risk) [52, 53], testicular abnormalities that
cause testosterone deficiency [52, 54], liver diseases [55], obesity [52, 56–58] and exogenous
estrogen exposure [59, 60], previous exposure to chest wall irradiation, like in patients with past
history of Hodgkin disease [25], history of breast trauma and nipple discharge [25, 54].
Having in mind these differences between MBC and FBC patients, studies in MBC setting are
warranted to define the best approach for these patients in the era of personalized medicine.
1.1 Objectives and Organisation of the Thesis
Nowadays MBC treatments are still extrapolated from FBC standards although many studies
had suggested that male patients present distinct aspects from females that could justify specific
approaches.
The present work addresses prognostic and predictive factors of response to endocrine ther-
apy, trying to define features with clinical relevance that could help in daily practice decisions.
The look for a better knowledge of this disease was assessed by specific objectives:
− The assessment of prognostic factors (related to patients, tumours and/or treatments per-
formed);
− The evaluation of the relations between these prognostic factors;
− The identification of new patients’ prognostic subgroups based on a routinely ImmunoHis-
toChemical (IHC)-panel;
− The characterization of recurrence as an important prognosis determinant;
− The assessment of the clinical relevance of CYP2D6*4 polymorphism in the efficacy of
response to adjuvant endocrine treatment (tamoxifen).
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Additionally, other topics were considered important for the present work and in the prepara-
tion of future developments:
− The construction of a flexible framework that allows clinicians to define the variables that are
important in patients’ characterization, enabling also basic data storage operations (insert,
edit or remove data) and finally export these data to standard formats such as excel or
SPSS;
− The identification of the better machine learning techniques to define patterns of BC recur-
rence.
According to the proposal and to integrate all the contents of this work, the thesis is organized
in three main chapters that come out after an introduction chapter. Chapter two is divided in two
sections dedicated to prognostic analysis and chapter three focuses on a potential predictive
factor to response to adjuvant endocrine therapy (tamoxifen).
A brief summary of the contents by chapter, is presented below:
Chapter 1 presents an overview about MBC disease, the description of PhD objectives,
organization of the thesis and a brief dataset description.
Chapter 2 is dedicated to prognostic analysis. In the first section, the principal prognostic
factors in these patients are addressed and new BC subgroups based on a six- IHC panel are
defined. In the second section, a recurrence analysis is described.
Chapter 3 concerns to the role of CYP2D6*4 polymorphism as a potential clinical marker of
response to tamoxifen.
These main chapters (2 and 3) start with a state of the art related to the analysed theme.
Chapter 4 presents the final remarks and future perspectives, highlighting the principal find-
ings of this work, and proposing future developments.
In order to perform a truly translational research that represents the holistic approach of can-
cer patients with the guarantee of high quality standards, this work was developed in partnership
with Serviço de Anatomia Patológica do IPOPFG, Grupo de Oncologia Molecular IPOPFG and
Laboratório CISUC, Departamento Engenharia Informática da Universidade de Coimbra.
1.2 Dataset: Brief Description
The work dataset comprised all MBC patients treated at Instituto Português de Oncologia do
Porto, Francisco Gentil EPE (IPOPFG), during 1976-2014 (115 patients), with age over 18 years,
histological confirmation of BC and minimum follow-up of one year.
The number of patients and the time periods analysed were fit according to the research
objectives and will be explain in the following paragraphs.
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In the first approach, clinical data were collected from files and presented in an international
meeting (European Society of Medical Oncology congress, ESMO congress 2012). In that time,
only patients treated until 2011 were considered, and there were no pathological revision of the
cases. This first analysis allowed the planning of the future research namely the elaboration of a
list of cases that did not underwent breast surgery in IPOPFG and so, after that many letters were
send to other laboratories to ask the blocks for central pathological revision in IPOPFG. From the
majority of subsequent works, time period considered were 1980-2014, for a total of 111 eligible
patients with a median follow-up of 5.5 years. The patients’ characteristics are presented in Table
1.1.
Patients presented a median age of 66 years, were previous or active smokers in 36.1%,
alcohol consumers in 44.8%, being over-weight or obese in 66.7%. BRCA2 mutation was present
in 8.3% and 12.5% developed a second malignancy, prostate cancer predominantly. Five-year
overall survival was 68.8%.
It was possible to do additional IHC markers (total of six markers) in 95 patients that had
tissue blocks available. With this information, unsupervised hierarchical clustering was performed
to look for new MBC subgroups, described in chapter 2.
In the relapse analysis, we selected all recurrent cases (27 cases) from the population of 111
patients. Twenty-three were considered eligible for the study (had complete information about
adjuvant and palliative treatments) and were matched with 69 FBC cases treated in the same
Institution, in the same time-period, with the same stage and with controlled age (± 5 years).
The CYP2D6*4 polymorphism study, chapter 3, was performed based on blood or tissue
sample from patients treated with adjuvant tamoxifen (53 patients), between 1992-2012.
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Table 1.1: Patients and tumours’ characteristics
Characteristics n Frequency (%)
Patients’ age ≤ 60 years 35 31.5
n=111 > 60 years 76 68.5
Histological type Ductal 99 90.1
n=111 Papillary 3 2.7
Lobular 1 0.9
Mixed 7 6.3
Grade 1 14 13.7
n=102 2 62 60.8
3 26 25.5
Tumour size ≤ 2cm 48 43.2
n=111 >2cm 63 56.8
Nodal status N0 43 38.7
n=111 N+ 68 61.3
Stage* I 25 22.6
n=111 II 29 26.1
III 49 44.1
IV 8 7.2
Estrogen Receptor (ER) Positive 107 96.4
n=111 Negative 4 3.6
Progesterone Receptor (PR) Positive 99 89.2
n=111 Negative 12 10.8
Androgen Receptor (AR) Positive 72 63.7
n=95 Negative 23 20.4
HER2 Positive 9 8.1
n=111 Negative 102 91.9
Ki67 Low 65 57.5
n=95 High 30 26.5
p53 Low 75 66.4
n=98 High 23 20.4
Surgery Yes 107 96.4
n=101 No 4 3.6
Adjuvant chemotherapy Yes 44 42.7
n=103 No 59 57.3
Adjuvant endocrine therapy Yes 86 83.5
n=103 No 17 16.5
Adjuvant radiotherapy Yes 71 68.9
n=103 No 32 31.1
* According to 7th edition of American Joint Committee on Cancer
(AJCC) staging.
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Abstract
Electronic Healthcare Systems have come to represent an important role in medical in-
stitutions, helping physicians and professionals in their activity. However, some of these
systems present some drawbacks, such as context-dependency; inability to support
knowledge extraction; and are sometimes developed without consulting the profession-
als that will use them, leading to low acceptance and use levels.
In this paper, we propose a flexible system that is context-independent, allowing any
physician to define the system’s working environment, thus being able to be used in any
service or department of a healthcare unit. The personalization capabilities allow it to
adapt to the needs of a team or person, promoting acceptance as well as collaborations
through the system.
The developed framework was tested by a team of 7 oncologists interested in studying
male breast cancer. The results are very promising, with high user satisfaction levels,
as well as system usability and performance levels.
Keywords: Flexible Healthcare System, Personalizable Healthcare System,
Personalized Queries, Digital Medical Records
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1 Introduction
An Information System (IS) can be defined as the overall information processing in
an organization, including the involved human players and the used information tech-
nology [1]. Recent advances in the technological field lead to a propitious context for the
developing of IS in healthcare environments, reducing clinical error, supporting health-
care professionals, increasing the efficiency of care or/and improving the quality of
patient care [2] [3].
Historically, and following Haux’s work [4], the evolution of IS in healthcare environ-
ments can be synthesized in seven direction: (1) from paper-based records towards
computer-based information storage and processing tools [5] (this migration was not
universally followed as illustrated below); (2) from local to global information system
architectures that include not only systems enclosing multiple hospital centers but also
changing the paradigm of the information system itself to a more patient-centered ap-
proach rather than an institution-centered approach [6]; (3) from healthcare profes-
sionals to patients and consumers, which reflects the need to provide support to more
actors than just healthcare professionals [7]; (4) from using data solely for patient care
towards supporting healthcare planning and clinical research [8]; (5) from technical to
strategic information management priorities emphasizing that the main problem today
is not technical but it encompasses organizational, social issues among others; (6) to-
wards including new types of data related to the appearance or improvement of new
exams/analysis [9]; and (7) towards ubiquity and the inclusion of new devices for data
collection and health monitoring.
In spite of such research works, many success and failures stories have composed
the spectrum of IS in healthcare [10]. In this particular topic, one question can arise:
how can the success of an IS be measured? Success, like failure, is a multidimensional
and contested concept [11]. Following Delone and McLean (two of the most cited au-
thors) [12], success can be classified in six dimensions: Information quality, system
quality, information use, user satisfaction, individual impact and organisational impact.
Ten years later, the same authors [13] updated their model presenting information qual-
ity, system quality, service quality, intention to use, user satisfaction and net benefits as
new dimensions to evaluate success in IS (a full revision work about this topic can be
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found in [14]).
One of the consequences of low IS acceptance levels is the use of ad-hoc databases
by the physicians for their research works, either directed towards a scientific publi-
cation of certain medical findings or simply to understand the reality of a particular
unit/service. However, this brings forward several drawbacks: since physicians are not
technically qualified to use more advanced tools, these databases are usually built us-
ing simple tools, not adequate for the task at hand; it is very hard to maintain these
databases up-to-date because they are frequently stored in a single computer, without
distributed/online access and in many cases only few physicians know of its existence;
patient characterization is based on the expertise of one physician (or a small group of
physicians), which means that if the characterization changes, the clinical files will need
to be revised again and a new file will be produced to conduct new studies.
To increase physician satisfaction, a flexible and fully configurable Clinical System
(CS) is proposed in this paper. A CS (sometimes called Department Electronic Medical
Record [15]) is a system that is a specialized service for a specific department [16].
As the system was developed in partnership with the department of medical oncology
of the Portuguese Institute of Oncology of Porto (IPO-Porto), one case was used for
the initial validation of the system: Male Breast Cancer. IPO-Porto is a tertiary cancer
center that treats more than 10.000 new patients per year. In Portugal (a country with
a population of approximately 10 million), there are more than 150 IS spread over 104
public healthcare institutions [17]. However, despite some institutions having more than
one IS being used at the same time (85% in 2011), half the information produced in hos-
pital units was in traditional paper format, and professionals usually prefer to maintain
their patient’s records in physical files, even if the digital information exists [18]. There
are several possible explanations for that fact: systems do not cover all the needs of
the clinician in his daily practice; in some cases the multiple systems in use are unable
to communicate with each other; the computational demands of the systems are some-
times too high for the available computers in the hospitals, thus turning the use of the
system into a time-consuming task; the rotation of different systems in a specific unit
(typically this change occurs every 3 years); or the need of specific training to be able to
proficiently use this type of systems (as these systems are not developed by clinicians,
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most of the operations are not too intuitive).
The main goal of this project it to provide physicians with a framework that allows
them to manage patient records in a simple and intuitive manner. This system presents
the following functionalities (these functionalities and others are fully described in sec-
tion 3:
• Automatic Database Model Creation. When using the developed tool, the database
model is automatically created during a file import operation or by specifying vari-
ables and relationships between them;
• Creation of Personalized Queries. Users can create their own queries by picking
the variables involved in the query and a set of logical operators to specify selec-
tion and presenation restrictions on the data. The framework also allows for these
queries to be shared with other professionals.
• Data Import/Export from other sources. The developed tool is able to import/ex-
port data from/to Microsoft Excel (probably one of the most used software tools)
and IBM SPSS software.
To the best of our knowledge, this constitutes the first effort to propose and develop
a flexible CS.
All project phases followed the general recommendations proposed by Ammenwerth
et al. [3] as well as the design-reality gap model [19] and the evaluation was inspired by
the framework proposed by Delone and McLean [13] (for a full revision on the evaluation
topic please consult [20] [16]).
The developed framework was tested by a team of seven oncologists for a period
of three months, and was then evaluated in terms of user satisfaction, system usability
and system performance.
The results show that the physicians were satisfied with the system, as it was rapidly
ready to use in accordance with the specifications they came up with. The versatility
and flexibility of the system are pointed out as some of the main features that contribute
to its acceptance.
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In the future, the goal is to expand this concept to an IS in a central hospital facility
promoting its use by the physicians, also promoting data and knowledge sharing across
departments.
The rest of this article is structured as follows. Section 2 describes some of the
related work done in the context of IS in healthcare, and in particular those developed
targeting a specific service. Section 3 describes the proposed system architecture and
the modules that compose it. Section 4 presents the system evaluations, in terms of
user satisfaction, system usability and performance. Finally, in section 5, the main
conclusions from the developed work are drawn and some pointers for future work are
provided.
2 Related work
There are several literature review works that clearly illustrate the past, present and
future directions in this area (Gunasekaran et al. [21]; Murphy et al.[22]; Yusof et al.
[16]; Fichman et al.[23]). In this section, a set of works englobing different pathologies
will be described.
Jordan et al. [24] developed a system called MAGIC that helps clinicians in the
detection of two classes of abnormal events related to hemodynamics (that includes
episodes of hypotension, hypertension, bradycardia, and tachycardia) and by labora-
tory results (including acidosis, alkalosis, hypercardia, hypoxia, low saturation, hypona-
tremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, ane-
mia, hypoglycemia, and hyperglycemia).
Monitoring patient information during surgery, such as vital signs, inhaled anesthet-
ics or ventilation parameters, among others and using several well-known scores, such
as Acute Physiologic and Chronic Health Status Evaluation, Multi-organ System Illness
Score and the therapeutic Intervention Severity Score, this system was able to detect
the two event classes.
At the end, the performance of MAGIC systems was compared with 46 clinicians
using 24 patients as the test set. The system presented very good accuracy in the
laboratory results (more than 95%); however, some differences were detected in com-
parison with the clinicians related to hemodynamics events, and should be a point to
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revise in the future.
Slater et al. [25] constructed a system that supports four levels of coding (non-
operative or post-procedural admission, diagnostic group, specific condition and for
injury and infection the aetiological factor) related to the reasons for admitting children
to intensive care. More than 19.000 children admitted in intensive care from the period
between 1997-2000 in New Zealand and Australia were enrolled in this study, with two
diagnoses detected in 61% of the cases, three diagnoses in 29%, four diagnoses in
13%, five diagnoses in 6% and finally, six diagnoses in 3% of the cases.
Cimino et al. [26] developed an ambulatory record application called DOP (Decision-
supported Outpatient Practice System). In its application, they support some services
like progress notes, review of reports from ancillary systems and health maintenance
reminders. This system uses the Medical Entity Dictionary composed by more than
67.000 terms to help physicians find relationships between used terms and to maintain
a controlled terminology in patient records. These terms were divided into five groups:
patient problems, adverse reaction, new medication, existing medication and medica-
tion modification. To evaluate the system, 27 different users (8 attending physicians,
18 resident physicians, and 1 nurse) used the system, in order to identify how physi-
cians deal with controlled terminology in a system. The users tried to add 238 terms,
151 related to medication. In almost 70% of the 151 cases, these terms are related
to adding dose route and dose frequency information. At the end, and in spite of the
fact that the authors detected some important lines of improvements (e.g sometimes
the user makes mistakes due to some lack of terms), they claimed that this application
constitutes an important contribution to the area.
Kinn et al. [27] presented an Electronic Medical Record (EMR) tool for cardiac pa-
tients. This tool stored medical information and allows physicians to produce some data
queries. After some developments they decided to merge the EMR tool with a new one
called Virtual Lipid Clinic, capable of monitoring cholesterol in enrolled patients. This
tool extracts key elements from data stored in the EMR tool and, most importantly, it
provides timely online alerts when the signals of the patients come outside the range
of the pre-established guidelines. At the end, two main groups were constructed and
divided: the first is the control group (the patients that are exclusively followed by pe-
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riodical consultations and whose data is stored in paper – n=764) and the test group
(the patients that have periodical consultation and whose data is stored in the EMR tool
and monitored by the Virtual Lipid Clinic – n=1109). The final results showed that the
cholesterol of the test group patients presented better values and statistical significance
in comparison to the control group patients.
In conclusion, in spite of the fact that many EMR have been developed for many
pathologies, some issues still remain. First, these systems are developed for a specific
domain, which means that if a new physician wants to use it for a new context (a new
pathology, for instance) it will not be possible, mainly because the system presents
specificities inherent to the primary domain. Also, and even when the physicians help
in the development phase (e.g. selecting the variables to be included in the system),
after the development it is not common to be able to update the set of variables that is
included in the system. These two issues were addressed in the solution proposed in
this paper.
3 Project Architecture
This section describes the project architecture, and the modules that comprise the
system, using the male breast cancer as the running example. The proposed system
is organized in three layers, as shown in Fig. 1.
The system supports two types of users: system administrators, responsible for
managing the system itself and the other users; and physicians, who use the system in
support of their daily activities. The Interface layer contains two front-ends, one for each
type of user, and each of which providing access to different modules on the Logical
layer of the system. The Administrator front-end provides access to the system and
user management modules, while the Medical front-end provides access to the Patient
Management module, the communications module and the search engine module. All
these modules require access to the system database.
3.1 System Administration
The administrator is responsible for defining the system model that will support all
physician activities. He has access to the system definition module (for system config-
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Figure 1: Global System Architecture
uration) and to the user management module, described below. The system interface
is made so that these administrative responsibilities can be performed by a physician,
and not necessarily by an informatics expert.
3.1.1 System Definition
The proposed approach uses a dynamic database phylosophy, where tables and
relashionships in a relational database are created dynamically as the model is defined
by the system administrator, attempting to mimic the model a database engineer would
come up with if modeling the specific reality.
The overall idea is based on a hierarhical variable definition. Variables can either
be simple (in which case, we’ll refer to them as fields) or compound, in which case they
can contain other variables. This structure allows for everything to be interpreted as a
variable, from patients to simple fields.
A patient, the main variable of the system, is defined as comprised by a set of
variables, each of which corresponds to a report on the patient (such as surgery report,
pathological report, and so on). Each of these reports is itself a variable, composed
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by other variables, which can be fields or compound variables (which act as groups of
variables).
From a more technical perspective, each compound variable is stored in the database
as a table, while fields are stored as columns in the table corresponding to the variable
containing the field. A set of relationships can be defined between variables, as to
express how they relate to each other:
1. One-to-many relationships. A column is added to the table on the many side of
the relationship that references the table on the one side of the relationship. For
instance, a patient can have many blood pressure (BP) measurements (which are
defined as compound variables having the test date, values, and other possible
variables or fields), but each BP measurement belongs to one patient only.
2. Many-to-many relationships. A new intermediate table is created to store the re-
lationship between the two variables, including the value and references to both
variables. This kind of relationship can be useful for shared information. A typical
example is geographical area information, such as the postal code. Since more
than one patient can share the same postal code, and to avoid information re-
dundancy, the intermediate table allows for the variable to be shared by several
patients.
All these relationships, as well as information regarding each of the variables, are
stored in one table, named the Master Variable Control Table (MVCT), which allows for
a centralization of this information, along with a reduction of processing costs during
database operations (including interface generation). Table 1 shows the structure of
this table, and the information it contains.
Table 2 shows an example of the MVCT with a variable (Epidemiological Data) con-
taining three other variables (Age, Family History and BRCA2 Mutation).
Figure 2 shows the interface used to define such information.
3.1.2 User Management
User management is based on the concept of users and user groups on one hand,
and variables on the other. User groups are used to group users with similar charac-
teristics (for instance, all chemotherapists are grouped together), in order to facilitate
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Table 1: Master Variable Control Table
Field Name Field Description
id Variable unique ID
pid Parent Variable ID (if any)
name Name of Variable
type Data Type
rel Relationship with Parent
min Minimum value (if applicable)
max Maxiimum value (if applicable)
default Default Value
format Accepted Formats
order Order during Form Generation
optional Variable Mandatory or Optional
target Variable alias target
notes Human-friendly Notes
cond Variable visibility in Form
user management. The system creates a permission matrix from existing variables and
existing users and groups, thus allowing the administrator to define which variables are
editable by each user. Associated with user management appears the concept of view,
which consists in pre-configured work desktops or dashboards associated with users or
user groups. If a user has no views associated to him, a standard generic view is used,
automatically generated with all variables he has access to. Customized views can be
used to provide access to more variables than the ones the user has permissions to
edit (in this case, the view will provide read-only access to those variables) or to restrict
the variables the user can see.
3.2 Medical Perspective
The system provides three main modules to be used by physicians: Patient Man-
agement module, Search Engine module and Communications module.
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Figure 2: Example Interface
3.2.1 Patient Management
This module provides physicians with functionalities to deal with patient records,
allowing them to list, search, create, view and edit patient details.
Given the generic and dynamic nature of the system, the user interface cannot
be predefined, but needs to be automatically generated from the information in the
database. This interface is based on the concept of nested forms, where each form
corresponds to one compound variable, as illustrated in Fig. 3a.
To facilitate user interaction, avoiding unnecessary long forms, nested forms are
initially collapsed, and can be expanded or collapsed again as the user navigates the
form.
Attending to the constraints on each variable and field, the form generator creates
the appropriate form element (text area, multiple selection fields, and so on) to display.
In the case of variables linked by one-to-many or many-to-many relationships, a table is
added to the form with the existing values, so that one (or more) can be selected for the
patient, or a new one can be created. Figure 3b shows an example of a form generated
by the interface generator, including the interface for the example presented above for
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(a) Nested Forms (b) Example Interface
Figure 3: Interface Generator
the Epidemiological Data variable.
3.2.2 Search Engine
The system provides full support for creating and sharing personalized queries. In
the developed system, the administrator can provide some pre-configured queries to be
available to all users, and physicians can create their own personalized queries, as well
as share them with other users. A personalized query is defined as a set of variables to
select, associated with possible group options (such as ’show results grouped by gen-
der’); a set of filters that define the patients whose records will be used to retrieve and
compile the data (e.g. ’all patients above 65 years’); and possible grouping operations
(such as averaging variables). The system transforms this configuration into a query to
be made on the database, and stores the query configuration so it can be reused in the
23
future, or shared with other physicians. Figure 4 shows an example of a personalized
query (one created by the administrator and shared with all users), in this case for the
overall survival of male breast cancer patients.
Figure 4: Overall Survival in Male Breast Cancer Patients
3.3 Communications
The system provides two means of internal communications between users: private
messages and forum. Private messages can be send to a single or multiple recipients.
User groups are used as a basis to send messages to multiple recipients, and the
system provides functionalities similar to those of a regular e-mail client (such as reply,
reply to all, forward, delete). Selected information from user profiles can also be used
to select multiple recipients (for instance, all users who belong to a certain department,
or have a certain specialization), which provides extra flexibility to the module.
The forum provides regular functionalities, with the additional feature of providing
group-based access control without the need of further configurations: user groups
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created for user management are automatically mapped into sections of the forum ac-
cessible only by users in that group. Additionally, some selected information from user
accounts (such as department and hospital unit) is also used to automatically create
and grant access to specific sections of the forum. This avoids the need to manually
create these groups, all the while still allowing new sections and sub-sections to be
created by the users.
4 System Evaluation
The system was made available to the breast cancer unit in IPO-P where it was
used by a team of physicians composed by 7 oncologists interested in studying the
male breast cancer pathology.
In an initial stage, a team comprised by the 7 oncologist and the specialists who
developed the system was assembled, and for a period of four weeks the group brain-
stormed, created and fine tuned a model for the system (this model is the set of vari-
ables and its structure, and is organized in the form of a clinical record, for familiarity
reasons). After that, the system was configured for the specific pathology, and data from
the first 12 weeks of use of the prototype system has been collected and analyzed.
At the end of this period, the system was evaluated, attempting to determine user
satisfaction, system usability and system performance.
4.1 User Satisfaction
To evaluate the user satisfaction, two different strategies have been used. The first
strategy consists in identifying the number accesses and operations performed in the
system. The second one consists in user satisfaction questionnaires.
The number of system operations was collected and divided into 5 categories, as
shown in Fig. 5.
We can see that insertions happen only in the first 5 weeks, when the oncologists
inserted the 100 patients into the system. The number of edits to patient records was
also higher in the first few weeks (possibly made after the insertion) and then stabilized
to approximately 2 edits per day. Patient record views has a similar behavior. Regarding
the creation and viewing of personalized queries, 14 queries were created during the
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Figure 5: Number of system access
operational test phase, most of them between weeks 2 to 6. The number of query views
was also higher during these weeks, stabilizing afterwards at about 7 query views per
week in the last weeks.
These results seem to indicate that after an inicial period of records creation, system
use stabilizes to ’normal’ levels. It should be noted that in the test context, there are no
new patients to handle, and thus patient insertions were effectively over at the end of
the fifth week.
4.2 System Usability
In order to evaluate system usability, users were once again faced with a question-
naire aimed at ascertaining the level of usability for the system. The Computer System
Usability Questionnaire (CSUQ) [28] was used to evaluate system usability. The ques-
tions that comprise the CSUQ are shown in Appendix Appendix A, and Table 3 shows
the obtained results for each question.
The overall CSUQ score was of 5.52, with a value of 5.61 for the System Usefulness
sub-scale, 5.37 for the Information Quality sub-scale and 5.52 for the Interface Quality
sub-scale.
Regarding the individual questions, most of them (16 of 19) obtained a median of 5
(out of 7) or higher, which constitutes good results. At this point it is import to highlight
that 10 questions present a median of 6 or higher. However, some questions obtained
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Table 3: CSUQ Results
Question Median Semi-Interquartile Range
1 6 0.5
2 6 0.5
3 4 0.5
4 5 0.25
5 5 0.5
6 6 0.75
7 6 0.5
8 5 0.5
9 3 0.75
10 3 0.75
11 6 0.75
12 6 0.5
13 7 0.25
14 5 0.75
15 6 0.5
16 7 0.5
17 5 0.75
18 5 0.75
19 6 0.25
lower classifications, and in particular 2 questions (questions 9 and 10) presented a
median of 3. These two questions are related to the output that the system generates
in an error situation, which attending to the achieved results should be a point to improve
in the future.
The oncologists were also asked to point out positive and negative aspects regard-
ing the system. The most cited positive aspects include the concept of views (this
concept, previously explained, was considered one of the key features of the system,
given the levels of personalization it provides); custom queries (the majority of the re-
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spondents mentioned this feature also as very helpful); data export capabilities (the
possibility to export the data to excel was also considered a key feature, as it allows the
clinicians to use the data on further studies without much effort in compiling or prepar-
ing the data). As negative aspects, the oncologists refer design issues (such as color
scheme, size of text and action buttons, and color of some icons); the several steps
necessary to create a custom query (respondents suggest that this process should be
made easier).
4.3 System Performance
System performance was evaluated by measuring access times to the system, and
operational demands.
Table 4 shows the results regarding load times for two pages (the Login Page (LP),
which is the first page of the system; and the Authenticated Page (AP), which shows the
authenticated user his View to the system) in two situations (First View, which means
that all resources are loaded from the web; and Repeat View, which means that most
resources are already cached and no download is necessary). These results were ob-
tained using the WebPageTest tool (WebPageTest is an online website performance as-
sessment tool, available at http://www.webpagetest.org/) and Mozilla Firefox Devel-
oper Tools (More information available from https://developer.mozilla.org/en-US/
docs/Tools).
The results show that page load times are within normal webpage load times, and
that, as expected, repeat views have much lower load times, since most resources are
already cached. Figure 6 shows the number and total size (in KB) of the requests
necessary to load the authenticated page of the system for the first time. As can be
seen in Table 4, for the following page loads, the number of requests decreases from
36 to 2, and the total size decreases from 1.7 MB to 31 KB, which translates into lesser
network demand during system use.
5 Conclusions and Future Work
In this work, a flexible framework to support different departments inside a health-
care institution was proposed. With this tool, a team of physicians can characterize
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Figure 6: Number of Requests and Bytes Transfered for the Authenticated Page (First View)
their patients and control all this information using personalized views of the system,
thus allowing them to manage this data in a more suitable and personalized manner.
The system is context-independent, which means that it can easily support every de-
partment, allowing each physician of each department to have customized views of the
system and data. This tool also supports the creation of personalized queries over the
data, providing physicians with a intuitive manner to create and share these queries,
and possible new information that can be extracted from them, with other physicians.
To the best of the author’s knowledge, this is the first tool that allows for a full customiza-
tion of both the system model and queries executed on the defined system model.
The implementation was tested with a team of 7 oncologists from a service inter-
ested in studying male breast cancer. After an initial setup, the oncologists’ use of the
system was monitored, as to extract some information. Results show that the use of
the system is consistent with the expectations, and the users show high levels of satis-
faction with it. Usability was evaluated with a standard questionnaire that showed the
users to believe the system has high levels of usability. Also, system performance was
evaluated and the results show that the system has standard performance levels for a
website.
Some aspects have been identified as improvements to the system, to be imple-
mented in the future. Most of these are related to the design and usability of the user
interface, as detected by the physicians. Other points have also been identified, such
30
as the diversity of formats supported for data import/export.
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Appendix A CSUQ Questions
Table A.5: Questions of the CSUQ
Number Question
1 Overall, I am satisfied with how easy it is to use this system
2 It was simple to use this system
3 I can effectively complete my work using this system
4 I am able to complete my work quickly using this system
5 I am able to efficiently complete my work using this system
6 I feel comfortable using this system
7 It was easy to learn to use this system
8 I believe I became productive quickly using this system
9 The system gives error messages that clearly tell me how to fix problems
10 Whenever I make a mistake using the system, I recover easily and quickly
11 The information (such as online help, on-screen messages, and other
information) provided with this system is clear
12 It is easy to find the information I needed
13 The information provided for the system is easy to understand
14 The information is effective in helping me complete the tasks and scenarios
15 The organization of information on the system screens is clear
16 The interface of this system is pleasant
17 I like using the interface of this system
18 This system has all the functions and capabilities I expect it to have
19 Overall, I am satisfied with this system
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Chapter 2
Prognosis
Classically, there is the misperception that MBC is an inherently aggressive disease, associated
with a poor outcome [1–5]. However, the unfavourable prognosis of these patients has been
attributed, in recent years, to important factors not controlled in previous publications [6–13],
namely age and stage [14]. Other implicated factors in MBC patients’ outcomes were: comorbid
conditions [15], delay in diagnosis [16] or even differences in tumour biology [1]. For example, in
a 1941 study [17] the average in diagnostic delay was 29 months, in 1995 the mean duration of
symptoms was 21 months [18], and it remains in more recent series with a mean of 6-10 months
[19, 20].
The principal large series that compared survival between the two genders are summarized in
Table 2.1, and present conflicting results even when important prognostic factors were matched.
Having in mind that BC is a heterogeneous disease, it is important to understand which
factors really affect prognosis and should be matched when comparing outcomes for MBC and
FBC.
As in female, tumour size and lymph nodes involvement are the most consistent prognostic
factors described in MBC patients [18, 25–33]. Males with tumours measuring between 2 and
5 cm have a 40% higher risk of death than those with smaller lesions and patients with nodal
involvement have a 50% higher risk of death than dose with N0 disease [14]. Ten-year breast
cancer specific-survival (BCSS) for N0 was described as 77-84%, for N1: 44-50% and for N2: 14-
14%. N+ disease is more prevalent in MBC patients [33], and was also reported in small (≤2 cm)
and hormonal receptor positive tumours, which means that this disease cannot be considered an
indolent one, a priori [35].
The prognostic relevance of histological grade is contradictory [14, 36, 37], with some studies
reporting the association between high grade and poor prognosis [36] while others have not state
it [14, 37]. Tumour grading is not always simple to assess and inter-observer discrepancies are a
major concern [35].
35
Table 2.1: Comparison of survival outcomes between genders
Reference n, male n, female Matched factors Results
Scott-Conner
CE, et al.
1999 [21]
4755 624174 Age, stage. Similar relative OS, trend
toward worst survival in
male with stage III/IV.
Giordano SH,
et al. 2004
[14]
2524 380856 Age, stage. Similar relative OS.
Miao H, et al.
2011 [3]
2665 459846 Age, year of diagnosis,
FU time, stage, treat-
ments.
Better relative BCSS for
male. Inferior survival and
BCSS for men when pa-
tients were not matched.
Nilsson C, et
al. 2011 [4]
99 369 Age, year of diagnosis. Inferior relative and OS for
male.
Foerster R, et
al. 2011 [22]
108 108 Age, year of diagnosis,
N status, grade, stage,
HR expression, HER2
expression.
Similar OS.
Shaaban AM,
et al. 2012
[23]
251 263 Age, grade, N status Similar OS.
Gnerlich JL, et
al. 2012 [2]
1541 244518 Controlling for con-
founders
Inferior BCSS for men with
stage I disease. Inferior
OS for men with stage I-III
Greif JM, et al.
2012 [5]
13457 1439866 NA Inferior OS for male. Bet-
ter 5-year OS for women
stage I-II.
Chen X, et al.
2013 [1]*
150 300 Age, year of diagnosis
and stage
Inferior DFS and OS for
male.
Kwong A, et
al. 2014 [24]*
132 8118 Year of diagnosis,
stage, size, N status
Inferior OS for male but
better BCSS for male.
* Chinese population;
BCSS: breast cancer specific-survival; DFS: disease free survival; FU: follow-up; HR: hormonal
receptors; NA: not applicable; N status: lymph node status; OS: overall survival.
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In the majority of series grade 2 is the most often observed [14, 15, 38], perhaps because
these difficulties could be bigger in male since there is lack of normal breast tissue that is a
prerequisite to assessing nuclear atypia correctly. Other factors related to prognosis namely
breast cancer subgroups and relapse will be analysed in next sections.
2.1 Breast cancer subgroups
From the publication of Perou et al. [39] in 2000, we understand that BC is a heterogeneous
disease that could be divided into comprehensive subgroups associated with differences in treat-
ment response and outcome [40]. This first work was done using gene expression profiles to
define the intrinsic BC subtypes, that were translated thereafter into clinical practice using surro-
gate IHC markers [41–43], based on expression of a small number of proteins. This expression
correlates with the transcriptional subtypes in 75-90% [44].
Over the years, IHC-based subtypes changed, with the addition of new markers (namely
ki67) and redefinition of IHC markers cut-offs. Now we have already three definitions [44–46],
summarized in Table 2.2, with proved prognostic implications in FBC patients [39, 47, 48]. Basal-
like and HER2 subgroups display the worst prognosis and luminal A the best one, while luminal B
tumours have an intermediate prognosis probably related to less sensibility to endocrine therapy
compared to luminal A and higher proliferation [49–52].
Table 2.2: Definitions of FBC subtypes based in IHC markers
Luminal A-like tumours:
Definition I: ER and/or PR positive, HER2 negative;
Definition II: ER and/or PR positive, HER2 negative, low ki67;
Definition III: ER positive, PR positive*, HER2 negative, low ki67.
Luminal B-like tumours:
Definition I: ER and/or PR positive with/out HER2 positive;
Definition II: ER and/or PR positive with/out HER positive and/or high ki67;
Definition III: ER positive, HER2 positive and/or high ki67 and/or PR
negative*.
Triple negative (basal-like) tumours: ER, PR and HER2 negatives,
and sometimes also CK5/6 and/or EGFR and/or CK14 positive.
HER2-enriched: ER and PR negatives, HER positive.
*Based on a 20% cut-off for PR;
ER: estrogen receptor, PR: progesterone receptor, CK: cytokeratin.
Contrarily to female, only a few studies were conducted in male that addressed BC subtypes
and showed conflicting results, probably related to different IHC definitions used, without an
uniform distribution of patients by all subtypes [53, 54]. The most important studies are listed
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in the following table (Table 2.3). There was no study that has used the new definition of BC
subgroups in MBC patients, that was proposed by Prat et al. [46] with the redefinition of PR
cutt-off.
Most MBC patients have luminal-like tumours, and HER2 positive and triple negatives are
rare, indicating that FBC subgroups could not be linearly translated for male and could have a
limited relevance in these patients.
Many explanations were stated to justify the disparities between frequencies of classical FBC
subtypes in male. Luminal tumours in female patients are associated with older age and post-
menopausal status [48]. Like in postmenopausal women, there are only low levels of circulat-
ing estrogen in males. Most of the estrogen is synthesized in peripheral tissue and has local
effects in a paracrine or autocrine manner, which is important for the development of hormone-
dependent breast cancers and probably explains the high incidence of this type of tumours in
males [14, 54, 59, 60]. However, and even in luminal tumours, there were already documented
differences in molecular basis (DNA aberrations and gene expression patterns), implying that
MBC may be a distinct disease [37, 61]. Weber- Chapuis et al. [62], described that although
a larger fraction of male tumours were ER positive compared to female ones, they were only
weakly associated with antigens under estrogen control and more often positive for antigens un-
der androgen control, while the opposite was true for FBC. This support the rationale that not all
ER positive MBC tumours behave in the same way as ER positive in women, but rather seem to
share features with both ER positive and ER negative FBC. In the same line, Johansson et al.
[61] compared the global gene expression in MBC and FBC patients and identified two new sub-
groups in male, with half of them remain unclassified by the previous definitions: luminal M1 and
luminal M2. The luminal M1 consists in a more aggressive phenotype with a poorer prognosis.
Even though MBC tumours were mainly ER positive by IHC, there was a significant difference in
ER-related gene signalling between the groups, with luminal M1 displaying an inferior correlation
to ER-signalling. This is different from female, where only ER negative tumours are identified
with similarly reduced ER-signalling scores [35, 37].
Triple negative tumours, are associated with young women [48, 63] and BRCA1 mutations
[64, 65] and the low frequency of these tumours in men could be explained by higher age at
diagnosis and low frequency of BRCA1 [14, 59, 66–69]. HER2 amplified tumours were observed
in no more than 11% of male patients and the prognostic impact of this factor was not evaluated
[70, 71]. Cecilia et al. [35] showed that the majority of HER2 amplified cases in their male series
were IHC 1+ or 2+ and not 3+. It has been hypothesized that tumours, which are negative for
HER2 by IHC, but amplified by in situ hybridization, could be falsely IHC-negative due to epitope
loss during fixation [72]. Another alternative explanation could be that protein expression is not
as highly correlated with gene amplification in MBC [35].
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All of these findings could suggest that female subgroups do not adequately identify the ag-
gressive forms of MBC [23, 35, 54, 57], and accurate subtyping of MBC is essential to developing
an appropriate therapeutic strategy, ideally based on a IHC-panel clinical feasibly and repro-
ducible in routine practice.
Related Articles
Article 2 - Male breast cancer: looking for better prognostic subgroups (Unpublished) 2.1.1.
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Male breast cancer: looking for better prognostic subgroups
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Abstract
Purpose: Male Breast Cancer (MBC) remains a poor understood disease. Prognostic
factors are not well established and specific prognostic subgroups are warranted.
Patients/Methods: Retrospective revision of 111 cases treated in the same Cancer
Center. Blinded-central pathological revision with immunohistochemical (IHQ) analy-
sis for estrogen (ER), progesterone (PR) and androgen (AR) receptors, HER2, ki67
and p53 was done. Cox regression model was used for uni/multivariate survival analy-
sis. Two classifications of Female Breast Cancer (FBC) subgroups (based in ER, PR,
HER2, 2000 classification, and in ER, PR, HER2, ki67, 2013 classification) were used to
achieve their prognostic value in MBC patients. Hierarchical clustering was performed
to define subgroups based on the six-IHQ panel.
Results: According to FBC classifications, the majority of tumours were luminal: A
(89.2%; 60.0%) and B (7.2%; 35.8%). Triple negative phenotype was infrequent (2.7%;
3.2%) and HER2 enriched, non-luminal, was rare (≤1% in both). In multivariate analy-
sis the poor prognostic factors were: size>2cm (HR: 1.8; 95% CI: 1.0-3.4years, p=0.049),
absence of ER (HR: 4.9; 95% CI: 1.7-14.3 years, p=0.004) and presence of distant
metastasis (HR: 5.3; 95% CI: 2.2-3.1 years, p<0.001). FBC subtypes were indepen-
dent prognostic factors (p=0.009, p=0.046), but when analyzed only luminal groups,
prognosis did not differ regardless the classification used (p>0.20). Clustering defined
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different subgroups, that have prognostic value in multivariate analysis (p=0.005), with
better survival in ER/PR+, AR-, HER2- and ki67/p53 low group (median:11.5 years;
95% CI: 6.2-16.8 years) and worst in PR- group (median: 4.5 years; 95% CI: 1.6-7.8
years).
Conclusion: FBC subtypes do not give the same prognostic information in MBC even
in luminal groups. Two subgroups with distinct prognosis were identified in a common
six-IHQ panel. Future studies must achieve their real prognostic value in these patients.
Keywords: Male breast cancer, prognostic subgroups, survival
1 Introduction
Male breast cancer(MBC) accounts for only 1% of all breast cancers [1] with an in-
cidence of 63/100.000 in 2008 in Portugal [2]. Despite its rareness, the morbi/mortality
associated to this disease [3] has led to a progressive interest on it over the recent years
although its etiology and tumor behavior remain poor understood [4]. Female breast
cancer(FBC) is a heterogeneous disease and since its first comprehensive classifica-
tion into four subtypes proposed by Perou et al. [5] and translated thereafter to clinical
feasible and reproductive immunohistochemistry(IHC) markers, much has been learned
about tumours behavior and patients outcomes and how different patients should be
managed with a special attention for poor prognostic subgroups (triple negative and
HER2 enriched tumours). The transposition of these subgroups to MBC reality indi-
cates that they do not adequately identify the aggressive forms of MBC [6, 7, 8, 9] as
the classical triple negative and HER 2 positive groups are rarely described in male
setting. Even in the luminal group, there is an actual understanding that some of these
tumours in male, might not have an active estrogen receptor(ER) pathway although they
express ER in IHC analysis, leading to the question whether these patients respond to
endocrine treatment in the same way as female with luminal tumours [10]. For these
reasons, the relation between MBC subtypes and prognosis is not yet been stablished
[6] and new subgroups, based on the conjunction of a limited biomarkers panel clinical
feasible and reproductive, are warranted to better understand this disease and to pro-
vide the basis for optimal patient management [4]. The purpose of this study is to define
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the subgroups that better describe the prognosis of MBC patients using the definitions
already described to FBC and proposing a new one.
2 Patients and Methods
Study population comprised 111 cases of MBC treated in the same Cancer Center,
the Portuguese Institute of Oncology of Porto, during 1980 to 2012 (maximum follow-up:
23 years).
Patients’ information was retrospectively collected from clinical files and active follow-
up was used to ascertain prognosis in patients that have been discharged the Institu-
tion. To reduce the effect of time, time-dependent variables were adjusted or grouped
in main categories (stage was adjusted to 7th edition of AJCC Staging, and treatment
was grouped in categories).
Patients, or in case of death their substitutes, given written consent to participate on
the study. This study was approved for local ethic committee.
2.1 Histologic evaluation
One breast Pathologist centrally reviewed the HE slides. The histologic classification
was based on WHO criteria and histologic grade in the Nottingham system. IHQ study
for estrogen (ER) and progesterone (PR) receptors and HER2 was performed in all
cases. Additional study for ki67, androgen receptor (AR) and p53 was performed in
the cases with tissue blocks available. ER was considered positive if≥1% cells showed
nuclear staining [11], and for PR, two cut offs of positivity were used (≥1% [11] or
>20% [12]). Ki67 was interpreted as low or high by use a 14% threshold [13], p53 was
considered high if≥5% cells showed accumulation [14] and AR was considered positive
when at least 10% of nuclei were stained [15]. Cases were considered HER2 positive
when they are IHC-3+ according to the Dako score or FISH-amplified defined according
ASCO/CAPO guidelines [16]. This analysis was blind for clinical outcomes.
2.2 IHQ subtyping
Molecular subtypes based on two surrogate IHQ definitions were evaluated. For all
cases (111) and according to the classical definition initially proposed by Perou et al.
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[5] and adapted to clinic using surrogate IHC markers [13, 17, 18], we set the typing
standard groups: ER positive and/or PR positive(≥1%) and HER2 negative for luminal
A; ER positive and/or PR positive(≥1%) and HER2 positive for luminal B; ER and PR
negative(0%) and HER2 positive for HER2 enriched; ER/PR negative(0%) and HER2
negative for basal-like(triple negative). This classification is referred on the text as 2000
classification, see Figure 1. In the 95 cases where it was possible to validate the ki67,
Figure 1: Subgroups analyzed
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we compare the previous classification to the most recent one proposed by Prat et al.
[12] reclassifying the luminal tumours in luminal A when they are ER positive(≥1%),
PR positive(>20%), HER2 negative and low ki67 and luminal B when they are ER
positive(≥1%), HER2 positive and/or high ki67 and/or PR negative(≤20%). This clas-
sification is referred on the text as 2013 classification.
2.3 Statistical Analysis
In the 91 patients with complete information for the six IHQ markers, hierarchical
clustering was performed to define subgroups, as this tool has been already used in
MBC setting and was described as a potent one for subdividing breast cancer patients
into novel, clinically relevant groups [8, 10, 19]. For this purpose the linkage algorithm
was used and, as all markers were categorical variables(negative/positive), similarities
between patients were achieved by the jaccard distance measure. This analysis was
performed using statistical program R (http://www.r-project.org).
Differences between patients and tumours’ characteristics were evaluated with Pear-
son’s x2 for categorical variables. Survival analysis was performed using Kaplan-Meier
survival curves and Cox-regression model was used to achieve prognostic rule of dif-
ferent factors in uni/multivariate analysis. SPSS for windows version 15.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical calculations. P-values ≤0.05 were regarded
as significant.
3 Results
All patients were Caucasians, with a median age at diagnosis of 66 years-old (range
from 33 to 95 years-old), see Table 1.
The tumours less differentiated were more frequently associated with N+ disease,
p=0.005 (in grade 3 tumours, N0: 19.2% vs N+: 80.8%) and with p53 accumulation,
p=0.033 (p53 accumulation in grade 3 tumours was 47.6%).
The expression of ER was correlated with expression of PR, p<0.001(ER+ tumours
were also PR+ in 92.5%) and the absence of expression of hormonal receptors(ER
and/or PR), were associated with advanced stages p=0.006 and 0.024 respectively (in
ER-: stage III: 50%, stage IV: 50% and in PR-: stage III: 41.7%, stage IV: 25%). PR-
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Table 1: Clinical and pathological characteristics
Characteristics n Frequency (%)
Patients age ≤60 years 35 31.5
n=111 >60 years 76 68.5
Histological type Ductal 99 90.1
n=111 Papillary 3 2.7
Lobular 1 0.9
Mixed 7 6.3
Grade 1 14 13.7
n=102 2 62 60.8
3 26 25.5
Tumor size ≤2 cm 48 43.2
n=111 >2 cm 63 56.8
Nodal status N0 43 38.7
n=111 N+ 68 61.3
Stage* I 25 22.6
n=111 II 29 26.1
III 49 44.1
IV 8 7.2
ER positive 107 96.4
n=111 negative 4 3.6
PR positive 99 89.2
n=111 negative 12 10.8
AR positive 72 63.7
n=95 negative 23 20.4
HER2 positive 9 8.1
n=111 negative 102 91.9
ki67 low 65 57.5
n=95 high 30 26.5
p53 low 75 66.4
n=98 high 23 20.4
Surgery yes 107 96.4
n=101 no 4 3.6
Adjuvant
yes 44 42.7
chemotherapy
n=103 no 59 57.3
Adjuvant
yes 86 83.5
hormonotherapy
n=103 no 17 16.5
Adjuvant
yes 71 68.9
radiotherapy
n=103 no 32 31.1
*According to 7th edition of AJCC Staging;
ER- estrogen receptor, PR-progesterone receptor, AR-
androgen receptor.
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tumours were also associated with N+ disease(91.7%), p=0.024. The expression of
AR was related to PR expression, p=0.002 (AR- tumours were also PR- in 71.4%) but
not with ER expression, p=0.39. Patients with expression of AR frequently present low
values of ki67, p=0.006, and low accumulation of p53, p=0.046. Low ki67 was also
related to low accumulation of p53 (p=0.04).
Apart from the classification used (2000 or 2013), most tumours were luminal: A
(89.2%; 60.0%) or B (7.2%; 35.8%), respectively. Triple negative phenotype was in-
frequent (2.7%; 3.2%) and HER2 enriched(non-luminal) tumours were rare (≤1% in
both). The introduction of ki67 determination and PR negativity in the distinction of lu-
minal groups in 2013 classification, changed 26 patients (32.1%) from the luminal A to
luminal B group.
3.1 Cluster Analysis
Cluster analysis divided patients in three distinct groups (A, B, C), Figure 2. Clinico-
pathological features and IHQ profiles of the principle ones(A and B) could be seen in
Table 2. Positivity of ER and PR were considered if≥ 1% cells showed nuclear staining.
The C group was composed only for one patient that had a large tumour (>2cm), with
nodal involvement (N+) and no expression of any marker, and was not considered for
comparisons with the others, in Table 2. The patients included in the A group were char-
acterized by the absence of PR. Half of them did also no expression of ER or HER2,
which means that this group contained the other triple negative patient that differ from
that included in the C group by the positivity of AR.
In B group, all patients had luminal tumours (expressed ER and PR) and are distin-
guished in 2 subgroups by HER 2 expression: B1(HER2-) and B2 (HER2+). The B1
subgroup (HER2-) could also be subdivided in B1.1 (AR- and ki67/p53 low) and B1.2
(others). According to 2013 classification, in B1.1 there was only luminal A patients and
in B2 there was only luminal B. In B1.2 there was also luminal A (62%) and B (38%).
The expression of AR differed between these patients: in B1.1, all were AR-, in B1.2
97% expressed it and in B.2 all were AR+.
Patients in A group differed from those in B group only in IHQ profile, see Table 2.
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Figure 2: Hierarchical clustering of 6 immunohistochemical markers in 91 patients. The clustergram and
corresponding dendogram indicate relationships between patients and immunohistochemical markers.
ER- estrogen receptor, PR-progesterone receptor, AR-androgen receptor.
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3.2 Survival Analysis
Fifty-five patients(49.5%) died, with a 5-year overall survival of 68.8%.
In univariate analysis, the patients with better survival had tumours≤2cm (HR: 2.3,
95%CI: 1.3-4.2 years, p=0,005), with ER expression (HR: 5.1, 95%CI: 1.8-14.3 years,
p=0.002), and did not have distant metastasis at diagnosis(HR: 6.9, 95%CI: 6.9-16.4
years, p<0.001), see Table 3.
When analyzed only the group of non-metastatic patients, survival was also different
(p=0.028): stage I median: 20.0 years 10.9-29.1 years; stage II median: 9.8 years, 8.0-
11.6 years; stage III median: 7 years, 4.7-9.3 years, Figure 3.
N status and PR expression seem to define different prognostic groups, although
not statistically significant (N0 vs N+, HR: 1.8, 95%CI: 0.9-3.2 years, p=0.05 and PR
positive vs negative, HR: 1.9, 95%CI: 0.9-4.0 years, p=0.07). In multivariate analysis
tumour size, ER expression and presence of distant metastasis at diagnosis remained
independent prognostic factors.
The two classifications used defined four patients’ subgroups with different survivals.
In 2000 classification (n=111) median survivals were: luminal A (n=99): 11.1 years (5.9-
16.1 years), luminal B (n=8): 9.6 years (4.6-14.5 years), HER2 enriched, non-luminal
(n=1): 6 years and for triple negative (n=3): 1.3 years (0-3.9 years), p<0.001.
In 2013 classification (n=95) median survivals were: luminal A (n=58): 10.5 years
(8.1-12.9 years), luminal B (n=33): 11.8 years (8.7-14.9 years), HER2 enriched, non-
luminal (n=1): 6 years and for triple negative (n=3): 1.3 years (0-3.9 years), p<0.001.
However, when analyzed only the luminal groups, prognosis did not differ regardless
the classification used (p>0.20).
According to cluster groups, the median survival for A group (n=4) was 4,5 years
(1.6-7.8), for B1.1 (n=66) was 11.5 years (6.2-16.8), for B1.2 (n=14) was 10.3 years
(8.4-12.2), for B.2 (n=6) was 4.9 years (3.6-6.2) and for C (n=1) was 0,5 year (0.5-0.5),
p<0.001.
When compared each subgroups and the prognostic factors not mutually exclusive
(tumour size and presence of metastasis), in a multivariate analysis, molecular-like and
cluster subgroups remained independent prognostic factors (p=0.009 for 2000 classifi-
cation, p=0.046 for 2013 classification and p=0.045 for cluster groups).
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Figure 3: Overall survival by stage, in non-metastatic patients
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4 Discussion
MBC is a rare disease and due to this, tumour biology remains poor understood
[3, 8, 10, 20]. Most published data derived from retrospective studies that cover long
time periods, with small samples and/or include patients from different hospitals and
sometimes countries [4]. Many authors used also data from cancer registries [21, 22]
with limitations regarding the absence of a clinical and pathological central revision and
lacking of important information not usually recorded like treatments performed.
From some years ago, we know that FBC is a heterogeneous disease and can be
divided into subgroups that define patients with different treatments response and out-
comes [5, 23, 24]. Compared to women, some differences in DNA aberrations and
gene expression patterns have been demonstrated, implying that MBC may be a differ-
ent disease and hence, the molecular subtyping may also differ [7, 10]. However only
a few studies were underwent in this field in male patients with different IHQ definitions
and non-standardized classifications used [3].
Our series was based in a retrospectively analysis of MBC patients treated in the
same Center, and clinical and pathological information were active collected and re-
viewed. Our sample characteristics show that we have a robust series. The majority
of patients had ≥60 years old [22], presented with ductal carcinomas (followed by pap-
illary histology and lobular is rare) [8, 25], moderately differentiated or undifferentiated
[8], with nodal involvement at diagnosis [7], that often expressed ER/PR [17, 25] and
AR [19]. The expression of HER2, high values of ki67 or p53 was not frequent [22].
The expression of AR relates to PR and low values of ki67 and p53 [8].
Like Nilsson et al. [7], tumour size and ER expression were independent prognostic
factors but contrarily to them nodal status presented a borderline value in univariate
analysis (p=0.05) with a tendency for worst prognosis to N+ disease. Similarly to us,
N status was also not described as an independent prognostic factor by Yu et al. [6].
Differences in sample size could explain these findings, namely the differences in the
ratio N+/N0 with a few N0 cases in our population. However the high prevalence of N+
disease in these patients compared to females [7], in our series 61.3%, even in small
and ER positives tumours, determined that ER positive disease in men can not be al-
ways considered an indolent one and it is important to take other factors into account to
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deal with them [7]. The notion of joint many markers to define distinct disease behav-
iors was first described in 2000, with the statement of the four intrinsic breast cancer
subgroups. In MBC patients and using the classification based only in three markers
(ER, PR and HER2), studies showed, like in our series, a high prevalence of luminal
A tumours (75-98%) followed by luminal B (0-21%) and few cases of basal-like (0-4%)
and HER2-enriched, non luminal (0%) [3, 8, 9]. Luminal patients showed better progno-
sis comparing to other subgroups but the low frequency of some groups (basal like and
HER2-enriched) limits these comparisons and some authors opted to analyze luminal
vs non-luminal groups [6]. Some hypotheses were stated to justify the low prevalence of
HER2/basal like tumours in male patients namely related to age at diagnosis, BRCA1
frequency and IHQ technique and so, prognostic value of these subgroups were not
conclusive [3, 6, 7].
The recent breast cancer subgroups proposed by Prat et al. [12], redefined the lumi-
nal groups using a new cut-off for PR. From the three markers classification to the new
one, in our series 26 patients (32.1%) changed from the luminal A to luminal B group
mainly because of ki67 discrimination. For our knowledge this new classification was
not previously used in male setting. The most cited MBC studies that already defined
luminal B patients using ki67 value [3, 26, 27] stated conflicting results. Similar to us,
Kornegoor et al. [3] showed that these patients are less common than luminal A (21%
vs 75%), but Snchez-Muoz et al. [27], described that they are more frequent than lu-
minal A (51% vs 44%) and had also a better prognosis. The difficulties associated with
the evaluation and standardization of ki67, namely the different cut-offs used, limit the
ability to draw any firm conclusions [28], and even in male patients there are studies that
found that it has no prognostic value [25, 29] while others found that it could be prog-
nostic [30]. Although all the considerations, our series show that both classifications
(2000 and 2013) defined different prognostic groups but when we look only for lumi-
nal groups, prognosis did not differ regardless the classification used (p>0.20), which
probably means that their survival prediction capacity was related to the extremely low
values of the rare groups, remained weak for the most frequent ones (luminals). Cause
of that we defined new groups based in a six-IHQ panel. With cluster analysis, two prin-
ciple groups were found, the biggest one with ER/PR positive tumours(distinguished by
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HER2 expression) and a small one that contained all PR negative tumours. In the
group with expression of hormonal receptors and absence of HER2, patients with low
ki67/p53 and AR negative constituted the group that had better prognosis. This find-
ing launches the debate about the role of routinely perform AR in male patients as it
is related to hormonal receptors and is rarely negative. However as it was described
as positive in some basal-like tumours there may be a subgroup of these patients that
benefit from the determination of AR, namely to distinguish some of them with better
prognosis. In this line, our cluster analysis separated the two triple negative patients
according to AR expression. In the literature there are three publications in MBC setting
that used hierarchical clustering analysis to define subgroups. Johansson et al. [10]
using gene expression analysis to demonstrate that male and female breast cancer are
different. Even in luminal patients, defined by expression of ER by IHQ, they reported
a group with low ER signaling by gene expression leading the notion that luminal group
is not homogeneous and there are some patients with a more aggressive behavior that
could probably respond not so well to endocrine therapy. Shaaban et al. [8] did a com-
parison between male and female patients with a focus on hormone receptor profile.
They described also a predominance of patients with expression of ER but they did
not use ki67 in the definition of luminal B patients which difficult the direct comparison
of the results. The publication that could be directly compared to our, with similar re-
sults, was performed by Kornegoor et al. [19] that performed a cluster analysis in MBC
patients using a nine IHQ panel to define four groups. The first one, called hormone
receptor-negative, contained tumours that do not express ER or PR. We remember that
our A group was only constituted by patients with PR negative and contained also pa-
tients that are ER negative. The prognostic value of PR in male patients was already
stated in a large retrospective study [31] and Kornegoor et al. [19] correlated it with
other adverse prognostic factors as high mitotic count. Like us, these authors [19] also
described three other clusters, all of them with tumours that express ER, one that con-
tained the HER2 positive tumours and the other two that did not differ in ki67, p53 and
AR but were distinguished by the histological grade (in low and intermediate grade).
However in the article there is not described the distribution of patients subgroups by
histological grade, and the prognostic value of this factor in MBC was not confirmed in
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many studies [6, 7, 32] possibly related to the difficulty of obtain a consistent histological
grade in male patients.
In conclusion this study show that tumour size, the presence of distant metastasis
at diagnosis and the expression of ER are independent prognostic factors in MBC.
FBC subgroups do not seem to provide similar prognostic information even with the
most recent classification. Two important prognostic groups were defined by the cluster
analysis: one with bad prognosis(the group with absence of PR) and one with good
prognosis (the group with expression of ER and PR, and absence of HER2, AR, and
low Ki67 and p53). More research is needed to confirm our findings and to clearly define
the MBC prognostic subgroups to optimize treatment strategies and improve survival in
these patients.
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2.2 Recurrence
Cancer recurrence is an important but missing variable in national cancer registries and the
majority of hospitals report incomplete information for more than half of their patients [73].
In MBC patients, there is no study that specifically addressed recurrence, and the major-
ity of data come from retrospective epidemiologic series, that covered prolonged time periods,
summarized in Table 2.4.
As we can see, relapse was documented in a large range of values, between 7.8 and 60.9%,
mainly in distant sites. In FBC patients, and for many years now there is a clear perception that
patterns of relapse influence prognosis and correlate with type of tumour and adjuvant treatments
performed [85].
In luminal tumours (HR positive), more than half of all recurrences occur 6 years or more af-
ter diagnosis, particularly following 5 years of adjuvant endocrine therapy, with an annual distant
recurrence risk after this therapy of 1-4%, depending on the extent of initial disease [86]. Late
relapses in HR positive BC represent a significant clinical challenge as there is limited under-
standing about the underlying mechanisms of hormone-resistance and late relapse. In HER2
negative luminal tumours recurrence risk is partitioned by tumour grade. Low grade cases have
very low early risk, but 20% of patients fall-off in 10 or more years after diagnosis. Higher-grade
cases have risk over more than 20 years [87]. The risk of locoregional relapse was not related
with type of breast surgery (conservative vs mastectomy) [88].
The luminal/HER2+ and HER2 enriched tumours (HR negative) are associated with higher
rates of brain, liver and lung metastasis [85]. The HER2 disease displays also different patterns
of relapse and metastatic spread depending on HR status, with a median relapse free survival
of 19.5 months after surgery in HR negative patients compared to 32.0 months in HR positive
patients. Younger age, stage III and no expression of ER were independent risk factors for relapse
in these patients [89]. HER2+ tumours seem to recur more locally than triple negatives after
conservative surgery, with no differences in local recurrence after mastectomy between these
BC subtypes [88, 90]. The effect of HER2 status on distant recurrence in early stage BC differs
according to recurrence site, ER expression and time [89]. For brain and pleura recurrences,
the effect of HER2 depends on ER status in ways that significantly changed over time. For bone
recurrences, the effect of HER2 does not depend on ER status but changes significantly over
time. For liver and distant lymph node recurrences, there is a significant effect of HER2 status
that does not change with time or ER status. For lung recurrences, rates do not significantly
vary with HER2 status [89]. When they occur, severe bone metastasis and massive hepatic
metastasis are independent risks for early relapse [91].
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Patients with HER2+/HR- tumours are more likely to present with high histologic grade and
higher stages than those with HER2+/HR+. The first ones are less likely to experience first recur-
rence in bone but more in brain, and this lower risk of bone involvement persists when adjusted
for age, stage and adjuvant trastuzumab and when first and subsequent sites of recurrence were
both considered [92]. Patients with HER2+/HR- disease have a significantly increase hazard of
early (0-2 and 2-5 years), but not late death (>5 years) compared to HER2+/HR+ [92].
Patients with triple negative tumours have an increased likelihood of distant recurrence and
death within 5 years of diagnosis. Risk of distant relapse peaks at 3 years with a rapidly declined
thereafter [93]. An 8-years follow-up study revealed that locoregional and distant metastases
were present in 25% of the patients, with a specific BC-mortality higher than 75% [94]. These
tumours are also associated with a significantly higher rate of brain, lung and distant nodal metas-
tasis but a significantly lower rate of liver and bone metastasis comparing with other BC-subtypes
[85]. Independent risk factors for recurrence included increased tumour size, positive nodal sta-
tus, advanced stage and type of chemotherapy (adjuvant vs neoadjuvant) [94]. Tumour size was
responsible for recurrence despite lack of involvement of lymph nodes [95]. Konigsberg et al.
[96] used a cut-off of age (65 years) to analyse the patterns of recurrence in triple negative pa-
tients. Distant visceral metastases occurred significantly more than bone metastases in both age
groups. However, local recurrences, bone and secondary lymph node metastases were more fre-
quent in younger patients [96]. The elderly received significantly less chemotherapy than younger
patients.
According to previous section, female BC subgroups are not linearly replicated in male and
even concerning adjuvant treatments, comparative studies showed inconsistent results between
genders, even with some prognostic factors controlled, as see in Table 2.5.
From these studies we could state that MBC patients seem to underwent less lumpectomy,
with distinct axillar approaches, and radiotherapy. However, breast-conservative surgery is ac-
ceptable in male because they have, commonly, unicentric disease and are amenable to adjuvant
radiotherapy [100, 101] and sentinel lymph node biopsy is also a valid option for nodal evaluation
in male with clinically node-negative disease [13, 102]. The use of radiotherapy in MBC patients,
with regional disease changed over time with an increase tendency to its use [103].
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Abstract
Background: Male breast cancer (MBC) patients seem to have inferior survival com-
pared to female (FBC) ones, which is not fully explained by usual prognostic factors.
Recurrence analysis could show differences in relapse patterns and/or in patients’ ap-
proaches that justify these outcomes.
Material/Methods: Retrospective analysis of 111 MBC patients treated in a cancer
center between 1990-2014. For each patient, three matched recurrent FBC patients
were selected by: diagnosis’ year, age (within 5 years), stage and tumors’ type (only
luminal-like were considered). Differences between cohorts were assessed by X2 test
and hierarchical clustering was performed to define subgroups according to local of
relapse. Survival curves were calculated by Kaplan-Meier and compared using log-
rank test. Statistical significance was defined as p<0.05.
Results: Groups were balanced according to age, histological grade, stage, expres-
sion of hormonal receptors and adjuvant treatments performed. Median time to recur-
rence was equivalent, 43 vs 48 months, p=0.72, with the majority of patients presented
with distant metastases, p=0.69, mainly in bone, with more lung involvement in male,
p=0.003. Male patients were more often proposed to symptomatic treatment (21.1% vs
4.4%, p=0.02). Survival was poorer for male, median: 5 years (95%CI:4.1-5.9 years)
73
vs 10 years (95%CI:7.8-12.2 years), p<0.001, and this tendency remained in the five
cluster subgroups, that identified five patterns of relapse, p=0.003.
Conclusions: MBC patients had the worst survival, even after controlling important
factors, namely the local of relapse. Palliative systemic treatment had favorable impact
in prognosis and its frequently avoidance in male could justify the outcomes differences.
Keywords: MBC, FBC, recurrence, luminal tumors, prognosis
1 Introduction
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all
breast cancer cases [1]. Recently and due to the increase in its incidence [2], some
studies were published suggesting a worst outcome for male [1, 2, 3, 4, 5] compared to
female (FBC) patients, justified by: comorbid conditions [6] and delay in the diagnosis
in male patients [1], different age and stage at diagnosis [2, 4, 7] or even differences
in tumors biology [5]. Despite the remarkable improvements in breast cancer (BC)
characterization, accurate prediction of breast cancer behavior is often still difficult to
achieve [8], particularly in luminal disease where the mechanisms of treatment resis-
tance, late relapse and dormancy are still not well-understood [9, 10]. Recurrence plays
an important rule in BC prognosis and although new therapies and approaches might
decrease the incidence of relapse, compared to past records [11], the hazard of dying
after metastization was equal for patients diagnosed between 1978-1984 and 1995-
2003 in a population-based study [11] demonstrate that a special focus to advanced
disease is still required.
In the absence of studies in MBC patients specifically designed to characterized
recurrence the aim of this study was to compare patterns of relapse and patients ap-
proaches in two genders groups, trying to estimate its real effect in patients’ outcomes.
2 Patients and Methods
Clinical records from MBC patients treated at Portuguese Institute of Oncology of
Porto (IPO-Porto) between 1990-2014, maximum follow-up of 30 years (median of 5.5
years), were retrospectively reviewed looking for cancer relapse. From a total of 111
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patients, recurrence was documented in 27 patients (24.3%). Four patients were lost in
follow-up, considering 23 patients for the final analysis. For each patient, three matched
recurrent female patients treated in the same Institution were selected. The variables
used to randomly assigned matches were: year of diagnosis, age at diagnosis (within
5 years), stage and biological subtype (only luminal-like tumors were considered in or-
der to obtain the necessary sample size and to compare more homogeneous groups).
Luminal-like tumors were defined by immunohistochemistry classification, IHQ, as tu-
mors that express estrogen receptor in more than 1% of their cells with or without
expression of progesterone receptor using the same cutoff and without co-expression
of HER2). The local ethics committee approved this study.
2.1 Statistical analysis
Differences between matched cohorts were assessed by X2 test to compare cate-
gorical variables. Hierarchical clustering was performed to define subgroups, according
to local of relapse. For this purpose, the linkage algorithm with the Unweighted aver-
age distance (UPGMA) to compute the distance between cluster was used and, as
all markers were categorical variables (present/absent), similarities between patients
were achieved by the mahalanobis distance measure. This analysis was performed
using statistical program R (http://www.r-project.org). At the end, the cophenetic
correlation coefficient was calculated for the hierarchical cluster tree and a value of 0.96
was obtained (for a maximum of 1.0). Survival curves were calculated by the Kaplan-
Meier method and compared using the log- rank test, considering survival from relapse,
the time from the diagnosis of recurrence to death and overall survival as the time from
diagnosis to death (from any cause). Statistical significance was defined as p<0.05.
SPSS for Windows version 19.0 (SPSS Inc., Chicago, IL, USA) was used for statis-
tical calculations.
3 Results
The analyzed population comprised 23 MBC patients and 69 FBC patients. Charac-
teristics of both cohort groups could be seen in Table 1. Groups were balanced accord-
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ing to age, histological grade, stage, expression of hormonal receptors and adjuvant
treatments performed.
Histological type presented some differences between groups, p=0.047, with no
lobular tumors in MBC patients and no exclusive papillary in FBC patients. Tumor size
showed also a slightly difference, p=0.06, with a tendency to more T3 tumors in FBC pa-
tients (18.8% vs 4.3%) and more T4 tumors in MBC patients (30.4% vs 7.2%). The type
of surgery and adjuvant treatments performed, were equal (p>0.05). The regimens of
chemotherapy were the same, p=0.30, composed by taxanes and antracyclines in 50%
(male) vs 38.1% (female). On the other hand, the type of endocrine therapy was dif-
ferent, p=0.01, with 84.2% of male underwent only tamoxifen vs 45% female, with no
cases of use of aromatase inhibitors in consecutive regimen after tamoxifen (switch
regimen) in male and with more women that did only aromatase inhibitors (43.3% vs
15.8%).
4 Recurrence
Median time from diagnosis to recurrence were equal: male 43 months (2-144
months) and 48 months in female (3-323 months), p=0.72. The majority of patients
were symptomatic (male: 17 (73.9%); female: 50 (72.5%), p= 0.89), and presented
with elevation of Ca15.3 marker (male: 8 (88.9%); female: 57 (89.1%), p=0.98), Histo-
logical and/or cytological confirmation of metastasis were performed in 7 male (30.4%)
and 36 female (52.2%), p=0.007 and showed IHQ changes related to primary tumor
in 3 male patients, with 2 new negative progesterone receptor (40% of change) and 1
new negative estrogen receptor (20% of change) and in female 5 new cases of nega-
tive estrogen receptor (12.8% of change), and 11 new cases of negative progesterone
receptor (36.7% of change).
Patients’ recurrence was illustrated in Table 2. The locals described are not mutually
exclusive. The majority of patients relapse at distant sites (male: 21 (91.3%) and in
female: 61 (88.4%), p=0.69), mainly in bone, male: 5 (21.7%) and female: 30 (43.5%),
with more lung metastasis registered in male, p=0.03. There was no brain or lymph
node metastases in MBC patients at time of first relapse. Two female patients recurred
for peritoneum and one for eye, described in Table 2 as other sites.
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Table 1: Patients’ characteristics
Characteristics MBC patients FBC patients p
n=23 n=69
Median age at diagnosis, 60 years 63 years
0.50
range (34-83 years) (30-84 years)
Post-menopausal status, n (%) ——– 48 (52.2) —-
Histological type, n (%)
0.04
Ductal 20 (87) 47 (68.1)
Mix 2 (8.7) 13 (18.8)
Other 1 (4.3) 9 (13.0)
Histological grade, n (%)
0.51
G1 2 (8.7) 7 (10.1)
G2 16 (69.6) 47 (68.1)
G3 5 (21.7) 15 (21.7)
T (size), n (%)
0.06>2 cm 16 (69.5) 50 (72.4)
≤2 cm 7 (30.4) 19 (27.5)
N (nodal status), n (%)
0.40N0 6 (26.1) 18 (26.5)
N+ 17 (73.9) 51 (73.5)
Stage, n (%)
1.00
I 2 (8.7) 6 (8.7)
II 7 (30.4) 21 (30.4)
III 14 (60.9) 42 (60.9)
ER, n (%)
Positive 23 (100) 69 (100) 1.00
PR, n (%)
0.40Positive 20 (87) 62 (89.9)
Negative 3 (13) 7 (10.1)
HER2, n (%)
Negative 23 (100) 69 (100) 1.00
Neoadjuvant treatment, n (%)
0.14Yes 3 (13.1) 16 (23.2)
No 20 (86.9) 53 (76.8)
Surgery, n (%)
0.11Mastectomy 22 (95.7) 56 (81.2)
Lumpectomy 1 (4.3) 13 (18.8)
Adjuvant chemotherapy, n (%)
0.06Yes 9 (39.1) 42 (60.9)
No 14 (60.9) 27 (39.1)
Adjuvant radiotherapy, n (%)
0.54Yes 20 (87.0) 53 (76.8)
No 3 (13.0) 16 (23.2)
Adjuvant endocrine therapy, n (%)
0.32Yes 19 (82.6) 63 (91.3)
No 4 (17.4) 6 (8.7)
MBC: male breast cancer; FBC: female breast cancer;
ER: estrogen receptor; PR: progesterone receptor;
—-: not applicable.
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Table 2: Type of recurrence by patients’ cohort group
Recurrence MBC patients FBC patients p
n=23 n=69
Local, n (%) 3 (13.0) 10 (14.4) 0.86
Regional Lymph nodes, n (%) 0 (0) 4 (52.2) —-
Distant Lymph nodes, n (%) 0 (0) 7 (10.1) —-
Bone, n (%) 12 (52.2) 46 (66.7) 0.21
. Number of bones involved
1-5 6 (50) 26 (56.5) 0.81
5-10 2 (16.7) 9 (19.6)
>10 4 (33.3) 11 (23.9)
. Spine involvement 11 (91.7) 35 (77.8) 0.28
. Surgery 2 (16.7) 9 (19.6) 0.82
. Bisphosphonates 5 (41.7) 34 (73.9) 0.03
. Radiotherapy 5 (41.7) 28 (60.9) 0.23
Lung, n (%) 9 (39.1) 12 (17.4) 0.03
. Bilateral disease 5 (50) 7 (43.8) 0.76
. Pleural involvement 4 (17.4) 10 (14.5) 0.70
. Number of lesions
≤5 4 (57.1) 5 (55.6) 0.90
>5 3 (42.9) 4 (44.4)
. Local treatment 1 (4.3) 0 (0) 0.38
Liver, n (%) 3 (13.0) 14 (20.3) 0.44
. Number of lesions
≤5 1 (50) 3 (23.1) 0.42
>5 1 (50) 10 (76.9)
. Hepatic insufficiency 1 (33.3) 2 (15.4) 0.47
. Local treatment 0 (0) 0 (0) 1.00
Brain, n (%) 0 (0) 3 (4.3) —-
. Parenchymal involvement 0 (0) 3 (100) —-
. Leptomeningeal involvement 0 (0) 1 (33.3) —-
. Number of lesions
=1 0 (0) 1 (33.3) —-
>1 0 (0) 2 (66.7)
. Local treatment 0 (0) 3 (100) —-
Other sites, n (%) 0 (0) 3 (4.3) —-
First line treatment
0.04
. Endocrine therapy 11 (57.9) 45 (66.2)
. Chemotherapy 4 (21.1) 20 (29.4)
. Symptomatic treatment 4 (21.1) 3 (4.4)
—-: not possible to compare because there were no cases in one cohort
group.
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Figure 1: Cluster subgroups according to local of relapse
Cluster analysis defined six different subgroups, according to local of relapse, please
see Figure 1. One of them (Subgroup F), included the patients with lymph node metas-
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tasis, brain metastasis and metastasis in other sites, that were all female patients, and
because of that, it was not considered for analysis. The other five subgroups were com-
posed by patients of both genders with, at least, one predominant site of metastasis:
Subgroup A (5 male and 28 female), the major one, that included only patients with
bone metastasis exclusively; Subgroup B (8 male and 3 female) that contained patients
with lung metastasis predominantly; Group C (3 male and 8 female) with patients with
liver metastasis; Group D (3 male and 9 female) with local recurrences and Group E (4
male and 6 female) that included a miscellaneous of patients, that included that ones
with more than 2 sites of relapse.
The good performance status in recurrence (ECOG: 1 in male: 10 (43.5%) and in
female: 31 (44.9%), p=0.64, allowed palliative systemic treatments in 15 (79%) of male
and 65 (95.6%) in female, with a median of lines of one in male and two in female,
p=0.60. Male patients were more often proposed to symptomatic treatment at first
diagnosis of recurrence than female (21.1% vs 4.4%,p=0.018).
5 Survival Analysis
Survival from recurrence diagnosis was worst in male: median 1 year (95% CI: 0-
2.1 years), and for female median 2 years (95%CI: 1.6-2.4 years), p=0.004; for a HR
of 1.9; as well as overall survival: for male median 5 years (95% CI: 4.1-5.9 years),
and for female median 10 years (95% CI: 7.8-12.2 years), p<0.001, for a HR of 2.5,
Figure 2 and 3. In first line, palliative systemic treatment instead of symptomatic one
had a positive impact in overall survival in both groups (in male: 7 years vs 2 years
and in female 10 years vs 3 years, p=0.013). Cluster analysis defined 5 subgroups with
different prognosis, p=0.003, with male patients having worst prognosis in all subgroups
than female patients, please see Figure 1.
6 Discussion
To our knowledge, this is the first study specifically designed to characterize re-
lapse in MBC patients, with a comparison between two well-balanced matched gender
cohorts.
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Figure 2: Survival from recurrence diagnosis by cohort groups (Green Line – Female, Blue Line –Male)
With important prognostic factors controlled, namely the adjuvant treatments per-
formed, we showed that MBC patients had a worse prognosis compared to female
ones. Although recurred more often to lung, the main cause for poor prognosis seems
to be the less aggressive treatment at recurrence diagnosis. Like in female, MBC pa-
tients that underwent palliative systemic treatments had better survival compared to
that proposed only for symptomatic treatment.
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Figure 3: Overall survival by cohort groups (Green Line – Female, Blue Line –Male)
Cancer recurrence is a critically important but missing variable in national cancer
registries and the majority of hospitals report incomplete information for more than half
of their patients [12]. In MBC, data from epidemiological series had a large range for
recurrence rate, varying from 7.8% [13] to 60.9% [14] reflecting also a huge variation
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in sample sizes, from 25 [14] to 489 [15] patients. Two of the largest published series
[15, 16] reported, similar to us, a recurrence rate of 29.0% and 29.8% (142 events in
489 patients and 16 events in 91 patients). In FBC relapse, changes in IHQ markers,
namely the non-expression of ER and/or PR [17] had a negative impact in prognosis,
but in MBC patients this is not previous stated. In our series, cytological/histological
confirmation of metastases in MBC patients was documented only in 7 cases, with PR
variation in most of them. The real impact of these changes in male patients survival
and the need to evaluate this in recurrence time must be evaluated in large series,
having in mind that these patients have luminal-like tumors predominantly [2].
In the majority of cases, distant recurrence was the most prevalent [18, 19] docu-
mented mainly in bone [20, 21] as in our study. Like FBC patients, visceral metastases,
in lung or liver, have a poor prognosis when compared to bone (exclusively) [22]. Brain
metastasis at the time of first recurrence seems rare in MBC patients, described in 2 pa-
tients (7.32%) in Forester et al.[14] series. However, in this study, there were 15 patients
(39%) with synchronous metastasis at diagnosis (stage IV) and 5 patients (16.7%) with
HER2 positive disease, which could bias these results.
The positive survival impact of chemotherapy [14] and endocrine therapy [23, 24]
in advanced disease was previously reported in male and was also corroborated in
our study. Palliative chemotherapy strategies should follow female treatment guidelines
[14] persisting some doubts about palliative endocrine therapy, namely about the need
to combine or not the aromatase inhibitors with GnRH [23] or the rule of fulvestrant in
these patients [24].
After controlling for important prognostic factors, we described a worse survival
to MBC patients that are similar to other studies [1, 5], present however, a lower 5-
year overall survival (65.2%) compared to some authors that reported more than 80%
[15, 25]. This could be probably explained by the selection of our population that only
contains patients that recurred and because of that have a poor prognosis.
In conclusion, this is the fist study in MBC setting that addressed a very important
prognostic determinant: recurrence. However, even with all methodological precautions
to avoid bias, there are also identifiable limitations in the study, strictly related to the
rarity of this disease that requires a long period of time to compare patients outcomes,
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with unavoidable changes in patients’ approaches over the years. Because of that our
findings need future confirmation, ideally in a large and prospective multicenter study
focus also in comorbidities and causes of death.
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Abstract
Background: Recurrence is an important cornerstone in breast cancer behaviour, in-
trinsically related to mortality. In spite of its relevance, it is rarely recorded in the majority
of breast cancer datasets, which makes research in its prediction more difficult.
Objectives: To evaluate the performance of machine learning techniques applied to the
prediction of breast cancer recurrence. Material and Methods: Revision of published
works that used machine learning techniques in local and open source databases be-
tween 1997 and 2014.
Results: The revision showed that it is difficult to obtain a representative dataset for
breast cancer recurrence and there is no consensus on the best set of predictors for
this disease. High accuracy results are often achieved, yet compromising sensitivity.
The missing data and class imbalance problems are rarely addressed and most often
the chosen performance metrics are inappropriate for the context.
Discussion and Conclusions: Although different techniques have been used, predic-
tion of breast cancer recurrence is still an open problem. The combination of different
machine learning techniques, along with the definition of standard predictors for breast
cancer recurrence seem to be the main future directions to obtain better results.
Keywords: Breast Cancer Recurrence, Machine Learning Techniques
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1 Introduction
Breast Cancer (BC) figures among the major causes of concern worldwide. Accord-
ing to the latest GLOBOCAN statistics [1], it was the second most frequently diagnosed
cancer and the fifth cause of cancer mortality worldwide, responsible for 6.4% of all
deaths.
The mortality associated to this pathology is mostly related to Metastization [2], the
spread of cancer to other parts of the body remote from the breast, and Recurrence
(or relapse), which describes cancer that reappears after treatment [3]. Being docu-
mented in 10-15% of all BC patients [4], recurrence assumes a pivotal importance in
their prognosis. However, it is not as well studied as BC itself. Searching in Thom-
son Reuters [5] platform for research works with the expression “breast cancer” in the
title yields more than 330.000 results. A similar search focused on recurrence yields
only around 20.000 results (approximately 6%), obtained when the search terms are
extended to “recurrence(s)”, “relapse(s)” and “metastasis (es)” (individually or in com-
bination). These results can be partially explained by the fact that, for instance, none of
the three major American cancer registries reports cancer recurrence information [6].
Besides the obvious implications of recurrence in mortality, BC patients also face se-
rious treatment-related complications, which increases their risk of death from causes
unrelated to breast cancer itself [7]. In this scenario, accurate prediction of breast
cancer behaviour assumes an important role, since it aids clinicians in their decision-
making process, enabling a more personalised treatment for patients. Some of the
studies regarding cancer recurrence involve the use of statistical methodologies, or
machine learning algorithms, which have a long history in cancer research[8][9][10].
This research work attempts to provide an overview of the prediction of BC recurrence
using machine learning techniques. The challenge is to accurately predict recurrence
events, within a binary outcome (yes/no). This challenge encompasses not only the
choice of a good dataset (containing quality data) but also the selection of the most
appropriate features, as well as the most advantageous algorithm.
The remainder of the paper is organized as follows: Section 2 covers the steps
used by different authors to predict BC recurrence, highlighting the datasets, variables
included in the reviewed studies, data mining algorithms, sampling strategies and eval-
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uation metrics used. Section 3 depicts the analyzed works in more detail and Section
4 presents a discussion on the different works. Finally, some conclusions and future
directions are discussed in Section 5.
2 Predicting Breast Cancer Recurrence phases and tasks
The most common processes to develop a data mining approach are Knowledge
Discovery in Databases (KDD) [11], Sample, Explore, Modify, Model and Assess (SEMMA)
[12] and CRoss-Industry Standard Process for Data Mining (CRISP DM) [13]. The first
two are composed by five steps each; despite the different designations, their steps
are generally equivalent [14]. The third strategy, CRISP DM, presents two novel steps
which consist in “Business Understanding”, where, after the Evaluation phase, the re-
sults are interpreted from a business perspective; and the “Deployment” step, where
the final process achievements are somehow incorporated in a product/service (more
related to a business perspective). Table 1 highlights the difference between these pro-
cesses. As all BC recurrence studies analyzed use a KDD strategy, its steps are used to
highlight the methodology followed by each of the works. In the following subsections,
we explore some of the steps in the KDD approach and how they were addressed in
the reviewed works.
Table 1: A comparison between KDD, SEMMA and CRISP-DM knowledge discovery processes [14]
KDD SEMMA CRISP-DM
Pre-KDD ————— Business understanding
Selection Sample Data UnderstandingPreprocessing Explore
Transformation Modify Data preparation
Data mining Model Modeling
Interpretation/Evaluation Assessment Evaluation
Post KDD ————— Deployment
2.1 Selection
This step consists ins the selection of a dataset and an appropriate set of features
for knowledge extraction. The datasets can be publicly available (e.g. online) or they
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may result from a collaboration between institutions and research teams, not available
for the general public. Feature selection may be performed manually, or using variable
selection algorithms. In particular for BC recurrence, 7/17 of the studies used manual
selection (5 with the help of medical experts), while some of the others took advantage
of well-known feature selection algorithms; for instance, Jonsdottir et al. [15].
The datasets and the number of patients used in the analysed studies are sum-
marised in Table 2. From the 17 reviewed works, the majority uses available datasets
(9 works). Among those, 4 works use the Wisconsin Prognostic Breast Cancer (WPBC)
dataset and 3 use the Breast Cancer dataset, both available from UC Irvine Machine
Learning Repository (UCI Repository) [16]. The remaining 2 datasets are available from
van’t Veer’s study [17] and the widely known SEER database (US National Cancer In-
stitute). The unavailable databases are collaborations with specialised Breast Cancer
centers, registers or teaching hospitals, in several different countries (Sweden, Spain,
California, Iceland, South Korea and Ljubljana). The Institute of Oncology in Ljubljana
was the greatest contributor for BC recurrence studies, providing the data for 5 of the
reviewed works.
Although the end-point for predicting BC recurrence is not defined for some cases,
most of the datasets are associated with a specific time period for recurrence prediction
(e.g. 4-5 years after the diagnosis, 10 years after surgery). Moreover, the great major-
ity of the datasets suffered from a considerable class imbalance, with uneven cases of
”recurrence’” versus ”no-recurrence”’, following a 30%-70% distribution. The most af-
fected works are Mani et al. [18] and Razavi et al. (2007) [19], with a class distribution
(recurrence/no-recurrence) of 10%-90% and 20%-80%, respectively. Going against this
trend, 3 works (Sun et al. [20], Strumbelj et al. [21] and Tomczak [22]) perform their
experiments on balanced datasets with approximately 50%-50% class distribution. The
distribution is unknown for 2 works, Razavi et al. (2005) [23] and Jerez-Aragone´s [24].
Concerning the feature selection, and for some years, many factors were linked to
BC recurrence, namely age at diagnosis, size, stage and grade of tumor, involvement
of lymph nodes, menopausal status, estrogen (ER) and progesterone receptors (PR)
and HER2 pattern (Human Epidermal growth factor Receptor 2) [3]. Frequently, some
of them are associated, given that tumors in younger patients (pre menopausal) tend to
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be high grade, with a triple negative phenotype: without expression of ER, PR, and also
HER2. Variables used in the BC recurrence prediction in the previously analysed stud-
ies were compared using three groups: Patient Characteristics, Tumor Characteristics
and Treatments.
From the analysis of Table 2, it is important to highlight that there are many datasets
with different origins (local and open source) used to deal with this problematic. Also,
different authors used dissimilar varieties with a weak attention for the treatment fol-
lowed by the patient (only 7/17 studies focused on this factor). Attending to Patient
Characteristics, the majority of studies (10/17) identified age as an important predictor,
followed by menopausal status (5/17). This last factor could not be totally independent
from age as very young patients are also pre menopausal and very old ones are always
post menopausal. All the studies considered Size as the main predictor in the Tumor
Characteristics group, followed by Lymph Nodes involvement (16/17).
2.2 Data Cleaning and Preprocessing
Data cleaning and preprocessing tasks are performed to reduce noise and increase
the consistency of data. The preprocessing steps most addressed in the reviewed re-
search works were Normalisation/Standardisation of data and Missing Data handling.
Two simple ways of data preprocessing are Normalisation (Min-Max transformation)
and Standardisation (Z-Score transformation) [25]. Normalisation refers to the feature
scaling between it minimum and maximum values, while Standardisation rescales the
features so that they follow a standard normal distribution (zero mean and unitary stan-
dard deviation). The objective of normalisation/standardisation is to make features with
different scales and ranges of measurement (e.g. age, hemoglobin values) comparable,
so that none has more influence than the others on classification task [26].
Missing Data (MD) can result from a huge variety of events and represents a com-
mon challenge in healthcare contexts[27].
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Table 2: Datasets and Feature Selection used in the analyzed studies (NU - not used, ER -Estrogen
Receptor, PR-Progesterone Receptor, ICD-International Classification of Diseases)
Publications Dataset (recurrence/no
recurrence
Patient Characteristics Tumor Characteristics Treatments
Mani et al., 1997
[18]
Breast cancer center Or-
ange, California (85/802)
Lymphedema Tumor presence and its
invasive nature, Size,
Lymph nodes involve-
ment, Stage
NU
Jerez-Aragone´s et
al., 2003 [24]
Hospital Clı´nico Universi-
tario Malaga, Spain (1035
patients, not effective, dis-
tribution unknown)
Age, Menarchy age,
Menopausal age, First
pregnancy age/pregnan-
cies number, Number of
miscarriages
Size, Grade, Lymph
nodes involvement, Ex-
pression of ER, PR, p53
accumulation, Ploidy,
S-Phase
NU
Razavi et al., 2005,
2007 [23][19]
Swedish Regional BC
Register (2005: 3949
patients, distribution
unknown; 2007: 3699,
664/3035)
Age Size, Perigland growth,
Lymph nodes involve-
ment, Expression of ER,
PR, S-Phase
NU
Sun et al., 2007
[20]
Publicly available microar-
ray data (van’t Veer et al.
2002 [17]) (46/51)
Age Size, Vascular invasion,
Lymphocytic infiltration,
Expression of ER, PR,
70-gene profile
NU
Ryu, 2007 [28] Breast Cancer Dataset
(Available from UCI
Repository) (85/201)
Age, Menopausal status Location, Size, Grade,
Lymph nodes involvement
Radiotherapy
Jonsdottir et al.,
2008 [15]
Rose dataset Univer-
sity Hospital in Iceland
(73/184)
Age, Comorbidities,
CEA/CA-15.3 values
Clinical detectable, Histo-
logical type, Size, Local
invasion, Inflammatory
component, Lymphovas-
cular invasion, Lymph
nodes involvement,
Metastasis (lung, bone),
Expression of ER, PR,
S-Phase
Chemotherapy
(pre and post
surgery), Hor-
monotherapy,
Radiotherapy
Fan et al., 2010
[29]
SEER Public-Use Data
2005 (46.996.113 pa-
tients, not effective,
distribution unknown)
Race, Age, Marital status Behaviour defined by
ICD-03, Location (lateral-
ity, breast regions), Size,
Grade, Local invasion,
Lymph nodes involvement
Surgery, Radio-
therapy
Continued on next page
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Table 2 – Datasets and Feature Selection used in the analyzed studies
Publications Dataset (recurrence/no
recurrence)
Patient Characteristics Tumor Characteristics Treatments
Belciug et al., 2010
[30]
Wisconsin Prognostic
BC (Available from UCI
Repository) (47/151)
NU Area, perimeter, compact-
ness, Texture, Concav-
ity, concave points, Size,
Lymph nodes involvement
NU
Strumbelj et al.,
2010 [21]
oncologyBCR (Institute
of Oncology, LjublJana)
(449/432)
Age, Menopausal status,
Personal or Familiar previ-
ous malignancies
Histological type, Size,
Grade, Local invasion,
Lymphovascular invasion,
Lymph nodes involve-
ment, Expression of ER,
PR
Chemotherapy,
Hormonotherapy
Kim et al., 2012
[31]
Tertiary Teaching Hos-
pital, South Korea
(195/484)
NU Number of tumors, Size,
Grade, Local invasion,
Lymphovascular invasion,
Lymph nodes involve-
ment, Expression of
ER
NU
Salama et al., 2012
[32]
Wisconsin Prognostic
BC (Available from UCI
Repository) (47/151)
NU Area, perimeter, compact-
ness, Texture, Concav-
ity, concave points, Size,
Lymph nodes involvement
NU
Murti, 2012 [33] Breast Cancer Dataset
(Available from UCI
Repository) (81/196)
Age, Menopausal status Location, Size, Grade,
Lymph nodes involvement
Radiotherapy
Tomczak, 2013 [22] Institute of Oncology,
Ljubljana (follow up from
Strumbelj et al.) (949
patients, distribution un-
known but assumed the
same as the one from
Strumbelj’s: 51%/49%)
Age, Menopausal status,
Personal or Familiar previ-
ous malignancies
Histological type, Size,
Grade, Local invasion,
Lymph/vascular invasion,
Lymph nodes involve-
ment, Stage, Expression
of ER, PR
Chemotherapy,
Hormonotherapy
Pawlowsky and Na-
gahashi, 2014 [34]
Wisconsin Prognostic
BC (Available from UCI
Repository) (46/148)
NU Area, perimeter, compact-
ness, Texture, Concav-
ity, concave points, Size,
Lymph nodes involvement
NU
Beheshti et al.,
2014 [35]
Wisconsin Prognostic
BC (Available from UCI
Repository) (47/151)
NU Area, perimeter, compact-
ness, Texture, Concav-
ity, concave points, Size,
Lymph nodes involvement
NU
Continued on next page
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Table 2 – Datasets and Feature Selection used in the analyzed studies
Publications Dataset (recurrence/no
recurrence)
Patient Characteristics Tumor Characteristics Treatments
Vikas Chaurasia et
al., 2014 [36]
Breast Cancer Dataset
(Available from UCI
Repository) (85/201)
Age, Menopausal status Location, Size, Grade,
Lymph nodes involvement
Radiotherapy
In brief, MD can be produced at random (MAR), completely at random (MCAR) or
completely not at random (MNAR) [37]. Over the years, several strategies have been
studied to handle this issue. The most simple one is Listwise Deletion, where records
with missing data simply discarded. This approach may be inappropriate, especially
in environments like healthcare, where most often patients are characterised with a
large number of variables with high probability of missing observations. According to
the literature, imputation is a more appropriate strategy to deal with MD: using the
available complete data, the MD are estimated and filled with plausible values [38] [39].
Mean/Mode is one of the simplest imputation strategies, where continuous variables are
imputed according to their mean, and categorial variables using their mode. Despite its
simplicity, this strategy causes the data to loose some variability, which constitutes its
major drawback.
A more sophisticated strategy is using mixture models trained with the Expectation-
Maximization (EM) approach, which consists of two steps [40]: the Expectation step
(“E-step”) and the Maximisation step (“M-step”). Basically, the EM algorithm is based
on finding the Maximum Likelihood of data in order to find the best estimates for missing
observations. For the algorithm to start, the E-step makes an initial guess of the model
parameters. Using those parameters, and according to the observed (complete) data,
it produces estimates for missing observations. The M-step is then responsible for
computing new model parameters using the current MD estimations. This process
continues repeatedly until the algorithm converges. More specific details can be found
in [40] [41][42].
Multiple Imputation (MI), substitutes every missing observation M times (M > 1),
using M different estimators (e.g. EM, Markov Chain Monte Carlo methods) [43]. As
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the name implies, multiple complete datasets are generated, each with different esti-
mates for the absent observations. Then, theM complete datasets have to be analysed
using standard methods – for instance, classification models – in order to combine the
different estimates and obtain a single set of results (a discussion on combination rules
is given in [37]). On one hand, MI is able to reflect the data variability due to missing
values. On the other hand, it is computationally expensive, given the generation of
different MD estimations, and the required time to further analyse its results.
2.3 Machine Learning Methods
Throughout the years, many Machine Learning (ML) algorithms have been used to
predict BC recurrence. These methods can be categorised as “black-box” or “white-
box”. Black-box algorithms work on the basis of “input stimulus” and “output reactions”,
without any knowledge on their internal procedures. From the user perspective, this
type of algorithms rises a wide range of questions that will always remain unclear, such
as how the results are generated and how can the results be explained by the internal
methods, given a specific input, among others. This issue becomes especially critical
when the user (e.g. a clinician) considers interpretability as a key requirement, in order
to use this kind of approaches and benefit from them in his daily decision-making ac-
tivities. Contrary to black-box algorithms, white-box algorithms allow the inspection and
explanation of their internal rules; that is, the results of a white-box algorithm may be
analytically (mathematically) derived from a given set of inputs. This section presents a
review on the algorithms used to predict BC recurrence in the studied research works,
starting with the white-box algorithms.
2.3.1 Decision Trees
Decision Trees (DT) are defined by recursively partitioning the input space from a
root node to multiple branch nodes [44][45]. The root node is the “first division” of a
DT, from which outgoing edges create several other nodes. Nodes with outgoing edges
(with the exception of the root node) are known as internal (or test) nodes, while the
remaining (that only have incoming edges) are called leaves, each one assigned to a
class. The test nodes divide the input feature space into p ≥ 2 sub-spaces according to
a condition test of the input features values. Typically, a single feature is considered in
95
each test node and the feature space is divided according to that feature’s values. For
continuous features, each outgoing edge represents a certain range. An input vector is
classified in the DT by sorting it from the root to a leaf, according to the results of the
conditions tested along the path. DT are computationally efficient, can easily handle
mixed variables (continuous and discrete) and the rules generated by them are rela-
tively easy to interpret and understand, particularly in healthcare contexts. Some of the
most popular DT approaches are the C4.5 algorithm [45][46] and CART (Classification
And Regression Tree) [47], which use entropy-based measures (typically, the gain ratio)
as splitting criterion during the tree construction process. C5.0 is an extension of C4.5
[48]. The main advantage of DT is its interpretability; however, noise and missing data
can contribute to drastically decrease the accuracy of these algorithms.
2.3.2 Naive Bayes
Naive Bayes (NB) classifier takes into account the probability distribution of the pat-
terns in each class to make a decision, assuming that there is a probabilistic relationship
between predictors (features) and the output (class) [49]. Bayesian classification deter-
mines the probability of a given pattern represented by x to belong to class ωi, P (ωi | x),
called posteriori probability. Considering a binary classification problem, where two
posteriori probabilities exist, P (ω1 | x) and P (ω2 | x), NB decision rule considers that:
If P (ω1 | x) > P (ω2 | x), then x belongs to ω1;
If P (ω1 | x) < P (ω2 | x), then x belongs to ω2;
Alternatively, if P (ω1 | x) = P (ω2 | x), then the choice is arbitrary. The posteriori
probabilities are calculated according to the well-known Bayes’ law (equation 1).
P (ωi | x) = p (x | ωi)P (ωi)
p (x)
(1)
where P (ωi) is the prior probability of class ωi, i.e., an estimate of the probability of
pattern x to belong to ωi; p (x | ωi) is the likelihood of x, that can be estimated through
the probability density function (pdf ) of x; and p (x) is the total probability of x, which
can be determined using equation 2.
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p (x) =
c∑
i=1
p (x | ωi)P (ωi) (2)
Due to the fact that NB uses probability rules, it inherits somehow the strong results
of the statistics. Also, another advantage of this method is allowing the researcher to in-
clude is domain experience in the modelling process of NB classifiers. Moreover, being
a white-box method, it can be more easily understood, for instance, by clinicians. How-
ever, its computational complexity, especially when a large dataset is used, constitutes
its main drawback [50].
2.3.3 Logistic Regression
Logistic Regression (LR) is a mathematical method which aims to describe the rela-
tion between a group of independent variables and a dichotomous dependent variable.
To achieve that, LR tries to estimate a set of unknown parameters using a maximum
likelihood method [51]. The term “Logistic Regression” may be slightly misleading,
since regression is mostly used to build models where the target feature is continuous.
However, LR is used for classification, not regression. In brief, LR involves a proba-
bilistic view of classification. It maps a point of a multidimensional feature space to
a value in the range [0,1], using a logistic function. The logistic model can therefore
be interpreted as a probability of class membership by applying a certain threshold to
such probability. In conclusion LR gives the class probability for each considered fea-
ture vector. The class assignment depends on the chosen threshold. One of the main
advantages of this method is that it clearly illustrates how the inputs justify the outputs
through the final generated equation. However, its performance drops when the dataset
contains MD.
2.3.4 K-Means Algorithm
K-Means is one of the most well-known clustering algorithms, due to its easy imple-
mentation, efficiency and success over a wide range of pattern recognition applications
[52]. K-Means is a partitional clustering algorithm, which means that it does not impose
a hierarchical structure and finds clusters through the recursive partitioning of data,
according to a similarity criteria between data points [53]. In brief, K-Means algorithm
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works as follows. First, the desired number of clusters, k, needs to be specified. Then, k
randomly chosen centroids (which are simply pseudo-data points with the same dimen-
sionality as the ones intended to cluster) are initialised. The distances (e.g. euclidean
distance) of each point to those k centroids is calculated, and each point is assigned to
its closer centroid. The initial partitions of data are defined at this point. However, the
objective of K-Means is to find a partition such as the sum of the squared error over all k
clusters is minimised [52]. For that reason, the centroids of each partition are updated
at each iteration of the algorithm. The new centroids are given by the mean vectors of
the point belonging to each cluster. Again, new distances are calculated for each point,
now considering the new centroids. This is successively repeated until there are no
changes in cluster membership (none of the points changes cluster).
It is worth mentioning that, unlike the previously discussed algorithms, K-Means is
an unsupervised learning algorithm. Moreover, despite its simplicity and low compu-
tational cost, K-Means has some drawbacks that relate to the number of clusters, the
initialisation of centroids, and the presence of noisy data [52] [54]. The number of cen-
troids k needs to be specified a priori, which sometimes is not trivial, especially without
sufficient knowledge domain. Also, since the initialisation of centroids is random, differ-
ent runs of the algorithm may return different results. Finally, K-Means is not robust to
noisy data, what may skew the update of cluster centers in some cases.
2.3.5 Bagging
Created by Breiman, Bagging (“bootstrap aggregating”) uses several bootstrap sam-
ples to train different classifiers, that are afterwards combined to achieve the final classi-
fication results. Each bootstrap sample is created by randomly selecting examples (with
replacement) from a training set of size m. From n bootstrap samples, n classifiers C1,
C2,...,Cn are built [55], each one using a different training set. The final classifier Cb is
built from all the Cn classifiers, by combining them through majority voting, where ties
are broken arbitrarily (for more details please refer to [56] and [57]).
2.3.6 Boosting
Boosting was created to improve the accuracy of a specific algorithms’ family called
“weak learning algorithms”, which are typically slightly correlated to the true classifi-
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cation. On the contrary, strong learners are algorithms well correlated with the true
labels, providing good classification results. One of the advantages of weak learners is
that they are usually much faster than strong ones. The first Boosting procedure was
introduced by Schapire [58] and worked somehow similarly to bagging. An subset of n
examples (n < the total number of training examples N ) was taken randomly without
replacement from a initial training set (considered to be the training subset Z1). Z1 was
the used to train a weak classifier C1. Afterwards, a training subset Z2 (with n < N ) was
built, containing half the samples misclassified by C1, and another weak classifier C2
was trained. Finally, all the samples of the initial training set N for whose C1 and C2 pre-
dictions disagreed were trained against a third weak classifier, C3. The final classifier
was obtained by a voting scheme of C1, C2 and C3 [59] .
In 1995, Freund and Schapire [60] introduced the most well-known boosting algo-
rithm, called Adaptive Boosting (AdaBoost). In AdaBoost, the idea is to consider a
weighting scheme to select the training subsets. This algorithm starts by considering
a maximum number of classifiers M and weighting each training example equally. The
misclassified examples get their weights increased for the next classification stages,
while the correctly classified examples get their weights decreased. These “weights”
simply determine their probability of being chosen for the training set in the next stages
and therefore, wrongly labelled examples have a higher probability of being used (learned)
again. Moreover, each classifier will get a specific weight attending to its performance
in the training set and the final classifier is defined by a linear combination all the con-
sidered M classifiers, each one contributing with its associated weight [59].
Formulated by Friedman et al., LogitBoost is a probabilistic interpretation of Ad-
aBoost. It fits an additive logistic regression model using Newton steps to find estimates
for its parameters via the maximum likelihood [61] [59]. Instead of using an exponen-
tial loss function (which AdaBoost does), LogitBoost minimises the logistic loss, which
makes it less sensitive to outliers (known to be a bad feature of AdaBoost).
2.3.7 Linear Discriminant Analysis
Linear Discriminant Analysis (LDA) is a linear transformation technique, generally
used to reduce the dimensionality of a dataset in the preprocessing phase, in order to
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decrease the computational cost of classification and avoid overfitting. Nevertheless,
it is also used for classification alone, based on the concept of searching for a linear
combination of features that allows the maximisation of between-class variance, while
minimising the within-class variance. In other words, the optimisation criterion of LDA
is to maximise the ratio of between-class and within-class scatter. LDA, also called
FDA (Fisher Discriminant Analysis), was first developed by Fisher to deal with only two
classes [62]. However, after more than 10 years, this method was extended to deal with
multiple classes [63].
2.3.8 Support Vector Machines
Support Vector Machines (SVM) were first introduced by Vladimir Vapnik for two-
class classification [64]. Basically, this algorithm tries to find the optimal decision hy-
perplane that maximises the separation margin between data points of distinct classes
[65]. The middle of the separation margin defines the decision boundary (optimal hy-
perplane) and the data points that are closest to it are the support vectors. SVM
belong to the general category of kernel methods. Kernel methods can operate in
high-dimensional spaces, since they depend on the data only through dot-products.
This has two main advantages: it allows the generation of non-linear decision bound-
aries and enables the classification of data that has no obvious fixed-dimensional vector
space representation [66][67]. SVM are known for excellent classification performance,
since they can handle high-dimensionality problems and have a good generalisation
behaviour. They balance the model’s complexity against its success at fitting the data,
which translates into a successful trade-off between the model’s flexibility and the error
in training data [67]. However, and despite being a white-box algorithm, they require
a comprehensive understanding of how they work. When training SVM, researchers
have to face several decisions concerning the preprocessing stages of the input data
and the SVM’s hyperparameters (e.g. kernel function, regularisation constant).
2.3.9 k-Nearest Neighbours
k-Nearest Neighbours (KNN) is a supervised classification algorithm in which the
k nearest neighbours of a point are chosen, found by minimising a similarity measure
(e.g. euclidean distance, mahalanobis distance) [68]. To determine the class of an
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unlabelled example, KNN computes its distance to the remaining (labeled) examples,
and determines its k-nearest neighbours and respective labels. The unlabelled object
is then classified either by majority voting – the predominant class in the neighbour-
hood – or by a weighted-majority, where a greater weight is given to points closer to
the unlabelled object. The major drawback of KNN is related to the fact that it is a lazy
learning algorithm. That means that there is no “model”: the training data is not used
to perform any generalisation. Therefore, whenever KNN searches for each instance’s
nearest neighbours, it needs to go through the entire dataset, which is especially prob-
lematic for large databases. Another issue is finding the optimal number of neighbours
(k) and the most appropriate distance metric to use. This requires a careful study of
the dataset and the development of several KNN models, in order to achieve the best
results.
2.3.10 Association Rule Learning
Association Rule Learning allows to unveil the relationship among variables in a
dataset. Proposed by Agrawal et al. in 1993 [69], this method assumes that all vari-
ables are categorical and because of that it is not a good algorithm to deal with nu-
merical data. Each identified association rule follows two main concepts: support and
confidence. Support identifies the percentage of the population that follows a specific
rule. Confidence is the measure of certainty associated with each discovered rule. In
a simple manner, association rules can be perceived as “if-then” rules which describe
relations between the data. They are extremely advantageous due to their exhaustive
exploration of the data [70]. Moreover, the final rules returned by this algorithm are
usually simple enough to be understood by users. Nevertheless, some of their incon-
veniences are that they are affected by noisy data and have a slight tendency to overfit
the data.
2.3.11 Isotonic Separation
Isotonic Separation, developed by Chandrasekaran et al. [71], is a linear program-
ming model that follows the principles of isotonic consistency. The isotonic consistency
constraint assumes an ordering relation of data points in the feature space, given by
“S = {(i, j) : ai ≥ aj}, where ai and aj are coordinate vectors” that represent the at-
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tribute values of i and j, in all d dimensions (for more details please consult [72]).
Therefore, S consists of (i, j) pairs of ordered data points such that, considering a two-
classification problem:
If i is classified as belonging to class ω1, then j must be classified as belonging to
class ω1 and conversely;
If j is classified as belonging to class ω2, then i must be classified as belonging to
class ω2;
Transposing this scheme to the problem of BC recurrence; if, for instance, certain
patients have registered values of age, size of tumour, expression of estrogen receptor,
and so on, that cause them to be classified as “recurrent”; then all patients registering
the same (or greater) values are also considered “recurrent”. Isotonic separation also
takes into account misclassification costs, where each misclassified data point receives
a penalty, for instance, α > 0 for each “recurrent” patient classified as “non-recurrent”
and β > 0 for each “non-recurrent” patient classified as “recurrent”. Isotonic Separation
minimises the total cost of misclassification, αni+βnj, where ni is the number of wrongly
classified recurrent patients and nj is the number of wrongly classified non-recurrent
patients.
2.3.12 Random Forests
Created by Breiman in 2001 [73] Random Forests (RF) instantly became a com-
monly used method, mainly due to its simplicity (in terms of training and tuning) and
performance [74]. Similar to the bagging algorithm (in the sense that it uses individual
decision trees as individual classifiers), RF construct correlated trees. However, in this
case, for each tree node, v features out of the total V input features are randomly se-
lected (considering v << V ) and the best split of v features divides the node. Finally,
the “forest” picks the most voted class, over all the trees in the forest, either by con-
sidering the mode of the classes of the individual trees (classification) or their mean
(regression). By designing a multitude of decision trees and later combining their pre-
dictions, RF decrease the risk of overfitting, usually associated with individual decision
trees [75].
102
2.3.13 Neural Networks
Artificial Neural Networks (ANN) [76] are mathematical-computational models in-
spired by neuronal cells’ functioning, simulating human reasoning. A generic ANN
model is composed by three layers: the input, output and processing layer (or hidden-
layer) [77]. The input layer receives the data, while the output layer communicates
the result. The hidden-layer is responsible for data processing and results’ calculation.
ANN analyse existing patterns in the information they receive and derive associations
between input and output variables. These associations are used to produce the most
correct output for each input, which is then compared to the correct output and, based
on this comparison, the algorithm resets the associations between the input data and
the previously determined output. This process continues iteratively until the correct
result is determined or the maximum of iterations is achieved. Then, the system memo-
rises the model of such association between inputs and outputs in order to classify new
cases.
A Multi-Layer Perceptron (MLP) is a modification of the standard linear perceptron
and can distinguish non-linearly separable data [78]. In is basic form, it is simply a
type of feed-forward ANN. It consist of multiple nodes interconnected in a direct graph,
where the input layer passes the input vectors to the network and the output layer
communicates the response. A MLP can have one or more hidden layers, composed
by neurones with non-linear activation functions (e.g. sigmoid, tangential), responsible
for the computation of results.
The major advantage of ANN models is that they avoid the construction of “if-then”
rules, and its definition by experts. They also do not need a very large set of data to
produce estimates, though the larger the training set is, the more accurate the results
are. On the other hand, the training phase can be time-consuming. However, the main
disadvantage of this type of algorithms is their model’s interpretation – these algorithms
are black-box models, since the associations between data are complex and difficult to
explain.
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2.3.14 Self-Organizing Maps
Self-Organizing Maps (SOM) are a type of artificial networks that use a form of unsu-
pervised learning (competitive learning) to represent the input data in a low-dimensional
space (a map), typically with one or two dimensions[79]. SOM network is built from a
grid of neurons (“nodes”), where each node has a specific position in the grid and is
completely connected to the input layer. Furthermore, each node is associated with a
weight vector, which has the same dimension as the input feature space: feature vec-
tors of d dimensions will origin nodes with weight vectors of size n. Like most ANN,
SOM performs training and testing, or in this case, training and mapping. In the training
phase, SOM builds the map using the input examples, by placing each one next to the
node with the most similar weights, known as “Best Matching Unit” (BMU) [38]. The
BMU’s and adjacent nodes’ weights iteratively adapt every time a new training input is
given to SOM. In the mapping phase, the test input vectors are classified according to
their distance to the existing nodes in the map, constructed in the training phase.
2.3.15 Classification Restricted Boltzmann Machines
Restricted Boltzmann Machines (RBM) are a variant of Boltzmann machines, with
the constraint that there can be only inter-layer connections, i.e., there cannot be con-
nections of nodes within a layer, only between layers. RBM can be seen as stochastic
neural networks, given their neurones-like units whose activation has a probabilistic
element [80]. They typically have one layer of visible units (inputs), and one layer of
hidden units. They may or may not have a bias unit. Each visible unit is connected to all
the hidden units, and the connections are symmetric, meaning that each hidden unit is
also connected to all the visible units. As mentioned above, no hidden unit is connected
to any other and no visible unit is connected to another visible unit.
Despite being mostly used as unsupervised learners, RBM can also be used as
supervised, black-box algorithms for classification [81]. Classification Restricted Boltz-
mann Machines (ClassRBM) are a variant of RBM oriented to classification. In clas-
sification tasks, RBM are treated as parametric models (considering that the number
of hidden layer is fixed) of the joint distribution between the layer of hidden units (neu-
rones) and the visible layer of inputs. Based on this joint probability, ClassRBM can
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compute the distribution p(y | x), that is, the probability of x belonging to y, which
allows the determination of the most probable class label (see [82] for more details).
2.3.16 Genetic Algorithms
Genetic Algorithms (GA) are inspired in Darwin’s Evolutionary Theory which ex-
plains the evolution of species through natural selection. As species evolve in order
to adapt to their environment, a GA also uses a “survival of the fittest” philosophy in
order to obtain the result that best fits the data from a population of individual potential
solutions [83]. A fitness function determines which solutions should be kept and which
should be eliminated. At each generation, a new population is generated and the fit-
ness values of all individuals are evaluated based on their performance in the problem
domain. Three main genetic operators can actuate over each selected population, so
as to generate the next-generation population – copy, crossover and mutation. These
mechanisms are repeated, and the population continues evolving, until the optimal so-
lution (fitness value) is produced, or a stopping condition is reached (e.g. a maximum
number of generations).
2.4 Sampling Strategies
To evaluate a classifier, researchers need to find its true error rate, i.e. the clas-
sifier’s error rate in the entire population. However, in real-world applications, it is not
possible to access the entire population. Only a finite set of examples is available, from
which an estimation of the true error rate must be calculated. A naive approach to
this issue of finite datasets would be to use all the available data to train and test the
models. However, this would return an overly optimistic error estimation and serious
overfitting [54]. For that reason, another approach must be pursued: the division of the
available (and labeled) examples into training and test sets. Following the principles
of supervised learning, the training set is used to build the model, while the test set
is used to perform its evaluation. The techniques to divide data into training and test
sets are called sampling strategies and in this section we will review the ones used
in the reviewed works: Holdout method, Random Subsampling, k-fold Crossvalidation
and Leave-One-Out [54][84][85][86].
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2.4.1 Holdout method
The holdout method simply divides the available examples into two disjoint sets,
according to some percentage. Traditionally, train and test sets are divided in a 50%-
50% partitioning scheme [54], although most authors consider a train/test division of
70%/ 30% or 80%-20%. Holdout is the simplest of the sampling strategies, but along
with its simplicity come some limitations. For small datasets, the holdout method may
be subjected to unfortunate splits, where the training data may not be representative of
the population, which may lead to biased results.
2.4.2 Random Subsampling
In Random Subsampling, we consider several p experiments (runs or splits). Each
split considers a fixed number of random training and test examples, selected without
replacement. Then, for each split, training and testing is performed individually. The
individual error rates ei (determined using each test set) are averaged to form the final
error estimate, according to equation 3. When choosing the samples for each split,
the samples cannot be repeated. However, between splits, the same samples may be
selected. Therefore, Random Subsampling does not guarantee that all samples are
used for training and testing, which constitutes its major drawback.
error =
1
p
p∑
i=1
ei (3)
2.4.3 k-fold Crossvalidation
k-fold Crossvalidation divides the data into k subsets (folds) that rotate, in order to
consider all folds for both training and testing. More specifically, k-fold Crossvalidation
considers k > 1 distinct folds, where k−1 folds are used to train a classifier and the left-
out fold is used for validation. This is performed k times, so that every fold is considered
in both training and test design. Similarly to Random Subsampling, the true error rate
is estimated by averaging the each error ei, obtained from each fold.
The choice of k influences the bias-variance tradeoff in performance estimation
through k-fold Crossvalidation. For small values of k, the bias increases, although the
variance is low; for higher values of k, the error estimate is more close to the true error
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(low bias), but the variance increases.
2.4.4 Leave-One-Out
Leave-One-Out (LOO) is a particular case of k-fold Crossvalidation, when k = N ,
the total number of available examples. Therefore, in LOO, N − 1 examples are used
for training, while the held out example is used to test the classifier. Thus, there are
N error estimates that need to be averaged to determine the final estimate of the error
rate.
In LOO, only one sample is used for testing, which leads to a high variance in error
estimation. On the other hand, since all N−1 are used in the training design, the bias is
low. For that reason, the averaged test set error is a good estimate of the performance
error. When the sample size is low, LOO is the best approach to provide an accurate
estimate of the true error.
2.5 Evaluation Metrics Background
The performance evaluation of a classifier is normally based on a confusion matrix
(Table 3). This matrix illustrates the actual versus the predicted class in classification
problems, where each column of the matrix represents the instances in an actual class
and the rows represent the instances in a predicted class.
Table 3: Confusion Matrix
Actual Class
Negative Positive
Predicted Class Negative True Negative (TN) Fase Negative (FN)Positive False Positive (FP) True Positive (TP)
Based on that matrix, many metrics can be derived. Precision shows the propor-
tion of the correctly predicted positive cases relative to all the predicted positive ones
(equation 4).
Precision =
TP
TP + FP
(4)
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Recall or Sensitivity represents how many positive examples the classifier was able
to correctly identify (equation 5).
Recall =
TP
TP + FN
(5)
Specificity represents how accurately the classifier behaves in terms of predicting
the negative class (equation 6).
Specificity =
TN
TN + FP
(6)
Mean Square Error (MSE) of a classifier represents the different between a vector
of n predictions (Yˆi) and the true observable vector (Yi) for all n examples (equation 7).
MSE =
1
N
n∑
i=1
(Yˆi − Yi)2 (7)
Accuracy represents how many predictions of the classifier were in fact correct
(equation 8).
Accuracy =
TP + TN
TP + TN + FP + FN
(8)
Other measures that can also be used are Area Under the Curve (AUC) and F-
measure. On one hand, AUC is a measure of how well a classification model can
distinguish between two classes. In practice, AUC is often used when a representative
measure of discrimination is needed and it can even replace accuracy as a performance
measure [87].
On the other hand, the F-measure is defined as the harmonic mean of Precision
and Recall, providing a balance between both performance metrics (equation 9).
F-measure =
2 ∗ precision ∗ recall
precision+ recall
(9)
3 Application of Breast Cancer Recurrence
In 1997, Subramani Mani et al. [18] compared the performance of rule-based
classifiers (DT and Association Rules) with a well-known probabilistic classifier (Naive
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Bayes), in the identification of tumor features associated with BC recurrence. The data
was collected from a Breast Care Center in California, where 887 patients were char-
acterised by demographics and tumour-specific information, including diagnostic and
treatment features. From the initial set of features, 6 were hand-picked by a medical
expert to proceed with the study. Since only 10% of the collected patients suffered
from a recurrence event (85 patients), the majority class (no-recurrence) was randomly
divided into 6 datasets, in order to follow a 60%-40% class distribution (no-recurrence /
recurrence) in each dataset. Naive Bayes proved to be the best approach with an aver-
age accuracy of 68.3%, overcoming all others in the majority of the tested datasets. A
particular type of association rule, the First Order Combined Learner (FOCL) has also
stood out with an average accuracy of 66.4%.
This work rises a common controversial topic within the bioinformatics community:
the discussion between classification results and interpretability. The use of rule-based
classifiers is generally encouraged in medical contexts [18][88][89], due to the addi-
tional information they provide. However, as shown by this work, they did not offer
leading results in terms of classification accuracy. Moreover, most of the generated
rules reflected a somewhat obvious knowledge domain, which does not constitute a
meaningful contribution to medical experts. From a technical perspective, there are
some points to be further discussed in this work, namely the feature selection phase,
the sampling phase and the evaluation metrics used. Although some works make use
of clinical guidance to select relevant variables to study, they should be clearly stated
to allow a proper comparison with related works. Furthermore, the explanation of the
division of patients into the considered 6 datasets is too vague. As it is stated, it seems
that the division of the majority class (no-recurrence) followed a random subsampling
method, which does not guarantee that all samples are used to model/test the clas-
sifiers. Therefore, important information might be unused due to the sampling phase
design. Finally, in spite of the authors’ efforts to design datasets with more appropriate
class distributions, they still suffer from a considerable imbalance, which requires the
evaluation of algorithms to go beyond the traditional accuracy measure, more efficiently
applied to balanced classes. However, accuracy was the only metric used, which may
hint on misleading conclusions.
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In 2003, Jose´ Jerez-Aragone´s et al. [24] employed a hybrid model, combining ANN
and DT, to a database from a hospital in Malaga, Spain, in order to determine whether
a patient will suffer a post-surgical relapse at any period during follow-up time, consid-
ering an end-point of 5 years. Out of 85 available features (including demographics,
post-surgical and treatment information), a subset of 14 features was selected by med-
ical experts as the most relevant for predicting outcome. The hybrid model was then
used to predict BC recurrence for seven different time intervals from the surgical in-
tervention. The first six intervals are equally spaced (10-month periods), while the
remaining one considered a period of over 60 months. Initially, the dataset was con-
stituted by 1035 patients, but records with Missing Data were discarded, resulting in a
decrease of the sample size: from 845 patients for the first interval to 466 patients for
the last interval. Using a holdout method (80% train / 20% test), the performance of
the proposed hybrid approach was compared to a Cox statistical technique, commonly
used by medical experts. In terms of accuracy, the proposed approach outperformed
the Cox model in all intervals (with results ranging from 93.4% to 96%), except for the
last interval (>60 months), lagging behind by just 0.3%. To complement the accuracy
analysis of the proposed method, recall, precision and specificity measures are also
included. Recall varied between 78.7% and 88.7%, while precision ranged from 64.8%
to 77.2% and specificity between 94.5% and 97.2%.
The combination of DT with ANN is an interesting approach, since it does not discard
the advantages of one in favour of the other. DT provides useful information for selecting
the most relevant prognostic factors for each considered interval, while ANN are able
to use that information to make an accurate prediction, using personalised topologies
for different time intervals. By not choosing one algorithm over the other, the authors
take advantage of each one’s potential, achieving accurate, yet interpretable results,
which is an improvement from the previous illustrated work. Also, in this work, the
authors have in mind that accuracy is not always the best classification metric, and
complement this information with additional metrics (such as sensitivity and specificity),
allowing for a better evaluation of the power of the proposed method. Nevertheless,
some topics remain for discussion. Although the authors mention that their approach
is appropriate for data with a considerable number of features with missing values, this
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is not supported by the work itself, since the MD perspective is ignored. Furthermore,
its application for a high number of features is not discussed yet, since a medical team
performed the feature selection phase beforehand.
Amir Razavi et al. followed the idea of combining DT with other algorithms to im-
prove the prediction of BC relapse during the first five years after diagnosis [23]. In
2005, they applied Canonical Correlation Analysis (CCA) as a preprocessing step,
prior to classification, to study the influence of dimensionality reduction in prediction
performance. They used a dataset obtained from a Swedish regional center, with 3949
patients characterised by more than 150 features. Following the same methodology as
the previous discussed works, the feature selection phase was performed by a team
of medical experts, resulting in a decrease of the feature space to only 17 predictors.
However, unlike previous works, values for MD fields were imputed using the Expec-
tation Maximisation (EM) algorithm [23]. A 10-cross validation procedure was used to
evaluate the performance of three different predictive models: (i) DT coupled with CCA,
(ii) DT without any preprocessing step and (iii) DT with MD imputation as the only pre-
processing step. The results showed that DT coupled with CCA overcame the other two
approaches in terms of accuracy (67%) and specificity (63%); yet lagging behind both
in terms of sensitivity, which is generally not a good indicator. However, it is important
to state that this solution yields trees with only 10% the size of those without prepro-
cessing, resulting in a simpler system, and improving interpretability. Still, it would be
interesting to make a comparison between rule-based models and other types of clas-
sifiers, and their behaviour when coupled with the mentioned preprocessing strategies.
In 2007, the same authors applied the previously developed combined model (CCA +
DT) to predict BC recurrence within four years after diagnosis [19]. The used dataset
consisted in 3699 patients (with absent observations), where 664 (18%) suffered recur-
rence in the first four years of follow-up. MD imputation was performed using Multiple
Imputation (MI), and 10-fold cross validation was used to estimate performance error.
A hundred cases were previously separated from the initial dataset (by stratified ran-
dom sampling) to validate the developed model against the predictions of two medical
experts (Oncologist 1 and 2).
Although the comparison of the AUC (area under the ROC curve) values between
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the three approaches (DT and two oncologists) did not significantly differ, a more de-
tailed analysis on the performance results is required. The authors present the confu-
sion matrix for the validation set of 100 patients (81 without and 19 with recurrence) but
at no point do they make a critic comparison of the results. In fact, despite a higher
accuracy (82%) and precision (57.1%), DT is overpowered by one of the two medical
doctors collaborating in the study (Oncologist 2) in terms of AUC values, specificity and
F-measure. With a training and validation set presenting such a high imbalance (80%
without recurrence - 20% with recurrence), the sensitivity should assume a pivotal im-
portance. Sensitivity results are poor for DT (21.1%); however, Oncologist 1 had an
even lower rate of sensitivity (5.56%), despite having a higher percentage of specificity
(97.5%).
The poor results of DT in this work might be explained by the dominance of “no-
recurrence” cases in the training model. Although the authors discuss the usage of
sampling strategies to balance the dataset, they do not apply them, presenting argu-
ments such as the small sample size or the lack of representativeness they would gen-
erate. However, this should have been considered since it is not clear that the proposed
approach is the most suitable to predict BC recurrence: Oncologist 2 had a sensitiv-
ity rate of 57.8% without severely compromising precision (50%), by analyzing patient
records with missing data.
In the same year, Yijun Sun et al.[20] combined clinical and genetic information to
create a “hybrid signature”, capable of predicting BC recurrence in the first five years
after diagnosis. This work makes use of microarray data, publicly available in the Na-
ture website [90]. The dataset includes 97 patients, 46 of which suffered recurrence,
while 51 remained recurrence-free. According to previous works using this dataset [91],
it also contains MD, although this perspective is not addressed throughout the work.
Preprocessing steps before classification include data standardisation (Min-Max) and a
feature selection algorithm (I-RELIEF), developed earlier by Sun and Li [92]. Four differ-
ent approaches are tested: one using only genetic markers; another using only clinical
markers; a hybrid signature (including genetic and clinical information); and St. Gallen’s
criterion [93], a consensus criterion to determine recurrence used in oncology guide-
lines. To compare the performance between the approaches, the authors specified a
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threshold for each one, in a way the sensitivity is 90% for all. Then, the comparison
was done by analysing the corresponding specificity values: 47%, 48%, 67% and 12%
for genetic-only, clinical-only, hybrid signature and St. Gallen approaches, respectively.
The ROC curves for the first three approaches were also compared, with the hybrid
signature outperforming the other two (which in turn showed a similar behaviour).
It must be noted that this is the work that includes the smallest number of patients.
With a small sample size, there is a higher danger of overfitting the training data. To
avoid this problem, a nested Leave-One-Out Cross Validation (LOOCV) is adopted [20].
In a nested crossvalidation, an inner loop is responsible for the selection of the optimal
classification parameters (for I-RELIEF in this case), while in the outer loop the clas-
sification of the held-out sample is performed. Linear Discriminant Analysis (LDA) is
used in the classification task (outer loop), since it does not require the estimation of
hyperparameters, and thus makes the experiments computationally less expensive.
Before Sun, some authors had previously attempted to combine genetic and clini-
cal information, but rather unsuccessfully [94][95], which reinforces the achievements
of this work. On one hand, one may argue that 67% is far from an optimal specificity
result. On the other hand, it must be noted that the proposed hybrid signature improved
the specificity of the remaining approaches by nearly 20% to 60%. This proves that the
combination between genetic and clinical information is a suitable approach to deter-
mine the prognosis of BC patients, even though combination strategies are difficult to
design.
Also in 2007, Young Ryu [28] used the Ljubljana Breast Cancer Dataset (Breast
Cancer Dataset available in UCI Repository [16]) to compare several methods to pre-
dict BC recurrence in the first five years after removal of tumour: isotonic separation,
robust linear programming (LP) and three variants of DT (C4.5, OC1 and QUEST),
SVM, AdaBoost and learning vector quantisation. The Breast Cancer Dataset con-
tains 286 patients, where 201 (70.3%) did not suffer recurrence and the remaining 85
(29.7%) had recurrence events. Each patient is characterised by 9 features, and there
are some missing values. In particular, “node-caps” and “breast-quad” are responsible
for the 9 missing observations present in this dataset. From those 9 missing values,
5 belong to the “no-recurrence” class while the other 4 belong to the “recurrence”. All
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the methods were evaluated according to a holdout method (70% for train and 30%
for test), except for QUEST decision three, which has its own sampling scheme (3-fold
crossvalidaton). The results are presented in terms of error rate; however, to make
them comparable with the remaining works, we translated them to accuracy values
(1 − error). Isotonic separation outperformed all others with 80% of accuracy. Only
the accuracy (conversely, the error rate) was determined for each classifier, which may
be considered a limitation, since the Breast Cancer Dataset is known to have a 29.7%
/ 70.3% of recurrence/no-recurrence distribution [16]. Moreover, a backward sequen-
tial elimination process for feature selection showed that age, menopause status, node
capsules, tumor grade and irradiation were the most relevant features for recurrence.
The most comprehensive study in terms of tested classifiers, feature selection al-
gorithms and performance measures was performed by Thora Jonsdottir et al. [15], in
2008. They implemented 17 classification algorithms, including NB, several variants of
DT and other rule base classifiers (OneR, PART, Jrip), Logistic Regression and some
meta-classifiers, including boosting, bagging and ensemble schemes. Moreover, this
work also uses a wide range of feature selection algorithms, such as OneR, correlation
based feature selection method (CFS), consistency subset evaluator (LVF), RELIEF,
information gain, and C4.5 decision tree. Furthermore, the existing knowledge domain
(from previously published works in BC, medical experts and authors’ experience) is
also explored to select the most relevant features. However, the results from these
feature selection methods are not discussed. The authors do not state if one returned
better results than the other, or, alternatively, if each one’s results were combined to
select a final subset of features. The classification results were evaluated in terms of
accuracy, kappa values, AUC, sensitivity and specificity. The algorithms were run on a
relatively small dataset (257 patients) with high dimensionality (400 features), obtained
from the University Hospital of Iceland (Rose dataset). Jonsdottir’s study focused on
two main goals: (i) predicting BC recurrence within five years after diagnosis and (ii)
predicting recurrence risk (low, intermediate or high) within the same time period. The
latter is out of scope of this review, although the recurrence risk, not as outcome but as
predictor, was also included in (i), in order to determine if the inclusion of this feature
had any influence in predicting recurrence events. In order to fulfil objective (i), the
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authors conducted a feature selection phase that resulted in 3 different datasets:
1. Base-DS, including 98 features selected according to the experience of a medical
expert and the results of the feature selection methods;
2. Med-DS, with 22 features selected from Base-DS by a medical doctor;
3. Small-DS, where only 5 features were manually selected from Base-DS.
The distribution of recurrence/no-recurrence events was 28.4% / 71.6%, exhibiting a
considerable imbalance between classes, which the authors have counteracted by ran-
dom subsampling of patients. The MD perspective was not directly addressed (there is
no information on absent observations in the data); however, all the used classification
algorithms can handle MD directly.
A 10-fold cross validation scheme was used across all classifiers for evaluation. Only
the results for the algorithms with the best results were discussed in this work, namely
NB, DT and PART. However, the incorporation of results for the remaining ones would
have been interesting to allow for a cross-sectional evaluation among different works.
In terms of accuracy, and considering the “risk of recurrence” as an extra feature, DT
overcomes the other two approaches in Base-DS (76%) and Med-DS (77%), lagging
behind PART in Small-DS by just 1% (PART achieves 80% of accuracy). When the
“risk of recurrence” is added, DT still maintains its superiority in both Base-DS (75%)
and Med-DS (76%), although lagging behind NB in Small-DS by just 1% (NB obtains a
78% accuracy). Regarding AUC values, NB outperforms the other two approaches with
and without considering “recurrence risk” as an extra feature, although its superiority
is not highly pronounced. DT obtains sensitivities of 48%, 45% and 37% for Base-DS,
Med-DS and Small-DS, rivalling with PART, whose results were 48%, 33% and 37%
for the same datasets, without considering “recurrence risk”. When the extra feature is
added, both approaches still obtain similar results: 48%, 40% and 30% for DT versus
the 51%, 40% and 32% of PART. Finally, in terms of specificity, all three approaches
obtain very similar (and high) results – from 87%-96% for NB, 86%-96% for DT and
78%-97% for PART – which makes it harder to asses the best one. The authors are not
very conclusive in assessing the best approach, suggesting either NB or C4.5 decision
tree are both suitable to be selected as the best classifier. It can be discussed that DT
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achieves the best performance for Base-DS and Med-DS while Small-DS benefits the
most by using PART. However, in a general view, DT seems to be the best approach,
since it always achieves higher sensitivity results, and higher or comparable specificity.
Furthermore, they have the advantage of producing interpretable rules, and, as the
authors mention, may be clearly visualised when the dataset is small. In addition, the
risk of recurrence did not improve the classification results; nor did the presence of a
high number of features: the results are similar across all datasets. Therefore, it can
be discussed that small dimensional spaces are suitable to address the BC recurrence
context, having as main advantage the reduced complexity of the classification models.
The study developed by Qi Fan et al. [29] in 2010 targeted the internationally avail-
able SEER dataset [96], where 46.996.113 patients are described by a set of 117 fea-
tures. The SEER Public-Use Data used in this work includes patients diagnosed with
breast cancer from 1973 to 2005; however the end-point for determining recurrence
is not specified. Records with Missing Data were ignored, but the number of patients
kept in the final dataset is not mentioned. The feature selection phase was performed
according to the validation of medical experts, with 13 features being selected as final
inputs. A holdout method (80% train / 20% test) was used to evaluate the performance
of five different algorithms, namely ANN and other four variants of DT. The results show
that all the DT variants outperformed ANN in terms of accuracy, with the best accuracy
results being achieved by C5.0 algorithm (71.17%). However, ANN had the highest
precision rate for recurrence events (77.79%), while CART had the highest precision
rate for no-recurrence events (73.75%).
Although nearly all accuracy and precision results are above 70%, a more detailed
discussion should have been presented. Since the final number of patients included
in the study (and of those, how many did or did not recur) is unknown, the readers do
not have the necessary information to evaluate the results. If the class distribution of
recurrence and no-recurrence is not balanced, the accuracy results are not reliable.
Furthermore, although precision results are a common finding in most machine learn-
ing study, they are so in combination with recall results, which translate the sensitivity
of the classifiers. This information is not presented in the paper, and is of much impor-
tance when the objective is to accurately predict a particular class of interest, in this
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case, the “recurrence” class. Furthermore, no single classifier overcomes all others
in the three considered metrics (accuracy, precision for “recurrence” and precision for
“no-recurrence”). Therefore, it is not possible to determine which is the most suitable
approach.
Smaranda Belciug et al. (2010)[30] compared the performance of k-means, SOM
and cluster network in the detection of BC recurrence events, using the Wisconsin Prog-
nostic Breast Cancer (WPBC) dataset [16]. Each record of WPBC dataset represents
the follow-up data for one patient. This dataset includes invasive breast cancer cases
with no evidence of distance metastases at the time of diagnosis, from 1984 to 1995.
Therefore, prior to any classification study, the dataset should first be filtered to translate
a defined end-point (e.g. recurrence within 2-years after diagnosis). The authors do not
specify such in their research, and thus the true BC problematic cannot be identified.
The WPBC dataset is available from UCI Repository, and contains 198 (47 recurrent
and 151 non-recurrent) patients characterised by 34 features. These features describe
the characteristics of the cell nuclei observable in an image of the patient’s breast mass.
According to the dataset description [16], it contains absent observations. Specifically,
“lymph node status” is missing in 4 cases (3 “non-recurrent” and 1 “recurrent”). How-
ever, the MD perspective is never mentioned in this work. From the 34 features in the
original dataset, the authors chose 12 to be used, discarding redundant information un-
necessary to the clustering algorithms. The feature selection process is not mentioned:
the features are selected according to the authors’ assumption on their relevance to the
study, without further elaboration on the subject. The authors compare both training
and testing performance between the used algorithms, except for k-means, where only
the training performance is assessed. For SOM and cluster network, a 10-fold cross
validation procedure is used, and the accuracy results are then averaged to achieve
the final classification results. Cluster network obtained the highest accuracy results in
both training (83%) and testing (78%), versus the 72% and 67% obtained for SOM and
the 62% (training) for k-means. On one hand, cluster network has shown an efficient
behaviour in predicting BC relapse, achieving accuracy results higher than the majority
of the discussed works. On the other hand, this paper fails by disregarding the clear
class imbalance between “recurrence” and “no-recurrence” events (76.3%/23.7%). In
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such cases, as previously mentioned, accuracy is not an appropriate metric, and other
metrics, such as sensitivity and specificity, should be presented.
Furthermore, the fact that the MD perspective is not addressed is quite intriguing,
since clustering methods cannot generally analyse data points with missing data, with-
out further constraints. Usually, if no specifications are provided to the algorithm, data
points with MD are discarded, and thus not clustered. Therefore, if MD has not been
handled in any way, the results may be somewhat biased. Also, the 10-fold cross val-
idation procedure could have been extended to k-means as well, for testing purposes.
Using a LOO approach, each sample would be held out while the remaining were used
for training. Then, the held out sample would be assigned to a class according to its
proximity to the cluster centers, by majority voting, for instance. This would provide the
testing performance for k-means, making it comparable with the remaining approaches.
Furthermore, the authors raise a question that is not further discussed in the paper:
“how many clusters are needed so that the clustering process is optimal?” [30]. SOM
and cluster networks do not require an a priori specification of the number of clusters,
and thus the data points are labeled according to a majority voting of the points belong-
ing to the cluster they are assigned. This could also be achieved by k-means, where
different numbers of clusters had to be tested. The fact that k-means was pre-defined
for k = 2 may help explain its poor results, when compared to the other two algorithms,
that do not have that limitation. In conclusion, despite proving good results, this work
raises some technical questions.
In the same year, Strumbelj et al. (2010) [21] addressed the problem of BC recur-
rence in two directions: as a classification problem, predicting recurrence/no-recurrence
events within 10 years after surgery, and as a regression problem, determining how
many years would it take until cancer reappears. The latter is out of scope of this
review.
Regarding the prediction of recurrence events, Strumbelj compared the performance
of several well-known classifiers, namely NB, DT, SVM, RF and MLP with the evaluation
of two oncologists. A bagging procedure coupled with NB was also considered. The
initial data was provided by Ljubljana Institute of Oncology (not to be confused with the
Breast Cancer Dataset), consisting of 1035 patients characterised by 32 features. After
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removing some features (due to their redundancy) and some patients (whose follow-up
was inferior to 10 years), the final dataset included 881 patients and 13 features, all cat-
egorical. Although the authors state that some of the collected features are redundant,
and that not all features are considered for classification, the criteria to select the most
relevant features is not depicted. Furthermore, no information was given regarding MD.
The distribution of recurrence/no-recurrence events is 51%/49%, thus class imbal-
ance is not a constraint and accuracy is considered an appropriate evaluation metric. A
10-fold cross validation scheme was used to access the performance of the chosen ML
algorithms, where DT, NB (both as a standard formulation and coupled with a bagging
scheme) and RF performed similarly with accuracies ranging from 67.4% to 68%, out-
performing SVM (59.9%) and MLP (60.8%). Therefore, the best approaches (DT, NB
and RF) were further compared with the predictions of two medical experts (two oncol-
ogists), using a validation test of 100 randomly chosen patients. NB classifier achieved
the best results (both standard and considering bagging) with an accuracy of 70%.
However, overall, the accuracy results were very similar, with DT and RF obtaining ac-
curacies of 67% and 68%. Both oncologists lagged slightly behind the ML algorithms,
with accuracies of 63% and 65%. In fact, ML results did not prove to be significantly
higher than the predictions of medical experts. The fact that the final dataset contains
only categorical variables is a topic for discussion in this work. The authors state that
their “preliminary analysis” has not shown significant differences between numerical or
discretised versions of some features in prediction results, although these results are
not presented in the work. This may explain the poor results achieved by SVM and
MLP, which generally tend to deal better with continuous variables [97][98]. However, it
has to be stated that the main objective of this work was not to achieve optimal classifi-
cation results. More than building a successful model to predict BC recurrence, the aim
of this work is to improve the interpretability of machine learning models and develop a
method to assess their reliability. This topic is also out of scope of this study; however,
it highlights the increasing interest of machine learning experts in developing accurate,
yet still easy to use and interpretable strategies to be used by non-machine learning
experts, in particular medical doctors, when dealing with a healthcare context.
In 2012, Woojae Kim et al. [31] studied the application of SVM, ANN and Cox-
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regression model to the prediction of BC recurrence within 5 years after surgery. To
assess the performance of the proposed approaches, three well-known BC prognostic
models were also selected: St. Gallen’s guidelines [93], NPI (Nottingham Prognostic
Index) [99] and Adjuvant! Online [100]. The initial dataset was composed by 1541 pa-
tients from a tertiary hospital in South Korea. However, after discarding patients with
incomplete follow-up, late-stage and male breast cancer patients, as well as patients
suffering from other types of cancers (besides BC), the study population consisted of
679 patients, with 195 recurrence cases (28.7%) and 484 no-recurrence cases (71.3%).
Out of 193 available features, 7 were chosen to be included in the prediction models,
namely “histological grade, tumor size, number of metastatic lymph nodes, estrogen
receptor (ER status), lymphovascular invasion (LVI), local invasion of tumour, and num-
ber of tumours” [31]. They were selected beforehand by the authors in collaboration
with medical experts, and further refined based on Kaplan-Meier and Cox-regression
analysis. The results were evaluated in terms of accuracy, sensitivity, specificity, preci-
sion, AUC, and negative predictive value (NPV), using a holdout method (70% - 30%).
Regarding the computational models, SVM and ANN performed similarly, outperform-
ing the Cox model except in terms of specificity: 73%, 52% and 94% for SVM, ANN
and Cox model, respectively. ANN achieved the best sensitivity (95%) and precision
(80%) results, followed by SVM with 89% and 75%, respectively. However SVM proved
to be the best approach, outperforming the others in terms of NPV (89%), accuracy
(84.58%) and AUC (0.85). The authors further compared the performance of SVM
with the previous mentioned prognostic models: St. Gallen’s, NPI and Adjuvant!. St.
Gallen’s achieved the highest sensitivity and NPV (100%); however, it had poor results
in the remaining metrics. Similarly, Adjuvant! also returned high sensitivity and NPV
results (95% and 83%), although its superiority was not verified for the other metrics.
The same may be said of Cox model, which had the highest specificity (94%), but failed
to keep its advantage over the other performance metrics. Thus, SVM proved a su-
perior performance over the “classic” models for the prognosis of BC recurrence. The
authors highlight that although machine learning algorithms generally achieve higher
performances, their use in clinical practice is still very limited “because they cannot be
easily calculated with a traditional calculator”. In our opinion, they are right in that ML
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are currently not used in practice, despite their undoubtedly higher performance. How-
ever, we don’t agree on the reason. The real reason boils down to the interpretability
again. Even if tools to calculate ML predictions are made available, medical doctor will
not “trust” models they cannot fully understand and interpret. Another point mentioned
by the authors is that ML algorithms can be adjusted to data. For instance, SVM hyper-
parameters may adjusted to different subject populations. This may bring an important
advantage over traditional prognostic models that impose a universal prediction model
for all races or countries.
In that same year, Gouda Salama et al. [32] compared the performance of DT, MLP,
SVM, NB and KNN in the prediction of BC recurrence using the WPBC dataset (similarly
to Belciug et al. the end-point is not defined). The fusion between classifiers was also
explored, to assess if a multi-classifier approach could bring some benefit in terms of
classification performance. The comparison between classifiers was performed using
a 10-fold crossvalidation sampling scheme, and evaluating their accuracy. Among the
five considered classifiers, SVM and DT outperformed all others, with an accuracy of
76.3%, followed by MLP, KNN and NB with 66.5%, 64.4% and 50.5%, respectively.
Moreover, a fusion analysis of two, three and four classifiers was conducted. The first
fusion considered SVM coupled with the remaining: SVM-NB, SVM-MLP, SVM-DT and
SVM-KNN. All the combinations have achieved the same accuracy results: 76.3%. The
fusion of three classifiers considered SVM and DT coupled with the remaining: SVM-
DT-NB, SVM-DT-MLP and SVM-DT-KNN. Once again, all the combinations showed
the exact same accuracy: 76.3%. Finally, the third fusion considered the coupling
of SVM, DT and MLP with the remaining: SVM-DT-MLP-KNN and SVM-DT-MLP-NB.
The combination of SVM-DT-MLP-KNN resulted in an improvement of accuracy, 77.3%,
while SVM-DT-MLP-NB did not improve the previous results, achieving an accuracy of
74.2%. In conclusion, the fusion of SVM, DT, MLP and KNN proved to be superior when
compared to the remaining combinations of classifiers and the other setups of stand-
alone classifiers. This work shows that the combination of classifiers may be beneficial
to the classification performance. However, the authors do not mention what type of
combination was used (using probability results, majority voting or combination rules,
for instance). Also, and as previously mentioned, WPBC is an imbalanced dataset, and
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therefore more appropriate performance metrics would be required, namely sensitivity
and specificity. Finally, the MD perspective is also ignored in this work, which constitutes
another of its limitations.
Also in 2012, Mahantappa Murti [33] used three rule-based classifiers to predict
BC recurrence within five years after surgery, namely RIPPER (Repeated Incremental
Pruning to Produce Error Reduction), Decision Table and DTNB (Decision Table with
Naive Bayes). To conduct the experiments, the database from the Oncology Institute
of Ljubljana (Breast Cancer Dataset) was used. The initial dataset was preprocessed
to remove missing values, and although the final number of patients included in the
study is not mentioned, we assume that all the 9 records with missing data are elim-
inated, thus resulting in a final dataset of (286 − 9) 277 patients. The algorithms are
compared in terms of precision, recall, F-measure and AUC, for both “no-recurrence”
and “recurrence” events. As previously mentioned for the case of Fan et al., when the
objective is to predict recurrence (and considering that this class has always a lower
number of cases), it should be defined as the positive class, and the metrics should be
analysed having that in mind. Only such analysis would provide a meaningful and suit-
able comparison with the other studied works. For that reason, only the performance
results of the “recurrence” class is analysed and compared within this review. Accord-
ingly, RIPPER obtained 72.3%, 36.5%, 84.6%, 50%, 0.4 and 0.58 in terms of accuracy,
sensitivity, specificity, precision, F-measure and AUC, respectively. In turn, Decision
Table achieved 72.7%, 23.5%, 91%, 53%, 0.33 and 0.64 for the same metrics. Finally,
outperforming these approaches, DTNB returned and accuracy of 75.2%, sensitivity,
specificity and precision of 36.5%, 89.6% and 59.6%, respectively, while achieving a F-
measure of 0.45 and AUC of 0.68. Although DTNB outperformed the other approaches,
achieving a good accuracy (75.2%) and specificity (89.6%), the sensitivity results are
very poor, being among the worst approaches reviewed. Similarly, the F-measure and
particularly the AUC results show that this is not a feasible approach to predict BC
recurrence, being only slightly better than random guessing.
In 2013, Tomczak [22] used the Classification Restricted Boltzmann Machine (Class-
RBM) to predict BC recurrence within 10 years after surgery and determine input fea-
tures (symptoms) relevant for disease reappearance. Several methods for learning
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ClassRBM are discussed, namely DropOut, Drop Connect and DropPart [22]. These
algorithms are compared to classical approaches such as NB, SVM, RF and CART
(coupled with AdaBoost, Bagging, and LogitBoost). This work also counted with the
collaboration of two oncologists in order to provide a comparison of machine learning
techniques with the opinion of medical experts. A holdout method (70% train - 30%
test) was used across all computational methods while predictions from oncologists
were obtained using 100 cases of the test set. Overall, the computational approaches
achieved better accuracy results than the medical experts, except for SVM, which per-
formed poorly. ClassRBM and ensemble approaches had very similar results; however,
from all the considered algorithms, the ensemble LogitBoost + CART outperformed
all others with an accuracy of 75%. This work is somewhat of a follow-up of Strum-
belj’s study, using the same dataset provided by the Oncology Institute of Ljubljana (not
Breast Cancer Dataset). However, in Tomczak’s study, the final dataset is composed by
949 patients (there are more patients with a minimum follow-up of 10 years) and 15 fea-
tures (the feature selection process is not discussed). These 15 features include all 13
used by Strumbelj and two more, regarding the application of two different types of ther-
apy (cTherapy and hTherapy). All input features were binarized, resulting in a dataset
composed by 55 binary features. As discussed in Strumbelj’s study, the binarization
of all input features could explain the poor performance of SVM. The distribution of
recurrence/no-recurrence events is not depicted; however, we assume it is very similar
to Strumbelj’s estimates (51% - 49%). The authors do not perform a thorough discus-
sion on the best approach to predict BC recurrence. Nevertheless, they highlight the
ClassRBM’s ability to retrieve relevant information regarding the most important input
features while also achieving a high classification performance.
Alberto Pawlovsky and Mai Nagahashi (2014) [34] proposed a method based on
scoring to select the best configuration to be used in KNN classification of WPBC
dataset (the end-point was not defined). In their approach, patients with missing data
are removed from the study (4 patients), and only 32 features are kept. After discussing
the effects of different combinations of training size and number of neighbours and runs
considered, the authors present their scoring scheme and perform its validation by
addressing the BC recurrence problem. The best classification setting is chosen ac-
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cording to the preprocessing method used (raw data, standardisation or normalisation),
number of k neighbours, number of runs, sample size for classification, average, maxi-
mum, minimum and standard deviation of the accuracy results. Their strategy provided
the best results for a configuration using raw data, 19 neighbours, 80% of samples in
classification and 100 simulation runs. These configurations achieved a mean accuracy
of 76%, and minimum and maximum values of 62% and 90%, respectively. It is also
important to note that, overall, the preprocessing method used does not significantly
affect the final classification results.
Although discussing an interesting topic, this work is more focused in finding a strat-
egy to select appropriate KNN configurations than addressing the particular problem
of BC recurrence: no feature selection is performed and the class imbalance prob-
lem is not addressed (again, only accuracy results are presented). Nevertheless, it
takes into account the existence of absent observations, removing them. The gener-
alisation of this work could be a topic for further research, and its extension to include
sensitivity/specificity results could possibly by a more suitable approach to the BC re-
currence problem. However, as discussed in Section 2.3, it must be noted that KNN
is a lazy learner, as it makes local approximations, without further generalisation, and
thus the classification task for this algorithm is very time consuming. With a consider-
able amount of data, given the number of different combinations to be tested, it could
become infeasible for real-time applications.
In the same year, Zahra Behesti et al. [35] tackled the principles of Genetic Pro-
gramming, by comparing the performance of several genetic approaches when cou-
pled with MLP: Centripetal Accelerated Particle Swarm Optimisation (CAPSO), Parti-
cle Swarm Optimisation (PSO), Gravitational Search Algorithm (GSA) and Imperialist
Competitive Algorithm (ICA). These four hybrid approaches (CAPSO-MLP, PSO-MLP,
GSA-MLP and ICA-MLP) were applied to nine medical datasets targeting different dis-
eases. Among them is the WPBC dataset [16], previously presented. Before running
the simulations, the dataset was normalised and absent observations handled with
mean imputation. All approaches were evaluated in terms of Mean Square Error (MSE),
AUC, accuracy, sensitivity and specificity, following a holdout scheme (80% train - 20%
test). GSA-MLP achieved 0.167 of MSE, 0.55 of AUC, and 79.3%, 7.86% and 80.23%
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of accuracy, sensitivity and specificity. In turn, ICA-MLP and PSO-MLP obtained MSE
results of 0.177 and 0.173 and AUC results of 0.57 and 0.6, respectively. In terms of
accuracy, sensitivity and specificity, these approaches have returned the same results:
78.3%, 43% and 83%. CAPSO-MLP achieved an MSE of 0.170 and an AUC of 0.63
while returning accuracy, sensitivity and specificity results of 80.3%, 52.3% and 83.4%,
clearly outperforming all others and being considered the most suitable approach for
unseen data.
According to the authors, the adjustment of the parameters of PSO algorithm is time-
consuming. The CAPSO approach was created to solve this problem, by using less a
priori parameters, resulting in a simplified tuning process (more automated). The inclu-
sion of the original PSO approach was an important step, to evaluate if the new tech-
nique (CAPSO) improves the results by comparison. However, applying only this type of
algorithms does not provide a real assessment of their performance. There should have
been a setup including a more traditional approach as a baseline for comparison, e.g.
backpropagation, in accordance with other authors cited in this work [101][102],[103]
[104] [105]. This would present the opportunity to compare the two different method-
ologies, verifying whether the proposed algorithms generate better results. Moreover,
the chosen algorithms do not agree with the literature review of this article: GSA is not
referred in any of the cited articles, while others were inexplicably left out (e.g. Arti-
ficial Immune System, Ant Colony Optimisation, and Artificial Bee Colony). ICA and
GSA happen to be the two most recent approaches mentioned, but there was no ex-
plicit indication of the reason to choose them. Nevertheless, the used algorithms are
thoroughly explained, which is especially important in modern techniques.
Still in 2014, Vikas Chaurasia et al. [36] investigated the performance of DT, ANN
and LR in BC recurrence within five years after surgical intervention, using the previ-
ously described Breast Cancer Dataset to conduct their experiments. The results were
evaluated through a 10-fold crossvalidation procedure, by determining the accuracy,
true positive rate, false positive rate, precision and recall for both “recurrence” and “no-
recurrence” classes. As discussed in previous works (Fan et al., Murti), the class of
interest is “recurrence”. For that reason, and to allow an appropriate comparison be-
tween all the research works, we strict our analysis to accuracy, sensitivity, specificity
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and precision results considering “recurrence” as the positive class. In terms of accu-
racy, specificity and precision, LR performed the best, with 74.5%, 92.5% and 64.3%,
respectively, versus the 71.3%, 92% and 54.3% of DT and 73..8%, 88.6% and 58.9%
of ANN. Regarding sensitivity, ANN was the best approach, with 38.8%, over the 31.8%
and 22.4% obtained by LR and DT, respectively. Although ANN achieves the best sen-
sitivity results (is the best classifier in identifying recurrence events), LR is overall the
best approach, outperforming all others in terms of accuracy, specificity and precision.
The authors have also analysed the impact of the chosen feature to recurrence pre-
diction, which revealed that tumour grade is the most explanatory features, followed by
lymph nodes involvement, node capsules, tumour size, irradiation, age, breast quad,
breast and menopause. As many of the works using WPBC dataset, the fact that this
works neglects the MD perspective is its main weakness.
Table 4 presents a resume of the ML algorithms used in each research work and the
performance results of the best approach (highlighted in bold). The results are mea-
sured in terms of accuracy (Acc), sensitivity (Sen), specificity (Spe) and AUC values.
The strategies used for data sampling and handling MD are also depicted.
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Table 4: Comparison of ML algorithms (bold indicates the one that presented the best performance),
achieved results and sampling strategies used in the analyzed studies.
Publications Algorithms Acc Sen Spe AUC MD Sampling
Strategy
Mani et al.,
1997 [18]
NB, CART, C4.5, C4.5
rules, FOCL
68.30% – – – – Stratified Ran-
dom Subsam-
pling Con-
struction of
6 datasets
(40%-60%)
Jerez-Aragone´s
et al., 2003 [24]
ANN+DT 93,4%-
96%
78,7%-
88.7%
94,5%-
97.2%
– Removed 10-fold Cross-
validation
Razavi et al.,
2005 [23]
C4.5+CCA, C4.5 + EM,
C4.5
67% 80% 63% – EM 10-fold Cross-
validation
Razavi et al.,
2007 [19]
C4.5+CCA, Two oncolo-
gists
82% 21.10% 96.30% 0.76 MI 10-fold Cross-
validation
Stratified Ran-
dom Sampling
for validation
Sun et al., 2007
[20]
LDA+hybrid,
LDA+genetic,
LDA+clinical, St.Gallen
criterion
– 90% 67% – Unknown Leave-One-Out
Ryu et al., 2007
[28]
Isotonic Separation,
Robust Linear Pro-
gramming, DT (C4.5,
OC1, QUEST), SVM,
AdaBoost, Learning
Vector Quantisation
80% – – – – Holdout (70% -
30%)
Jonsdottir et al.,
2008 [15]
C4.5, NB, LMT, REP
tree, RF, SVM, Log,
Slog, MetaClass1,
MetaClass2, Meta-
Class3, Bag +REP tree,
DT, OneR, PART, Jrip,
VFI
79%
(Small-
DS)
48%
(Base-
DS)
96%
(Small-
DS)
0,70
(Base-
DS)
Not
men-
tioned,
but
han-
dled by
algo-
rithms
10-fold Cross-
validation
Fan et al., 2010
[29]
C5.0, ANN, CHAID,
CART, QUEST
71.20% – – – Removed Holdout (80% -
20%)
Belciug et al.,
2010 [30]
Cluster network,
k-means, SOM
78% – – – Unknown 10-fold Cross-
validation
Continued on next page
127
Table 4 – Comparison of the DM algorithms, achieved results and sampling strategy used in the analyzed studies
Publications Algorithms Acc Sen Spe AUC MD Sampling
Strategy
Strumbelj et al.,
2010 [21]
NB, NB+Bagging DT,
SVM, RF
70% – – – Considered
as a
sep-
arate
feature
value.
10-fold Cross-
validation
Kim et al., 2012
[31]
SVM, ANN, Cox model,
St. Gallen, NPI, Adju-
vant!
84.58% 89% 73% 0.85 Removed Holdout (70% -
30%)
Salama et al.,
2012 [32]
SVM-DT-MLP-KNN, DT,
MLP, SVM, NB, KNN,
SVM-NB, SVM-MLP,
SVM-DT, SVM-KNN,
SVM-DT-NB, SVM-DT-
MLP, SVM-DT-KNN,
SVM-DT-MLP-NB
77.30% – – – Unknown 10-fold Cross-
validation
Murti, 2012 [33] DTNB, RIPPER, Deci-
sion Table
75.17% 37% 90% 0.676 Removed Unknown
Tomczak, 2013
[22]
CART+LogitBoost,
ClassRBM, Class-
RBM+DropOut, Class-
RBM+DropConnect,
Class-
RBM+DropConnect,
CART+Bagging,
CART+AdaBoost,
NB, SVM, RF, Two
oncologists
75% – – – Unknown Holdout (70% -
30%)
Pawlowsky and
Nagahashi,
2014 [34]
KNN 76% – – – Removed n.a
Beheshti et al.,
2014 [35]
CAPSO-MLP, PSO-
MLP, GSA-MLP, ICA-
MLP
80.25% 52.33% 83.38% 0.63 Mean Holdout (80% -
20%)
Vikas C. et al.,
2014 [36]
LR, C4.5, ANN 74.50% 31.80% 92.50% – Unknown 10-fold Cross-
validation
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4 Discussion
Predicting BC recurrence is a very important challenge for oncological clinicians
because it has direct influence in their daily practice e.g. in choosing the most beneficial
treatment for a patient. Over the past decade, several works have tried to propose
suitable approaches to model BC behaviour; however, after performing this revision, it
is clear that this is still an open problem. This observation is based on five problems
detected in the Reviewed Works (RW):
Lack of data. The majority of RW used local datasets (datasets that contain only data
from a local/regional center), which complicates the replication and further comparison
of results by other researchers. Also, the number of patients enrolled in most of these
studies can be considered small (less than 1000 patients), especially for a common
pathology like BC. The reduced size of the datasets becomes even more critical when
most of the works does not deal with MD, either at all (more than 80%) or with proper
thoroughness. Only three research works have addressed this issue (Razavi et al.,
2005, 2007 [23][19]; Beheshti et al. [35]).
Imbalanced Binary Decision Problem. The second problem, as mentioned in the Intro-
duction, is that the prediction of BC recurrence is a binary classification problem where
the goal is to accurately predict whether a BC patient will or will not recur. To achieve
that, these two classes should be balanced (have similar proportions in the dataset);
otherwise, the algorithms could predict one class better than the other. From our anal-
ysis, it can be noted that the majority of the RW presented imbalanced datasets, which
will somehow degrade the performance of ML techniques. This point could be easily
overcome by using appropriate sampling strategies to balance data, such as Synthetic
Minority Oversampling Technique (SMOTE) [106].
Feature Selection. The third problem concerns feature selection. Only a small num-
ber of works used computational feature selection techniques. Most of the RW use
a manual feature selection process, in which medical doctors are consulted to select
the variables to use in the prediction studies. However, this process has one great
disadvantage: the information that the algorithms are able to find is exactly what they
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were expected to find: the doctors select the variables using previously established
knowledge or informed intuition, which may prevent potentially useful variables from
being used in the models, and new relationships between variables and recurrence to
be found. Also, it is important to note that only one study tried to mix clinical markers
with genetic information [20]. Many of the variables selected in the RW were not mu-
tually exclusive (e.g. BC stage is the conjunction of tumour size, lymph nodes involved
and presence or absence of metastasis) and some were not routinely described as im-
portant recurrence factors (e.g. tumour location included breast regions and laterality),
which could return somewhat misleading conclusions. Moreover, important factors that
must be present in daily clinical practice are missing, such as HER2 expression. The
determination of HER2 expression is mandatory for the definition of intrinsic subgroups
that define BC behaviour. Even in the most frequent BC subgroup (that express hor-
monal receptors - HR), patients with HER2 enriched tumors are associated with a high
rate of brain, liver and lung metastasis [107]. These tumours display also different pat-
terns of relapse and metastatic spread depending on HR status, with a median relapse
free survival of 19.5 months after surgery in HR negative patients compared to 32.0
months in HR positive. Patients with HER2+/HR- disease have significantly increased
hazard of early (0-2 and 2-5 years), but not late death (>5 years), when compared to
HER2+/HR+ [4]. The non-standardization of such set also hampers direct comparisons
between studies and compromises future investigations in the field. A consensus in the
definition of important variables to study and its validation over appropriate datasets is
still a current challenge.
Interpretability. The fourth problem is interpretability, an important concept in the health-
care area. If the expert/clinician cannot validate the approach, it will never be ac-
cepted by the community as a valid one. This sometimes leads to a scenario where
researchers try to find a trade-off between interpretability and performance for their
approaches. Accordingly, it is not surprising that 13 out of the 17 RW used ML tech-
niques that are well known for their interpretability, like Decision Trees. However, other
techniques that are in the opposite side (traditionally achieving higher performance,
although less interpretable) have not been neglected, such as ANN. The comparison
between these different methods is impossible due to a number of factors: the used
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datasets are different, the selected set of features and algorithms do not always match,
and finally the evaluation metrics used are not always the same. Some studies even
use clinicians to validate their approaches. However, hybrid or combination algorithms
generally seem to be among the best approaches.
Evaluation Metrics. Finally, regarding the metrics used in the evaluation phase, it is
quite surprising how 8 of the 17 RW only used accuracy to measure classification per-
formance, specially considering the class imbalance present in the associated datasets.
Accuracy is not the most appropriate metric for imbalanced datasets, since it does not
properly identify the true positive and true negative rates (i.e sensitivity and specificity).
When considering other studies that present both accuracy and sensitivity results, it
can be noted that it is easier to achieve a good accuracy performance than sensitivity
results (only three of the RW presented good sensitivity). This may also be explained
by the imbalanced distribution between “recurrence” and “no-recurrence” cases.
5 Conclusions and Future Work Challenges
As discussed in this revision, predicting recurrence is a key point in the BC context.
However, and in spite of the fact that researchers have tried to address this topic in the
past decade, it remains an open challenge. Based on the previously analysed works,
this can be justified by several factors: it is difficult to obtain a representative dataset
for BC recurrence; there is no standard characterisation of patients (a predefined set
of variables) for this disease and there is still a long path to follow regarding the use
of appropriate ML algorithms, especially when it comes to high performance results
and generalisation ability. Regarding some future directions, a multi-center study can
be created to include the highest number of patients as possible. Also, with the help of
clinicians, a consensus regarding the most important predictors for BC recurrence could
be achieved. From the MD perspective, the use of previously implemented approaches
in other oncology centers, trying to obtain a generalisation of results, can constitute a
good contribution. Another possible direction is to try to combine different techniques for
performance improvement, following to work proposed by Jerez-Aragone´s [24]. Finally,
the development of new ML algorithms or the exploration of ML algorithms never used
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in this context may also constitute a valid perspective.
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Chapter 3
Predictive Factors of Response to
Therapy
Treatment approaches in MBC patients have been extrapolated from female, in the absence of
trials in MBC [1].
Actually, there are already some differences regarding endocrine therapy between genders.
In MBC patients with tumours that express hormonal receptors, the standard endocrine therapy
in early and advanced disease is tamoxifen [2]. Aromatase inhibitors (AI), namely anastrozole did
not appear to have as a complete estrogen suppression as in women, and also raise testosterone
levels by 58% [3], leading to an increase of androgens that become available for conversion to
estrogen [4]. In adjuvant setting there was a retrospective study that compared tamoxifen and AI
in MBC patients [5]. For a total of 257 men with BC in stage I or II, 50 were treated with AI and
207 with tamoxifen with a higher risk of death for AI group (HR: 1.55, 95% IC:1.13-2.13).
The evidence to tamoxifen use in adjuvant setting in MBC patients come from retrospective
studies [6–8] that demonstrated survival benefit (17% improvement in 5-year overall survival)
[9] compared to controls that did not perform any endocrine therapy. In that time, the duration
of tamoxifen was less than 2 years, and so these results could probably underestimate the real
impact of this drug in male, which may improve with longer duration of therapy. The longer against
shorter (ATLAS) trial in women [10], than supported the administration of 10 rather that 5 years
of tamoxifen, did not include MBC patients, and so the decision on whether to continue treatment
beyond five years in these patients should be based on an individual consideration having into
account the side effects. These adverse symptoms may include: decreased libido (22-29%),
weight gain (22-25%), hot flashes (13-21%), mood alterations (3-21%) and depression symptoms
(3-17%) [11, 12], and are responsible for a large proportion of treatment discontinuations before
5 years with a negative impact in outcomes [11–13] . The adherence of MBC patients falls from
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65% at first year to 18% at the fifth year [13] and low adherence was associated with lower
10-year rate of DFS (42 vs 73%) and OS (50 vs 80%) [11].
Comprehensive analysis of tamoxifen and 22 of its metabolites confirm that endoxifen is the
most abundant active metabolite of tamoxifen [14–16]. Bioactivation of tamoxifen to endoxifen
is mediated by a multitude of cytochrome P450 (CYP) enzymes, with CYP2D6 being central to
metabolic activation [17, 18]. There are some geographic variations described in this expression
[19] and over the years more than 25 reports investigating whether or not CYP2D6 genotype
influences the efficacy of tamoxifen treatment in FBC patients have been published [20]. The
principal studies about this issue are summarized in Table 3.1.
The conclusions of these studies are contradictory and range from a possible longer DFS
interval to a substantially shorter recurrence-free survival time for patients carrying CYP2D6
genotypes conferring diminished tamoxifen metabolism. The inconsistency in these results is
likely attributable to heterogeneity in study designs and patients populations regarding to: DNA
sources (tumour, blood), phenotypes evaluated (efficacy, toxicity, pharmacokinetics), study de-
signs (retrospective, prospective), different treatment settings (adjuvant and palliative), different
tumours (with and without expression of hormonal receptors), and different concomitant medi-
cations (other anticancer medications and CYP2D6 inhibitors) [43]. These findings have led to
confusion among clinicians regarding whether or not CYP2D6 genotyping should be performed
in daily practice, and Peppercorn et al. [44] reported that in USA, 31% of oncologists ordered this
test outside a clinical trial and 14% reported routine use of the test in their clinical practice.
In MBC there was no study that addressed the role of CYP2D6 polymorphism in the efficacy
of tamoxifen despite of the importance of this drug in these patients’ approach.
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Abstract
Background: Tamoxifen remains the standard hormonotherapy for Male breast cancer
patients (MBC). Previous studies, in women, tried to evaluate the impact of CYP2D6
polymorphisms in tamoxifen efficacy with conflicting results. Herein we analyze the
relation between CYP2D6*4 polymorphism and survival in MBC patients.
Patients and Methods: Fifty-three patients, proposed to tamoxifen in adjuvant set-
ting, were enrolled. Clinical information was collected from records and histological
revision with additional immunohistochemical analysis was done to better characterize
the tumours. Comprehensive CYP2D6*4 genotyping from blood or tumour tissue was
performed and translated into two predictive metabolic activity groups.
Results: Patients included in the two CYP2D6*4 groups did not differ concerning to
age, histological characteristics, and primary treatments performed. Median age at
diagnosis was 63 years-old and patients were submitted at least to mastectomy and
adjuvant hormonotherapy. Recurrence was observed in 7 patients (13.2%) and 13
patients (25.5%) died with a 5-year disease-free survival of 86.2%. The poorer metab-
olizer group had a high risk for recurrence (p= 0.034) and this outcome effect remains
in different subgroups: in tumours larger than 2 cm (p < 0.001), nodal status, N0 vs N+
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(p= 0.04) and in advanced stage, stage III (p< 0.001). Poorer metabolizer patients had
also a worse overall survival when tumours were larger than 2 cm (p= 0.03).
Conclusions: In our series, there was an association between CYP2D6*4 polymor-
phism and a probability of recurrence, with a consistent effect in risk groups defined
by classic prognostic factors. Multicentric studies with larger samples are needed to
validate these results.
Keywords: Male breast cancer, Tamoxifen, CYP2D6*4 polymorphism, Disease-free
survival, Overall-survival
1 Introduction
Male Breast Cancer (MBC) is a rare disease, accounting for approximately 1% of
all breast carcinomas [1, 2, 3]. Its incidence has limited the development of research
studies and treatment recommendations are presently derived from the standards for
female breast cancer, even though there are already many established differences be-
tween them [4, 5, 6].
Tamoxifen remains the standard adjuvant hormonotherapy in the treatment of MBC
with expression of hormonal receptors (the vast majority of the cases) [7, 8], as the use
of aromatase inhibitors without concomitant suppression of testicular steroidogenesis is
not ineffective and did not appear to have a complete estrogen suppression compared
to that observed in postmenopausal women (with only a 50% decrease in estradiol
level). In addition, therapy with anastrozole raise testosterone levels by 58% with a
secondary elevation of estrogen levels (loop effect) [9].
The growth inhibitory effect of tamoxifen is mediated by its active metabolites (4-
hydroxytamoxifen and endoxifen), and this conversion to active formulas is mediated by
polymorphic cytochrome P450 2D6 (CYP2D6) enzyme [9, 10].
The wide variety of responses and side effects of tamoxifen in different patients,
questioned whether these differences result from an inter-individual genetic variability
[11, 12]. Since 2003, more than 20 studies tried to define the role of CYP2D6 poly-
morphisms in the efficacy of tamoxifen in females with breast cancer [13, 14]. These
studies lead to conflicting results and several reasons are given to justify the inconsis-
tency, namely the designs used and the types of patients enrolled [11, 13].
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In the absence of studies regarding male breast cancer, the present study was per-
formed to determine whether CYP2D6 variation is associated with clinical outcomes in
patients receiving adjuvant tamoxifen.
2 Material and methods
2.1 Study population
The study population comprised 53 males with breast cancer treated in the same
tertiary cancer Institution (Portuguese Institute of Oncology of Porto), from 1992 to
2012, with a median follow-up of 5 years (1-19 years). The patients’ inclusion criteria
included: male gender, histological confirmation of breast carcinoma, tumour expres-
sion of hormonal receptors, stage I, II or III and adjuvant treatment with tamoxifen 20
mg/day. From the clinical records, information about patients and tumour characteris-
tics, treatments and survival was collected by the same Oncologist. This study was
approved by the local ethics committee.
2.2 Study design
The association between CYP2D6 variations and clinical outcomes was assessed
based in two end points: disease-free and overall survival, defined as the time from
surgery to first occurrence of a breast event and as the time from surgery to death from
any cause, respectively.
2.3 Immunohistochemical characterization of the tumours
The histological specimens available were reviewed by two independent breast Pathol-
ogists and additional immunohistochemical analysis was performed to better character-
ize the tumours. This process was done in a blinded way from clinical information. The
histological grade was assessed with the Nottingham score. From the immunohisto-
chemical analysis, estrogen and progesterone receptors were considered to be positive
if ≥ 1% cells showed nuclear staining [15], Ki67 staining was interpreted as low or high
by the use of a 14% threshold [8], p53 staining was considered to be positive if ≥ 5%
cells showed accumulation [8] and androgen receptors were considered positive when
at least 10% of nuclei were stained [8]. Cases were considered to be HER2-positive
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when they were 3+ by immunohistochemically test, according to the Dako score, or
FISH-amplified.
2.4 DNA source, genotype and definition of phenotype
Genomic DNA was prospectively collected and extracted from whole blood in live
patients (n = 38, 71.7%) and retrospectively from paraffin-embedded tumour tissues
in dead patients (n = 15, 28.3%). Peripheral blood was sampled in K2EDTA plastic
vacutainer tubes and after centrifugation, germ line DNA was extracted from the pre-
cipitated leucocyte cell fraction according to the commercial Kit ”QIAmp DNA Blood
Mini Kit” (Qiagen c©), following the manufacturer’s instructions. For paraffin-embedded
tumour tissues, extraction of DNA was performed using a manual extraction method.
Genotyping for the CYP2D6*4 polymorphism (rs 3892097 1846G> A) was analyzed
by allelic discrimination using 7300 real-time polymerase chain reaction system (real-
time PCR) (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed
in a 6 ul reaction mixture, containing 1 × Master Mix (Applied Bio- systems, Foster
City, Ca, EUA), with 1 × probes (TaqMan assay C 27102431 D0, Applied Biosystems,
Foster City, CA, EUA) and 90 ng of the DNA sample.
Quality control procedures implemented for genotyping included double sampling
in about 10% of the samples to assess reliability and the use of negative controls to
step-away false-positives. The genotype frequencies from tissue samples are in Hardy-
Weinberg equilibrium.
To analyze the proposals, patients who have the A allele (in a homozygous or het-
erozygous form) were considered the poorer tamoxifen metabolizers, and were referred
in the text as CYP2D6*4 A+ versus those that do not have the A allele mentioned as
CYP2D6*4 A−. Pharmacogenetic analysis was performed in a blinded way from clinical
information.
2.5 Statistical Analysis
To reduce the effect of time, time-dependent variables were adjusted or grouped
in main categories (stage was adjusted to 7th edition of AJCC Staging, and treatment
was grouped in categories). X 2 test was used to compare categorical variables and
t-student test was used to compare parametric continuous variables.
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Survival curves were calculated by the Kaplan-Meier method and compared using
the log-rank test. Statistical significance was defined as p < 0.05. SPSS for Windows
version 19.0 (SPSS Inc., Chicago, IL, USA) was used for statistical calculations.
3 Results
All patients were Caucasians, with a median age at diagnosis of 63 years-old (range
from 35 to 95 years-old).
The majority (51.0%), had at least one risk factor for cardiovascular diseases, with
34 patients (64.2%) presenting excessive weight or obesity (body-mass index superior
to 25 or 30 kg/m2 respectively). In 46 patients (86.8%) it was possible to evaluate the
family history. Twenty-eight patients (52.8%) had a positive history of cancer and 37.5%
of these patients had a first degree member (women) with breast cancer. The genetic
test was performed in 23 patients (43.4%) and 3 of them (13.0%) presented mutation
of BRCA genes (BRCA2 in 67%). During the follow-up, 8 patients (15.1%) developed a
second primary tumour (prostate cancer in 75% of the cases).
All patients were evaluated for CYP2D6*4 mutations and 36 patients (67.9%) were
considered CYP2D6*4 A−. The principle characteristics of patients and tumours clas-
sically related to recurrence and/or death were well balanced between groups defined
by CYP2D6*4 genotypes (see Table 1).
All patients underwent, at least, mastectomy and adjuvant hormonotherapy with ta-
moxifen. There were no major problems registered concerning therapeutic adherence.
Chronic patients’ medication did not include paroxetine or fluoxetine. The only variable
related to adjuvant treatment choice was stage (p = 0.001).
3.1 Survival Analysis
Recurrence was observed in seven patients (13.2%), with a 5- year disease-free
survival of 86.2%. In half of the cases (50%), there was only visceral metastasis (lung,
33.3% or liver, 16.7%), and in 16.7% bone was the only site affected. In metastatic
setting, five patients (71.4%), received palliative treatment, with chemotherapy in 80%.
CYP2D6*4 genotypes were associated with recurrence (p = 0.03), with the CYP2D6*4
A− group having an estimate disease-free survival of 17.9 years (95% CI: 16.4-19.3
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Table 1: Patients and tumours characteristics by CYP2D6*4 subgroups.
Characteristics
Overall CYP2D6*4 A− CYP2D6*4 A+
P value
(N=53) (N=36) (N=17)
Age at diagnosis, median (range), years, n = 53 63 (35-95) 63.5 (44-85) 61 (35-95) 0.25
Follow-up, median (range), months, n = 53 57 (9-228) 54.5 (9-228) 99 (20-225) 0.12
Tumor laterality, left, No. (%), n = 53 28 (52.8) 20 (55.6) 8 (47.1) 0.56
Tumour size, cm, No. (%), n = 53
≤2 27 (50.9) 15 (44.1) 12 (70.6)
0.07
>2 24 (45.3) 19 (55.9) 5 (29.4)
Nodal status, No. (%), n = 53
N0 22 (41.5) 14 (38.9) 8 (47.1)
0.57N+ 31 (58.5) 22 (61.1) 9 (52.9)
Histological grade, No. (%), n = 51
1 11 (21.6) 7 (20.6) 4 (23.5)
2 25 (49) 15 (44.1) 10 (58.8) 0.42
3 15 (29.4) 12 (35.3) 3 (17.6)
Stage, No. (%), n = 53
I 16 (30.2) 11 (30.6) 5 (29.4)
II 16 (30.2) 11 (30.6) 5 (29.4) 0.98
III 21 (39.6) 14 (38.9) 7 (41.2)
Hormonal receptor positive (ER and/or PR), No. (%), n = 53 53 (100) 36 (100) 17 (100) 1
HER2, No. (%), n = 47
Negative 43 (91.5) 29 (87.9) 14 (100)
(a)Positive 4 (8.5) 4 (12.1) 0 (0)
AR, No. (%), n = 41
Negative 7 (17.1) 5 (16.1) 2 (20)
0.77Positive 34 (82.9) 26 (83.9) 8 (80)
Ki67, No. (%), n = 41
≤14% 25 (61) 19 (61.3) 6 (60)
0.94
>14% 16 (39) 12 (38.7) 4 (40)
p53, No. (%), n = 42
Low 32 (76.2) 23 (74.2) 9 (81.8)
0.61High 10 (23.8) 8 (28.8) 2 (18.2)
Primary treatment, No. (%), n = 53
Surgery + hormonotherapy 18 (34) 11 (30.6) 7 (41.2)
Surgery + hormonotherapy + radiotherapy 15 (28.3) 11 (30.6) 4 (23.5) 0.62
Surgery + hormonotherapy + radiotherapy + 20 (37.7) 14 (38.9) 6 (35.3)
chemotherapy ± trastuzumab (b)
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor.
(a) Not possible to compare (there were no tumors in CYP2D6*4 A+ that express HER2).
(b) The use of trastuzumab was done according to HER2 expression.
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Figure 1: Disease-free survival by CYP2D6*4 genotype.
years) in contrast with the 13.1 years (95% CI: 9.5-16.6 years) in the CYP2D6*4 A+
group, Figure 1.
Thirteen patients (24.5%) died with a 5-year overall survival of 78.5%. In general,
CYP2D6*4 genotypes were not related to overall survival (p = 0.95), with an esti-
mate survival for CYP2D6*4 A− group of 13.7 years (95% CI: 10.6-16.8 years) and
for CYP2D6*4 A+ group of 13.2 years (95% CI: 9.8-16.6 years).
The survival effect of CYP2D6*4 genotypes was also evaluated according to dif-
ferent groups, in classical predictive factors of recurrence and death: age, tumour
size, nodal status, histological grade, stage, expression of HER2, androgen recep-
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tors, Ki67, p53 and primary treatments. The groups with sufficient cases that allow
survival comparisons, between CYP2D6*4 genotypes, can be seen in Table 2. In re-
currence, CYP2D6*4 genotypes maintain their discriminatory capacity in tumours larger
than 2 cm (mean disease-free survival for CYP2D6*4 A− :17.9 years vs 3.6 years for
CYP2D6*4 A+, p < 0.001), nodal status, N0 and N+ (mean disease-free survival for
N0 tumours CYP2D6*4 A−: 17.7 years vs 11.7 years for CYP2D6*4 A+, in N+ tumours
14.3 years vs 13.1 years, p = 0.04) and in advanced stage, stage III (mean disease-free
survival for CYP2D6*4 A− :17.8 years vs 9.1 years for CYP2D6*4 A+, p < 0.001).
In tumours with more than 2 cm, CYP2D6*4 genotypes predict a different overall
survival (mean of 13.9 years for CYP2D6*4 A− vs 4.6 years for CYP2D6*4 A+, p =
0.02).
4 Discussion
For our knowledge this is the first study that addresses the role of CYP2D6*4 poly-
morphism in survival outcome of receptor positive MBC patients treated with tamox-
ifen in adjuvant setting. In our series, the poorer metabolizer patients, defined by the
presence of A allelle (CYP2D6*4 A+ group) had an early recurrence and CYP2D6*4
genotypes remain their discriminatory capacity for recurrence in classical risk groups
for metastization: in tumours with more than 2 cm, in N+ disease (versus N0) and in ad-
vanced stage (stage III). Although we did not find a global impact in overall survival, the
association between CYP2D6*4 genotypes and death in patients with tumours larger
than 2 cm, could guide future investigation in this particular group of worse prognosis.
The rarity of MBC hinders the development of randomized controlled trials. How-
ever and particularly in the controversy between CYP2D6 genotype and tamoxifen re-
sponse in postmenopausal women, there are already many authors that agree that
purely observational studies may have equally good standardization of the population
and the outcomes of interest as randomized controlled trials [16]. Still in women do-
main, many possible factors have been proposed to justify the variations among the
studies: many DNA sources (tumour, blood), different phenotypes evaluated (efficacy,
toxicity, pharmacokinetics), several studies designs (retrospective, prospective), with
different populations (adjuvant and palliative settings), different tumours (with and with-
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out expression of hormonal receptors), and different concomitant medications (other
anticancer medications and CYP2D6 inhibitors) [9]. This heterogeneity weakens the
comparisons between studies as demonstrated in the published revisions and meta-
analysis [13, 14, 17] and compromises future works.
In relation to our population study, all patients were Caucasian, all tumours express
hormonal receptors and all patients were treated with the same intention (adjuvant)
with the same drug (tamoxifen). As previously described, CYP2D6 polymorphisms
have geographic and ethnic variations (Caucasian vs Asiatic), and some studies (71%,
according to Lum et al. [14]) enrolled patients with a mixture of tumours with and with-
out expression of hormonal receptors, who do not benefit from tamoxifen, and therefore
would not have differential benefit based on CYP2D6 activity. Other possible confound-
ing factors consisted in the adherence to tamoxifen, the used dose, and the admin-
istration of CYP2D6 inhibitors that could influence the endoxifen concentrations and
potentially tamoxifen efficacy [18, 19, 20]. Contrarily to Bijl et al. [21] and Lammers LA
et al. [22], the used dosage in our series was the same (20 mg/day) and any patient
reported concomitant administration of paroxetine or fluoxetine. In compliance domain,
the published studies [23, 24] show that the rates of tamoxifen discontinuation in males
are near 20.3%, fewer than in women (range from 30 to 50%) [25] and are secondary
to side effects, mainly weight gain and sexual dysfunctional/loss of libido. In our series
there was no major compliance problems registered. The free delivery of hormonother-
apy in our Institution could have contributed to this fact.
Another major limitation of the new studies [26, 27, 28] is the use of tumour DNA to
determine germline genotypes. As the CYP2D6 phenotype results from germline pre-
disposition, it must be assessed from DNA that is derived from normal cells, because
tumour cores contain insufficient numbers of normal epithelial cells for detection [29].
The DNA analyzed in our series was extracted from blood in the majority of the cases
(71.7%) and the genotype frequencies from the tumour DNA are consistent with those
expected by Hardy-Weinberg equilibrium, which are compatible with genotyping quality
[30]. We choose the CYP2D6*4 to genotype, to be the most prevalent in the Caucasian
race, the more frequent analyzed in the adjuvant setting and to have also a pharma-
cogenetic model developed based on it [13, 14, 17, 31, 32]. The possible limitation
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of this approach, namely the misclassification phenomenon [33, 34], was not probably
relevant attending the rarity of MBC, with less impact in the evaluated endpoints.
With the knowledge from the recent studies, we could state that MBC is a different
entity from female breast cancer [5], with a more advanced age at diagnosis (median of
63 years-old in our report) and with some distinct risk factors proposed, like imbalance
between androgen and estrogen and constitutional variables (63.6% of patients had
excessive weight or obesity) [5, 35, 36].
The tumour size (>2 cm) and lymph nodes involvement are documented prognostic
factors, and others like age and stage were already proposed with some controversy
results [37, 38]. This could justify different approaches even in metastatic setting, where
there were only few publications described the role of aromatase inhibitors in MBC
patients [39, 40, 41], remaining doubts about the best hormonotherapy sequence in
tamoxifen-refractory patients.
Having into account the differences between genders, the absence of studies achiev-
ing the role of CYP2D6 polymorphisms in MBC patients and due to the variety of
methodologies used and populations enrolled in women studies, comparisons between
our study and the published data must be done with precaution. When looking for stud-
ies that have been performed in Caucasian women with sporadic breast cancer, treated
with tamoxifen in adjuvant setting and with a genotyping comprehensive analysis that
include the CYP2D6*4, we find controversial results. The two studies published by Weg-
man et al. in 2005 [42] and 2007 [43] did not find a relation between CYP2D6*4 poly-
morphism and disease-free survival. The first study included pre and post-menopausal
women that presented only large tumours with lymph node involvement and all of them
were treated with 40 mg of tamoxifen. In the second study there are no patients in
stage I (only stage II and III) and the subgroup treated before 1994 also received 40
mg of tamoxifen. These could be possible reasons for their negative findings. In an-
other direction Schroth et al. [10], described a relation between CYP2D6*4 variants
and recurrence rates in patients treated with adjuvant tamoxifen and no chemotherapy.
However this finding was not replicated in other studies that enrolled only Caucasian
patients [44].
Contrarily to our findings, Bijl et al. [22], stated a relation between CYP2D6*4 geno-
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types and breast cancer mortality in a population-based cohort study. However in this
study there was no reference to the type of adjuvant treatments performed by the pa-
tients beyond hormonotherapy and we do not know the immunohistochemical profile of
the tumours related to the expression of hormonal receptors.
In conclusion, our study demonstrates a possible role in recurrence prediction of
CYP2D6*4 genotypes in MBC patients which could mean that some of them benefit
less from adjuvant tamoxifen, starting the debate about the need of changing the sys-
temic treatment in some subgroups. The relation between these genotypes and other
recurrence and prognostic factors could signify that a longer follow-up and the enroll-
ment of a large number of patients in future studies are necessary to provide definitive
evidence for the value of this biomarker in clinical management.
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Chapter 4
Final Remarks
Due to its rarity and different biology, MBC patients are seldom included in BC trials from which
standard treatment recommendations are made, and because of that, are still managed as FBC
patients. Data related to MBC come from retrospective analysis that cover long time periods, dif-
ferent regions, distinct therapeutic approaches and a large range of missing variables from cancer
registries that could definitively be sources of potential confounders and must be noticed when
analysing the results. However, retrospective studies have much relevance in rare diseases, as
they may equally standardize the population and the outcomes of interest as randomized con-
trolled trials namely when they are performed in a high-volume centers, where bias related for
example with treatment standards could be diluted.
The present work addressed two main important issues when defining BC patients’ approach:
prognostic and predictive factors to response to adjuvant endocrine therapy (tamoxifen). In prog-
nostic domain, there are already many doubts about the factors that influence MBC patients’
survival and if these patients present or not poorer survival than female, even when some impor-
tant factors are controlled. The developed research work tried to find specifically subgroups that
translate MBC patients’ behaviour and also addressed an important issue never specifically stud-
ied in these patients: recurrence. Worst prognosis was independently associated with tumours
larger than 2 cm that did not express ER and presented distant metastasis at diagnosis. N+
disease showed borderline relation with prognosis. FBC subgroups, based on three or four IHC
markers and the most recent one with new IHC cut-offs for PR, had prognostic implications also
in MBC patients, but lost their relevance when analysed only luminal- like tumours (the majority
of them), which means that FBC subgroups did not provide the same information in male, as the
others types of BC (triple negative and HER2-enriched) are rarely documented. This was the
first time that the new classification of FBC subgroups (2014 classification) was tested in MBC.
Based on a routine IHC panel of six markers, cluster analysis identified two new MBC subgroups;
one related to good prognosis (patients that express ER and PR without expression of AR, HER2
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and ki67 and p53 low) and other related to bad one (patients without expression of PR). The high
frequency of luminal-like tumours and the preferential use of tamoxifen in these patients, make
it important to find clinical markers to response to this therapy. According to our findings, MBC
patients treated with adjuvant tamoxifen that were considered poor metabolizers according to
CYP2D6*4 polymorphism, had higher risk for relapse, and this effect was independent for classic
prognostic factors (size>2cm, N+ disease and advanced stage). In patients with tumour larger
than 2 cm, CYP2D6*4 polymorphisms confer also a negative impact on prognosis.
Recurrence was studied to clarify the doubts regarding survival differences between female
and male BC patients based on two well-balanced cohorts. Male presented poorer prognosis
than female and recurred more frequently to lung, although the local of relapse was not related
to survival differences between groups. MBC patients were proposed more often to symptomatic
treatment at first recurrence, which probably justify the distinct outcomes, as it was also proved
in this work that palliative systemic treatment had favourable impact in survival in male patients
like in female.
In summary, with this work clinicians must look with major concerns for MBC patients that
present with tumours with more than 2cm, or have lymph nodes involvement or do not express
ER or PR or present with distant metastasis at diagnosis (stage IV). Poor tamoxifen metabolizers
based on CYP2D6*4 polymorphism seem to have higher risk for relapse and probably need
a more aggressive adjuvant approach. In recurrence time, palliative systemic treatment had
favourable implications in these patients survival.
Future Perspectives
With this work, many interesting aspects about MBC disease were clarified defining new research
directions that started with replication of these findings in large and, ideally, prospective series. A
multidisciplinary meeting on MBC topic 1 stated that for rare diseases, the key to understanding
them could be the pooling of data from a wide range of sources and so international consortia
are essential to moving research forward. Breast International Group (BIG) and North American
Breast Cancer Group (NABCG) have joined efforts to develop an International MBC Program to
pool epidemiologic data, clinical information and tumour specimens. This program has two es-
sential parts that will determine, at the end of the process, the feasibility of a randomized clinical
trial in these patients. The first one, also called retrospective part, has the objective of performing
a meta-analysis based on clinical data retrospectively collected and a central pathological re-
view of tumour specimens from MBC patients diagnosed and treated at participating institutions
1Korde LA, Zujewski JA, Kamin L, et al. (2010) Multidisciplinary meeting on male breast cancer. Summary and
research recommendations. Journal of Clinical Oncology, 28(12), 2114- 2122.
168
over the last 20 years. The second one, or prospective part, has the coordination of European
Organization for Research and Treatment of Cancer (EORTC) and will registry all MBC treated
for a period of 2 years (remaining the follow-up ideally for a period of 10 years) and is linked
to biologic material collection (paraffin-embedded and frozen tumour samples and blood/serum)
and evaluation of quality of life (QOL) in these patients. This study is already registered by the
names EORTC-10085, BIG 2-07, TBCRC 029, and there are actually two centers in Portugal
that are recruiting. One of them is IPOPFG, and I was granted with the Principle Investigator
position in this study, based on my interest on the topic. Nowadays we have recruited 7 patients
that constituted 5% of the series already enrolled. This could be also the opportunity to confirm
some of our findings as the collected biological samples could be used for additional tests.
With the present findings, the principal research directions with a larger series could be:
− Evaluate specifically the group of PR negative patients and compare it with the others
groups;
− Reanalyse recurrence, collecting patients’ comorbidities information and causes of death
to compare BC specific survival between genders;
− Define relapse model prediction for MBC patients;
− Test gene dose effect based on the three MBC metabolizers groups defined by CYP2D6*4;
− Perform comprehensive genotyping of CYP2D6, evaluating the effect of multiple CYP2D6
alleles in MBC outcome.
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